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ABSTRACT
Virulence Regulation in Pseudomonas aeruginosa via the Regulators, AlgU and AlgR,
Posttranscriptional Regulator, RsmA, & Two-component System, AlgZ/R
by
Sean Denver Stacey
Pseudomonas aeruginosa is a Gram-negative bacillus able to colonize a wide variety of
environments. In the human host, P. aeruginosa can establish an acute infection or persist and
create a chronic infection. P. aeruginosa is able to establish a niche and persist in human hosts
by using a wide array of virulence factors used for: movement, killing host cells, and evading
immune cells and antibiotics. Understanding virulence factors and their regulation has proved to
be an important means of combating the morbidity and mortality of P. aeruginosa as well as the
ever-increasing threat of drug resistance. By targeting virulence factors or their regulators with
antivirulence compounds, the bacterium is rendered defenseless and more readily cleared by the
immune system. In this study, we examine three different contributors to virulence factor
regulation. First, we examined the role of the extracellular sigma factor AlgU and its
contribution to regulating a post-transcriptional RsmA. AlgU is most commonly active in
chronic infecting strains that produce copious amounts of the virulence factor, alginate. We
confirmed that not only was their more RsmA in this background, but that there was a previously
unidentified promoter for rsmA regulated by AlgU. In concert with this study, we followed up
by studying the effects of AlgR on this unknown promoter. AlgU and AlgR are known to work
together, specifically on the alginate operon, and we hypothesized based off of bioinformatics
data this was the case with RsmA. Second, due to increased RsmA in this chronic infection
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strain, we set out to identify potential unknown virulence targets of RsmA. A previously
unrevealed target, pasP, was shown to directly interact with RsmA. Third, in an acute infection
model strain we identified a new regulatory loop involving the two-component system AlgZ/R.
In a pilW strain deficient in the motility virulence factor type IV pili, we showed increased levels
of AlgZ/R compared to wildtype, PAO1. The pilW strain produced less pyocyanin, rhamnolipid,
and elastase and was attenuated in J774a.1 macrophages. Overall, these studies push the
understanding of virulence factor regulation and open the door to potential therapeutic targets in
treating P. aeruginosa infections.
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CHAPTER 1
INTRODUCTION
Pseudomonas aeruginosa
P. aeruginosa is most commonly known as an opportunistic pathogen. The Gram
negative, bacillus P. aeruginosa can also colonize any tissue in the human host (Figure 1). In
nature, P. aeruginosa can be found in a variety of environments from soil to water.

Figure 1.1 Gram Stain (left) and Transmission micrograph (right) of
Pseudomonas aeruginosa
Besides humans, P. aeruginosa is a known pathogen to plants, insects, and other animals. As an
opportunistic pathogen P. aeruginosa preys on hosts with compromised immune systems, which
includes individuals with HIV/AIDS, on chemotherapeutic regimens, burns on a majority of
their body, type II diabetes, or cystic fibrosis. P. aeruginosa causes infections in human hosts
with optimal immune systems too. The bacterium is known to cause ear infections in swimmers
as well as “hot tub rash,” which is widespread folliculitis, due to a hot tub or pool not being
properly treated. Pseudomonas aeruginosa has a long history as a hospital acquired infectious
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agent and continues today to be a leader in morbidity and mortality from nosocomial infections.
At the end of the 19th century, Pseudomonas aeruginosa née Bacillus pyocyaneus was isolated
from the surgical wounds of two patients at a French hospital (Villavicencio 1998). The
bacterium was characterized based off the blue appearance from the purulent discharge of the
patient’s wound and the rod-like shape under microscopic observation. In modern day hospitals
ventilator associated pneumonia (VAP) due to P. aeruginosa has a 30% mortality rate (Gellatly
and Hancock 2013). P. aeruginosa is also the leading cause of morbidity and mortality in
patients with cystic fibrosis (CF) (Salunkhe et al. 2005). P. aeruginosa produces a resilient
biofilm that aids in colonizing the endotracheal tube of ventilated patients or the CF lung. This
biofilm is also important in establishing a niche in catheter associated urinary tract infections
(CAUTI). As technology has advanced in treating microbial infections, so has the ability for P.
aeruginosa to evade antibiotics and continue to infect hospital patients.
Pseudomonas Pathogenesis
The versatility of P. aeruginosa to thrive in a variety of environments and infect so many
different hosts can be found in its ability to switch between planktonic and sessile states. As the
bacterium scavenges for nutrients or a new niche P. aeruginosa will exhibit a number of
structures used for locomotion, attachment, and obtaining foodstuffs (Moradali et al. 2017;
Valentini et al. 2018). This Pseudomonad state is also believed to represent the phenotype of
establishing an acute infection (Figure 1.2) (Luo et al. 2015; Valentini et al. 2018). The
bacterium will use its flagellum and type IV pili (TFP) to adhere to a surface or host cell and
proceed to lay down on the surface (Luo et al. 2015). From here, the bacterium will cease to
express the structures most recognized by the host

17

Figure 1.2. Generalization of Pseudomonas aeruginosa attachment, initiating and
establishing an acute infection, and development of a chronic infection.
immune response and begin to reproduce and express various other weapons or virulence factors
for uptake of nutrients (Gellatly and Hancock 2013; Valentini et al. 2018). Over time the
bacteria will transition from the planktonic to sessile phenotype. The sessile state of the bacteria
will produce compounds that will deter the inflammation response and immune cells to target P.
aeruginosa (Gellatly and Hancock 2013; Valentini et al. 2018). As the chronic infection
develops, the bacteria will express even fewer recognized targets of the immune system to curb
the inflammation response (Gellatly and Hancock 2013; Valentini et al. 2018). In some cases,
chronic P. aeruginosa infections have lasted for over 20 years (Gellatly and Hancock 2013). A
number of researchers have mapped out some hierarchal pathways for both acute and chronic
virulence factors, but there are still holes and question marks to be completed. By understanding
the role virulence factors help in the two phenotypic states of P. aeruginosa, better ways to
prevent acute infections or ameliorate chronic infections can be discovered.
Virulence Factors
P. aeruginosa has one of the most well stocked caches of virulence factors of any
bacterium. P. aeruginosa can thrive in most environments and colonize any host tissue due to its
wide array of weaponry. P. aeruginosa asserts dominance over other species of bacteria by
18

injecting toxins into competitors via the type VI secretion system, sequestering iron with
siderophores, and secreting a force field of exopolysaccharide that protects from phagocytosis
and antibiotics (Gellatly and Hancock 2013; Park et al. 2014; Valentini et al. 2018). P.
aeruginosa has also developed a series of ways around antibiotics besides the exopolysaccharide
alginate like: drug efflux pumps, modified surface receptors and beta-lactamases (Moradali et al.
2017). These enhancements have been either acquiring foreign plasmid DNA or mutations that
enhance resistance (Moradali et al. 2017). However, understanding the role P. aeruginosa uses
its virulence factors can lead to new ways to target and disarm this pathogen.
Secretion Systems
In Gram negative organisms there is no ATP energy available inside of the periplasmic
space, so transport of virulence factors out of the cell the bacteria will use a variety of secretion
systems (Costa et al. 2015; Green and Mecsas 2016). P. aeruginosa has multiple secretion
systems, but lacks a type IV secretion system, which is commonly used by bacteria to inject
DNA or DNA-protein complexes into host cells (Costa et al. 2015). P. aeruginosa uses multiple
type I, type II, and type V secretion systems to secrete proteases, adhesins, and other enzymatic
proteins (Filloux 2011). However, the most well studied secretion systems in P. aeruginosa are
the type III and type VI.
The type III secretion system (T3SS) has been shown to have homology to the bacteria
flagellar apparatus, but serves a completely different purpose in pathogenesis (Green and Mecsas
2016). Once P. aeruginosa contacts the host cell surface the T3SS is used to compromise the
cell membrane. The needle-like apparatus pierces the membrane and will inject a series of
toxins, some of which are extremely lethal (Filloux 2011; Gellatly and Hancock 2013). Multiple
studies have shown the importance of the T3SS’s importance in virulence of P. aeruginosa and
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establishing an acute infection (Anderson et al. 2010; A.K. Jones et al. 2010; Filloux 2011;
Schulmeyer and Yahr 2017).
The type VI secretion system (T6SS) is another needle-like appendage P. aeruginosa
uses for injecting toxins. The T6SS is homologous to the T4-bacteriophage tail spike and used in
a similar fashion (Green and Mecsas 2016). Uniquely, P. aeruginosa has three T6SS that have
not been completely characterized fully, although it is believed one is for harming host cells
(T6SS-2) while the first identified T6SS-1 is used to inject toxins into nearby bacteria (Filloux
2011 Jul 16; Costa et al. 2015; Green and Mecsas 2016). P. aeruginosa has one of the most
lethal identified T6SS in Eubacteria, even dominating Vibrio cholera (Basler et al. 2013). The
genetic loci for the T6SS also include antitoxins so that sister cells that may be fired upon do not
lyse from injection of toxins (Filloux 2011). The T6SS-1 is also characterized as a chronic
virulence factor (Valentini et al. 2018). P. aeruginosa uses secretion systems like the T6SS and
T3SS to dominate its niche amongst other microbiota, pathogens, or host cells.
Secreted Virulence Factors
Besides using secretion systems, P. aeruginosa can use various membrane transporters or
even outer membrane vesicles to release virulence factors into the extracellular milieu.
Exopolysaccharides are used for a variety of functions to help P. aeruginosa persist in its
environment. P. aeruginosa secretes three types of exopolysaccharide that contribute to biofilm
formation: alginate, pel, and psl. Alginate is a combination of beta-D-mannuornic and alpha-Lguluronic acids that has a overall negative charge and the consistency of mucus(Moradali et al.
2017). Alginate not only shields the bacteria from antibiotics, but also causes frustrated
phagocytosis because the pseudopods of the immune cell cannot wrap around the biofilm
protected colony of cells (Lee et al. 2011; Moradali et al. 2017). Most commonly, P. aeruginosa
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isolates from CF sputum undergo phenotypic shifts where the strains will produce copious
amounts of alginate.
While alginate production is clearly seen on a plate, P. aeruginosa PAO1 still produces
biofilms from the exopolysaccharides pel and psl (Figure 1.3). Pel has been

Figure 1.3 Nonmucoid (PAO1) and mucoid (mucA22) strains of Pseudomonas
aeruginosa on Pseudomonas isolation agar.
characterized to have an overall positive charge has consists of linked N-acetylgalactosamine and
N-acetylglucosamine (Moradali et al. 2017). Psl contains rhamnose, glucose, and mannose with
an overall neutral charge (Moradali et al. 2017). Psl has also been shown to be regulated by the
transcriptional regulator AmrZ, as well as the sigma factor RpoS and post-transcriptionally by
RsmA (Irie et al. 2010; C.J. Jones et al. 2013). RpoS is considered the stress response sigma
factor (Potvin et al. 2008). If P. aeruginosa is under attack by the innate immune response,
biofilm production is a means of resisting the siege.
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While most proteases are large and require secretion systems, there are other secreted
virulence factors besides biofilm components that are secreted by diffusion or efflux pumps.
Pyoveridine is a compound secreted by the efflux pump PvdRT/OmpQ system (Moradali et al.
2017). Pyoveridine acts as an iron chelator in order for P. aeruginosa to acquire exogenous iron
from a host (Moradali et al. 2017; Little et al. 2018). Pyoveridine also reacts under ultraviolet
light and can be used as a biomarker for Pseudomonas infections (Yin et al. 2014; Norbury et al.
2016). Hydrogen cyanide is a virulence factor produced by P. aeruginosa that is able to diffuse
across its membrane and the membrane of host cells (Moradali et al. 2017). Hydrogen cyanide is
a secreted weapon that compromises cellular respiration in host cells, limiting the ability for
immune cells to attack (Gellatly and Hancock 2013; Moradali et al. 2017). RsmA has been
shown to post-transcriptionally regulate hydrogen cyanide production in nonmucoid/acute
infection strains, but in mucoid/chronic infection strains (Burrowes et al. 2006; Brencic and Lory
2009; Stacey et al. 2017). Secreted virulence factors are important for P. aeruginosa to establish
and persist in a host or natural environment.
Motility Virulence
The most important virulence factors are those involved in motility. P. aeruginosa has a
single polar flagellum, type IV pili, and produces surfactants called rhamnolipids for the ability
to move across surfaces and swim in aqueous environments (Okkotsu et al. 2013; Kazmierczak
et al. 2015; Moradali et al. 2017). The flagellum has been shown not only important in motility,
but also has the ability to aid in surface attachment (Kazmierczak et al. 2015). The
Pseudomonas flagellum is considered an acute virulence factor because it is solely expressed
when the bacterium is searching to establish a niche in the environment (Kazmierczak et al.
2015; Valentini et al. 2018).
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Touch is crucial for P. aeruginosa to take advantage of its environment and that is
exactly what the type IV pili is used. Type IV pili are localized like the flagellum at the poles of
the cell (Gellatly and Hancock 2013). The apparatus can be extended or retracted out of the cell
and has an adhesin at the tip called PilY1 (Giltner et al. 2010; Kazmierczak et al. 2015). The
stalk is comprised of a major pilin unit, PilA, and several minor pilin subunits, FimUPilVWXE
(Giltner et al. 2010). Minor pilin mutants have been shown to have decreased virulence but the
implications as to why have not been elucidated (Siryaporn et al. 2014; Luo et al. 2015; Marko et
al. 2017). It is hypothesized that the type IV pili act not only as a mechanosensory system, but
also relay expression of the sessile-phenotype upon touching a surface (Siryaporn et al. 2014;
Kazmierczak et al. 2015; Luo et al. 2015; Marko et al. 2017). Marko et al. allude that there is
influence of minor pilins on AlgZ, but to what effects have not been clarified (Marko et al.
2017).
Virulence Regulation
P. aeruginosa virulence is more complicated than just identifying virulence genes.
Understanding the regulation of virulence factors proves to be just as important. Virulence
factor regulation can in some cases consist of global networks activating , repressing or coregulating targets. Virulence mechanisms can consist of cascades that go from a chemical signal
sensed from outside the bacterium to the P. aeruginosa reacting, producing, and secreting a
toxin. Luo et al. has shown that upon contact with a surface, the type IV pili will activate the
diguanylate cyclase SadC to start producing cyclic di-GMP and in turn produce a biofilm (Luo et
al. 2015). Knowledge of virulence regulation has potential for chemotherapeutic treatments to
exploit P. aeruginosa and turn virulence weaponry on itself.
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Sigma Factor
A sigma factor is the variable portion of the RNA polymerase holoenzyme to initiate
transcription of a gene (Potvin et al. 2008). In P. aeruginosa there are a variety of sigma factors
used for the expression of virulence factors, while most housekeeping genes and core metabolic
processes are regulated by the main sigma 70, RpoD (Potvin et al. 2008). There are specific
sigma factors in P. aeruginosa for expressing flagella, FliA, and nitrogen metabolism, RpoN
(Potvin et al. 2008). Another type of alternative sigma factor is the extracytoplasmic function
(ECF) sigma factors. These sigma factors will respond to extracellular signals or stresses and
lead to the expression of protective targets (Potvin et al. 2008).

Figure 1.4 The alginate regulators, AlgU and AlgR, both converge on the algD
promoter to activate alginate production in mucoid strains of Pseudomonas
aeruginosa like the mucA22 strain.
The most important ECF sigma factors involved with P. aeruginosa infections in the
cystic fibrosis lung is AlgU. AlgU is normally sequestered by the anti-sigma factor, MucA, to
the inner membrane (Potvin et al. 2008). If any oxidative damage causes stress to the cell
membranes or denatures MucA, then AlgU is released to activate its regulon. A key component
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of P. aeruginosa virulence and a chronic infection in the CF lung is the production of alginate
(Hershberger et al. 1995; Gellatly and Hancock 2013). Clinical isolates from CF sputum very
often contain mutations in mucA (Potvin et al. 2008; Gellatly and Hancock 2013). The algD
operon is regulated by AlgU (Figure 1.4) (Hershberger et al. 1995). AlgU has been shown to
also regulate AmrZ, which inhibits flagellum biosynthesis and conceals the bacterium from
immune cells (Tart et al. 2006). Recently AlgU has been shown to regulate rsmA, in doing so,
AlgU regulates hundreds of other targets via this post-transcriptional regulator (Stacey and
Pritchett 2016).

Figure 1.5 The post-transcriptional regulator RsmA inhibits translation
in Pseudomonas aeruginosa by binding and blocking the ribosomal
binding site of target messenger RNA.

Post-Transcriptional Regulation
Bacteria use post-transcriptional regulation as a means to control translation of mRNA.
Depending on the strain of P. aeruginosa there is up to three post-transcriptional regulators of
secondary metabolites, RsmA/F/E (Lapouge, Sineva, et al. 2007; Schulmeyer et al. 2016). These
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regulators function by binding the ribosomal binding site (RBS) of the mRNA target (Figure
1.5). This site presents a binding motif usually consisting of AGGA on a stem-loop structure
(Brencic and Lory 2009; Kulkarni et al. 2014). In P. aeruginosa the action of RsmA binding the
mRNA represses the translation of the target, which is believed to be RsmA’s sole function.
However, the homolog of RsmA, CsrA, has been shown to interact with other proteins and
positively influence mRNA targets(Wei et al. 2001; Mukherjee et al. 2011).

Figure 1.6 The Rsm/Gac hierarchy in Pseudomonas aeruginosa. The twocomponent system GacS/A activate the RsmA antagonists RsmY/Z. The
GacS/A system is inhibited by the hybrid sensor kinase, RetS. RsmA is
activated by two individual promoters. In strains with mucA mutations, the
extracytoplasmic sigma factor, AlgU, increases expression of RsmA at its distal
promoter.
RsmA is part of a larger network of virulence regulation called the Gac/Rsm system
(Figure 1.6). In P. aeruginosa RsmA has two small noncoding RNA (ncRNA) antagonists,
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RsmY and RsmZ (Janssen et al. 2018). These ncRNAs are regulated by the response regulator,
GacA, which is part of the GacS/A two-component system (TCS) (Lapouge, Schubert, et al.
2007). GacS responds to a still unknown signal and phosphorylates GacA that in turn activates
expression of the ncRNAs (Lapouge, Sineva, et al. 2007). An inhibitor of GacS
autophosphorylation is the hybrid sensor kinase RetS. RetS, the regulator of exopolysaccharide
and T3SS, will heterodimerize with GacS prohibiting the phosphorylation event (Vakulskas et al.
2015). Contrary to RetS is the lost adherence sensor, LadS, which will assist GacS in activating
the ncRNAs (Vakulskas et al. 2015).
The Gac/Rsm components are all crucial for virulence as both mutations in rsmA or gacA
lead to attenuation(Lapouge, Schubert, et al. 2007; Gellatly and Hancock 2013; Vakulskas et al.
2015; Valentini et al. 2018). The Gac/Rsm system has also been shown to play an important role
in shift from planktonic to sessile states or acute infection to chronic (Valentini et al. 2018).
Removing any portion of the Gac arm of the network will produce an unregulated RsmA strain
that expresses T3SS, flagellum, and type IV pili, while removing rsmA or retS will cause
increase in biofilm and T6SS expression (Valentini et al. 2018). As a result of either mutation
the P. aeruginosa strain will be readily cleared by the host immune response.
Two Component Systems
P. aeruginosa has over 60 two component systems in its genome (Francis et al. 2017). A
TCS consists of a sensor histidine kinase and a response regulator (Figure 1.7). These
components are highly conserved and are usually arranged in an operon together (Galperin et al.
2016; Francis et al. 2017). The sensor will received an extracellular signal and
autophosphorylate itself, this phosphate will then be transferred from the histidine residue to the
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aspartate residue of the response regulator (Podgornaia and Laub 2013). Once phosphorylated,
the response regulator will then activate the expression of its target genes.

Figure 1.7 A classical interpretation of a two-component system in Pseudomonas
aeruginosa. The sensor histidine kinase receives an external signal, which causes
an autophosphorylation event from free ATP. This phosphate group is then
transferred to the sensor’s cognate response regulator at a conserved aspartate
residue. The activated regulator causes the expression of its regulon.
The AlgZ/R two-component system has been shown to target multiple virulence genes in
P. aeruginosa. The algZ/R loci are located in an operon and shown to be regulated by the
virulence factor regulator, Vfr (Luo et al. 2015) (Figure 1.8). Upon phosphorylation, AlgR will
activate expression of the minor pilin operon (Belete et al. 2008; Okkotsu et al. 2013). However,
conflicting studies show AlgR influencing rhamnolipid production and the Rhl quorum sensing
system, which also controls pyocyanin and elastase (Morici et al. 2007; Okkotsu et al. 2013;
Little et al. 2018). AlgR when unphosphorylated can co-regulate with the ECF AlgU as seen in
Figure 1.4 and 1.6 on the algD operon and rsmA (Salunkhe et al. 2005; Stacey et al. 2017). Most
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recently Luo et al. and Marko et al. have shown that the AlgZ/R TCS plays a larger role in P.
aeruginosa pathogenesis. Luo et al. demonstrated that the type IV pili regulated AlgZ/R has a
feedback loop where by removing a minor pilin that expression of the minor pilin operon
increased significantly (Luo et al. 2015). Marko et al. also demonstrated via bacterial adenylate

Figure 1.8 The AlgZ/R two-component system in Pseudomonas aeruginosa. Vfr
regulated the algZ/R operon in P. aeruginosa. The signal that activates the
phosphorylation cascade of AlgZ is still unknown. AlgZ phosphorylated AlgR at
aspartate residue 54. AlgR can control the expression of targets dependent and
independent of phosphorylation.
cyclase two hybrid system that AlgZ interacted with a portion of the minor pilins (Marko et al.
2017). The role of AlgZ/R is more complex than just regulating the minor pilin operon and may
have greater implication in the mechanosensory network of the type IV pili.
Antivirulence Therapeutics
Treating P. aeruginosa infections with conventional antibiotics has become increasingly
difficult due to the bacterium’s ability to adapt and evolve like many other drug resistant
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bacteria. A new means of eradicating P. aeruginosa infections is by targeting virulence factors
with antivirulence chemotherapeutics. Multiple researchers are investigating ways to inhibit
aspects of P. aeruginosa’s ability to cause an infection by impairing different virulence factors.
Novel targets include blocking adhesins from attaching to host cells, biofilm dispersal, and
impairing the quorum sensing system, which all would lead to host clearance of P. aeruginosa
(Fothergill et al. 2014). Understanding virulence factor regulation is crucial for developing
antivirulence compounds. The regulation of the post-transcriptional regulator rsmA is
characterized. Upon discovery of the alginate regulators AlgU and AlgR contributing to RsmA
levels, the RsmA regulon is characterized in a mucoid strain, mucA22. Lastly, the role of AlgR
on virulence in a minor pilin mutant, pilW, is characterized. Overall, through the understanding
of how these regulators contribute to virulence, there is potential to utilize and target these
virulence factors as an vulnerability to help clear P. aeruginosa acute and chronic infections.

Specific Aims
Aim1:
Analyze and characterize a potential second promoter upstream of the rsmA allele in
Pseudomonas aeruginosa.
Aim 2:
Analyze and characterize the RsmA regulon in a mucA22 strain, since there is more RsmA made
in a mucA22 strain of Pseudomonas aeruginosa due to the distal promoter.
Aim 3:
Analyze the expression and protein levels of the algZ/R operon in a pilW mutant and potential
effects on virulence in Pseudomonas aeruginosa.
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CHAPTER 2
PSEUDOMONAS AERUGINOSA ALGU CONTRIBUTES TO POSTTRANSCRIPTIONAL
ACTIVITY BY INCREASING RSMA EXPRESSION IN A MUCA22 STRAIN
Authors: Sean D. Stacey1, Christopher L. Pritchett1
Affiliations: 1Department of Health Sciences, East Tennessee State University, Johnson City,
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ABSTRACT
Pseudomonas aeruginosa thrives in multiple environments and is capable of causing lifethreatening infections in immunocompromised patients. RsmA is a posttranscriptional regulator
that controls virulence factor production and biofilm formation. In this study, we investigated the
expression and activity of rsmA and the protein that it encodes, RsmA, in P. aeruginosa mucA
mutant strains, which are common in chronic infections. We determined that AlgU regulates a
previously unknown rsmA promoter in P. aeruginosa. Western blot analysis confirmed that
AlgU controls rsmA expression in both a laboratory strain and a clinical isolate. RNase
protection assays confirmed the presence of two rsmA transcripts and suggest that RpoS and
AlgU regulate rsmA expression. Due to the increased amounts of RsmA in mucA mutant strains,
a translational leader fusion of the RsmA target, tssA1, was constructed and tested in mucA,
algU, retS, gacA, and rsmA mutant backgrounds to examine posttranscriptional activity. From
these studies, we determined that RsmA is active in mucA22 mutants, suggesting a role for
RsmA in mucA mutant strains. Taken together, we have demonstrated that AlgU controls rsmA
transcription and is responsible for RsmA activity in mucA mutant strains. We propose that
RsmA is active in P. aeruginosa mucA mutant strains and that RsmA also plays a role in chronic
infections.
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IMPORTANCE
P. aeruginosa causes severe infections in immunocompromised patients. The
posttranscriptional regulator RsmA is known to control virulence and biofilm formation. We
identify a new rsmA promoter and determine that AlgU is important in the control of rsmA
expression. Mutant mucA strains that are considered mucoid were used to confirm increased
rsmA expression from the AlgU promoter. We demonstrate, for the first time, that there is RsmA
activity in mucoid P. aeruginosa strains. Our work suggests that RsmA may play a role during
chronic infections as well as acute infections.
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INTRODUCTION
Pseudomonas aeruginosa produces a myriad of virulence factors and can cause both
acute and chronic infections (1, 2). To survive and persist, P. aeruginosa must coordinate gene
expression in response to changing environmental conditions. Global regulatory networks
respond to changing environmental conditions to allow the physiological changes necessary for
survival to be made. The P. aeruginosa genome encodes many global regulatory systems,
including posttranscriptional regulators, such as RsmA. RsmA is important in regulating several
virulence factors involved in acute and chronic infections (3).
Acute infections are characterized by motility and expression of the type III secretion
system (4). RsmA positively regulates both motility and type III secretion system expression (4–
6). A defining characteristic of chronic infections is biofilm formation, which includes the
production of exopolysaccharides, such as alginate, and the type VI secretion system (T6SS) (7,
8). RsmA is a negative regulator of the exopolysaccharide gene psl and the first hemolysincoregulated secretion island type VI secretion system (HSI-I T6SS) (5, 8, 9). A characteristic of
some P. aeruginosa isolates causing chronic infections, such as those found in cystic fibrosis
patients, is alginate overproduction, which is the result of the extracytoplasmic sigma factor
AlgU (7, 10).
AlgU is normally sequestered at the cytoplasmic membrane by the anti-sigma factor
MucA (7, 10). MucA prevents AlgU from binding and activating target promoters (7, 10). Once
liberated from MucA, AlgU activates a variety of genes, including those important for
biosynthesizing alginate (7, 10–13). Strains overproducing alginate are termed mucoid. P.
aeruginosa strains that initially colonize cystic fibrosis patients frequently evolve into strains that
overproduce alginate, often because of mutations in the mucA gene (7, 10). A previous study
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found that a mucA mutant has increased rsmA expression (14). Because mucA mutations lead to
hyperactive AlgU (7, 10), we hypothesized that AlgU might regulate rsmA transcription.
RsmA is a global posttranscriptional regulator that regulates several mRNAs involved in
virulence (5, 6). RsmA positively regulates type III secretion and type IV pilus production, both
of which are important virulence factors for acute infections (6, 14). In the case of biofilm
formation, RsmA inhibits exopolysaccharide production (5, 9). Therefore, RsmA is important in
determining what virulence factors are expressed by P. aeruginosa. RsmA activity is regulated
by two small RNAs, RsmY and RsmZ, that bind RsmA and prevent RsmA from binding target
mRNAs (15). RsmY and RsmZ sequester RsmA, allowing the production of exopolysaccharides
and other RsmA target mRNAs (9, 16). Increased RsmY and RsmZ levels or decreased RsmA
activity can allow bio- film formation to occur. The expression of rsmY and rsmZ is positively
controlled by RsmA, GacA, and LadS and negatively con- trolled by RetS (16–18). RsmA binds
to highly conserved GGA motifs. Usually, one of the GGA motifs is found in a stem-loop
structure formed near the ribosome-binding site (19). Multiple copies of the same GGA motif are
also found in the inhibitory small RNAs RsmY and RsmZ (20, 21).
Although RsmA is important for virulence and global gene expression (5, 22, 23), little is
known regarding the genetic controls governing rsmA expression. Currently, only a single rsmA
promoter region, which resembles a s70 (RpoD) promoter, has been identified in P. aeruginosa
(24–26). A recent chromatin immunoprecipitation sequencing study showed that both RpoD and
RpoS likely control rsmA expression (27). However, another study found similar RsmA levels in
both an rpoS mutant and the wild- type strain (9). Early studies found that optimal rsmA
expression requires GacA and that rsmA expression increases throughout growth (28), findings
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which support a role for RpoS in controlling rsmA expression. These seemingly contradictory
data have not yet been clarified.
Given the importance of RsmA in controlling P. aeruginosa virulence and biofilm
formation, there is a critical need to under- stand rsmA expression. In this study, we determined
the genetic elements controlling rsmA expression. We identified a new promoter region and
determined that AlgU and RpoS contribute to rsmA expression. Importantly, we demonstrate that
RsmA is active in P. aeruginosa mucA mutants. This work suggests that RsmA has a role in
regulating gene expression in mucA mutants and that AlgU is an important activator of rsmA
expression.
METHODS
Strains, plasmids, and media
The strains used in this study are presented in Table 2.1. Escherichia coli strains were
maintained on LB (Difco) plates or broth without or with antibiotics, as appropriate.
Pseudomonas aeruginosa strains were grown on Pseudomonas isolation agar (PIA), LB medium,
or Vogel-Bonner minimal medium (VBMM) supplemented with the appropriate concentrations
of antibiotics. For E. coli, antibiotics were used at the following concentrations when
appropriate: 10 mg/ml tetracycline, 15 mg/ml gentamicin, 100 mg/ml ampicillin, and 35 mg/ml
kanamycin. For Pseudomonas strains, antibiotics were used at the following concentrations: 150
mg/ml gentamicin, 50 mg/ml tetracycline, and 300 mg/ml carbenicillin. For allelic exchange,
sucrose was supplemented at 10% in YT (1% tryptone and 0.5% yeast extract) medium.
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Table 1. Strains and plasmids used in this study.
Strain or Plasmid

Genotype or Relevant properties

Reference
or Source

fhuA2 Δ(argF-lacZ) U169phoA, glnV44
Φ80Δ(lacZ)M15 gyrA96

New
England
Biolabs
(59)

E. coli strains
NEB5α
SM10

Thi thr leu tonA lacY supE recA::RP4-2-Tc::Mu
KmR
pRK2013
Helper strain
pEX18Tc
Allelic exchange vector
pEX18Gm
Allelic exchange vector
∆rsmA pEX18Tc
Allelic exchange for rsmA non-polar deletion
∆algU pEX18Tc
Allelic exchange for algU non-polar deletion
∆rpoS pEX18Tc
Allelic exchange for rpoS non-polar deletion
rsmAHA pEX18Gm Allelic exchange for rsmA HA allele
miniCTXlacZ
Transcriptional fusion vector
TF1-lacZ miniCTX Transcriptional fusion
TF3-lacZ miniCTX Transcriptional fusion
TF3USDM-lacZ
Site-directed mutagenesis transcriptional fusion
miniCTX
TF2-lacZ
Transcriptional fusion
pTJ1
Integrating vector used for overexpression
algU pTJ1 (pAlgU) algU complementation/overexpression
P. aeruginosa
strains
PAO1
Wild type
∆algU
algU mutant
mucA22
mucA22 mutation
mucA22 ∆algU
mucA22 strain, ∆algU
2192
383
∆rsmA
rsmA nonpolar deletion
mucA22∆rsmA
rsmA nonpolar deletion in mucA22 strain
PAO1
rsmA transcriptional fusion strain
TF1-lacZ
∆algU
rsmA transcriptional fusion strain
TF1-lacZ
mucA22
rsmA transcriptional fusion strain
TF1-lacZ
mucA22, ∆algU
rsmA transcriptional fusion strain
TF1-lacZ
2192
rsmA transcriptional fusion strain
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(31)
(30)
(30)
This study
(60)
This study
This study
(37)
This study
This study
This study
This study
(43)
This study
(61)
(60)
(62)
This study
(45)
(45)
This study
This study
This study
This study
This study
This study
This study

TF1-lacZ
383
TF1-lacZ
383HA
2192HA
2192HAΔalgU
PAO1
PE3-lacZ
∆algU
PE3-lacZ
mucA22
TF3-lacZ
mucA22, ∆algU
TF3-lacZ
PAO1
TF3USDM-lacZ
∆algU
TF3USDM-lacZ
mucA22
TF3USDM-lacZ
mucA22, ∆algU
TF3USDM-lacZ
PAO1 TF2-lacZ
mucA22 TF2-lacZ
ΔalgU TF2-lacZ
mucA22 ∆algU
PAO1HA
ΔalgUHA
mucA22HA
mucA22 ∆algUHA
PAO1HA pTJ1
PAO1HA palgU

rsmA transcriptional fusion strain

This study

Nonmucoid clinical isolate with rsmAHA allele
Mucoid clinical isolate with rsmAHA allele
2192 with rsmAHA allele and algU deleted
rsmA transcriptional fusion strain

This study
This study
This study
This study

rsmA transcriptional fusion strain

This study

rsmA transcriptional fusion strain

This study

rsmA transcriptional fusion strain

This study

Mutant rsmA transcriptional fusion strain

This study

Mutant rsmA transcriptional fusion strain

This study

Mutant rsmA transcriptional fusion strain

This study

Mutant rsmA transcriptional fusion strain

This study

rsmA transcriptional fusion
rsmA transcriptional fusion
rsmA transcriptional fusion
rsmA transcriptional fusion
PAO1 with epitope tagged RsmA
ΔalgU with epitope tagged RsmA
mucA22 mutant with epitope tagged RsmA
mucA22, ∆algU with epitope tagged RsmA
PAO1 rsmAHA allele and vector pTJ1 alone
PAO1 rsmAHA allele and algU under pBAD
promoter

This study
This study
This study
This study
This study
This study
This study
This study
This study
This study

Strain construction
All PCR products were amplified from P. aeruginosa PAO1, unless otherwise noted,
using Q5 polymerase (New England BioLabs [NEB], Ipswich, MA) and primers listed in Table
2.2. Crossover PCR (splicing by overhang extension PCR) (29) was used to construct deletion
mutations and to clone sequences into the suicide vector pEX18Tc or pEX18Gm (30). All cloned
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constructs were confirmed via sequencing. P. aeruginosa strains were conjugated with E. coli as
a donor strain and the pRK2013-containing helper strain (31). Conjugations were performed
overnight on LB plates at 37°C, and the conjugants were plated on the appropriate selective
medium to obtain single-crossover mutants. Merodiploids were grown without selection and then
screened for sucrose sensitivity on YT medium–10% sucrose plates. Mutations were confirmed
using PCR with primers containing the suffix intF and intR in Table 2.2 and sequencing of the
resulting PCR fragment. Hemagglutinin (HA) tagging of the proteins was accomplished using
primers containing the HA tag at the 3= end of the gene, and HA was introduced as described
above using the suicide vector pEX18Gm.
Table 2. Primers used in this study.
Primer Name
rsmARHindIII
rsmAFHindIII
rsmARXbaI
rsmASOEF
rsmASOER
algUKOF
algUKOR
algUTJ1F2
algU HindIIIR
algRTJ1F2
rpoS EcoRIF

Sequence
GCGCAAGCTTCACGCGAATATTTCAGGAC
AAC
GCGCAAGCTTCGGCAACATCACCACGCTG
G
GCGCTCTAGAGCACGGTGATCCTGCAGAC
C
GCGTGAGGAGAAAGGAATGCTGCAT
TAATTTTTATCTAATTTTCCCTTTGC
GCAAAGGGAAAATTAGATAAAAATT
AATGCAGCATTCCTTTCTCCTCACGC
GCGCGAGCTCGACAGCAACTCGATGTTCG
GTC
GCGCTCTAGAGTCGTACCAGGAAGCCAGC
TG
GCGCCCATGGGAATGCTAACCCAGGAACA
GGATCA
GCGCAAGCTTTCAGGCTTCTCGCAACAAA
GGCTGCA

Use
TF
Mutant
Mutant
Mutant
Mutant
Mutant
Mutant
Complementa
tion
Complementa
tion

GCGCCCATGGGAATGAATGTCCTGATTGTC Overexpressio
GATGAC
n
GCGCGAATTCGATGGCACTCAAAAAAGAA
Mutant
GGGCC
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rpoS HindIIIR

rsmAPE1

GCGCAAGCTTTCACTGGAACAGCGCGTCA
CT
CGTCGCTGACCGGGAGTTCG
CATTTATCTACTTAGGCTCACACG
GCGCTCTAGAGCACGGTGATCCTGCAGAC
C
GCGCAAGCTTCGGCAACATCACCACGCTG
GG
GCCAAGGTTTCCATCGTCGG
TACCCATACGATGTTCCAGATTACGCTTA
ATTTTTATCTAATTTTCCCTTTGC
TTAAGCGTAATCTGGAACATCGTATGGGT
AATGGTTTGGCTCTTGATCTTTCTC
CAGAATTCTTCATTCCGGCGGGACTG
CCAAACGGTCAAAAACGACAAAAG
GCGCGGTACCAAGGATCGCGCTCTTGATTT
CTGCGGATCCGCCGCCATTTCTT
GCGCGGTACCGCTGACAGGCGAAAGGCG
GCGCGGATCCTCACCCAGTATTGACCAGTC
C
GCGCGAATTCACGAGTCAGAATCAGCATT
CCTTTC
GGCGCGTTGACGCCGATGCGC

rsmAPE3

CACGCGAATATTTCAGGACAACAGTCTG

rsmAPE4

GCGCGATCCTTCACCCAGTATTGACCAGTC
C
GCGCGAGCTCGAGGCGACCTTGCGTCATTC
GCGCTCTAGACGGCGATCGCCGAAACCAG
GCGACGAGGTGCAGCGTGATTGTGAATTC
CGCCAGCTAGATGAGCG
CGCTCATCTAGCTGGCGGAATTCACAATCA
CGCTGCACCTCGTCGC
CCAGGGTGCTTGCGCTTTAC
CCACGTAGAGAAGCTTGGCC
GCGCGAGCTCGAACGTCGCCATCGACGTG
C
GCGCAGTACTCAGCACGGTGACGATCTCC
C
GCGCAAGCTTAACCTTTCGAGTCATCCAAT
ATTC
GCGCGGATCCTCGAAAGGTTGGCAAAATT
CTTGT
GGCCGCTGTTGACAATTAATCATCGGCTCG

rpoS intF
rpoS intR
rsmARXbaI
rsmAFHindIII
rsmASDMcheckF
rsmAHAF
rsmAHAR
rsmASDMAlgUF
rsmASDMAlgUR
rsmAPE1F
rsmAPE3F
rsmAPE3R
rsmAEcoRIR

gacAF
gacAR
gacASOEF-2
gacASOER-2
gacAintF
gacAintR
retSFSacI
PA0082lacZCP
tssA1HindIIICTXC
P
PA0082RminiCTX
tacNotIF
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Mutant
PCR check
PCR check
Mutant
Mutant
PCR check
HA allele
HA allele
SDM
SDM
TF
TF/RPA
TF
TF
Primer
extension
Primer
extension
Primer
extension
Mutant
Mutant
Mutant
Mutant
PCR check
PCR check
Mutant
TLF
TLF
TXF
TLF vector

TATAATGTGTG
tacBamHIR

GATCCACACATTATACGAGCCGATGATTA
ATTGTCAACAGC

TLF vector

retSRXbaI
retSSOEF

GCGCTCTAGAGCAGGTCTGGCTATGCCGG
Mutant
GACTTCGCCGTGGTACGGCTTTCCTGAGGG
Mutant
CAGCGACGTGCT
retSSOER
AGCACGTCGCTGCCCTCAGGAAAGCCGTA
Mutant
CCACGGCGAAGTC
retSintF
CAAGGTCGAGGCGACCTGGG
PCR check
retSintR
GAATAACCGCGTGCGGTTATCC
PCR check
lacZScaIF
GCTATGACCATGATTAGTACTGATTCACTG
TLF vector
GCCGTC
lacZRXhoI
CCCCTCGAGCAGACATGGCCTGCCCGGTTA
TLF vector
TTA
lacZRforTF
GATGTGCTGCAAGGCGATTAAG
SEQ
pHERDSF
ATCGCAACTCTCTACTGTTTCTC
SEQ
rsmASDMAlgRF
GAATTCGGCAGGAACTTTCATTCCGGC
RPA
rsmARPAR
TAATACGACTCACTATAGGGAGAGATAAA
RPA
AATTAATGGTTTGGCTCTTG
Abbreviations: TF, transcriptional fusion, TLF, translational fusion, SEQ, sequencing primer;
RPA, RNase protection assay
Transcriptional and translational leader fusion analysis
Upstream DNA fragments containing promoter regions were generated by using the
primers listed in Table 2.2 in conjunction with Q5 polymerase (NEB, Ipswich, MA). PAO1
genomic DNA was used as the template. PCR products were cloned into pCR2.1 and then
subcloned into miniCTXlacZ using the restriction enzymes HindIII/BamHI, HindIII/EcoRI, or
KpnI/BamHI (New England BioLabs, Ipswich, MA). To construct rsmA transcriptional fusions,
the primer pair rsmAHindIII/rsmAEcoRIR was used and the product was inserted into the
SalI/EcoRI sites of miniCTXlacZ using T4 DNA ligase (NEB, Ipswich, MA). The transcriptional
fusion PE3-lacZ was constructed using the primers rsmAPE3F and rsmAPE3R and cloning into
the KpnI/EcoRI site of miniCTXlacZ. The transcriptional fusion TF2- lacZ was constructed
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using primer pair rsmAPE1F/rsmAEcoRIR and cloned into miniCTXlacZ. The translational
fusion vector CTXlacZCP was constructed by amplifying the lacZ gene using the primers listed
in Table 2.2 in order to delete the lacZ ribosome-binding site and the translational initiation
codon. The tssA1 leader fusion was constructed using the lacUV5 promoter in the 5= primer
(PA0082FUV5) and primer PA0082ScaIR to amplify the tssA1 untranslated region on the basis
of the data from the study of Brencic and Lory (5) and cloned into CTXlacZCP. The fusion
constructs were confirmed by sequencing and conjugated into P. aeruginosa strains by
triparental conjugation. Strains were selected for tetracycline resistance and then conjugated with
pFLP2 to remove vector sequences (30). Strains were selected for carbenicillin resistance, grown
overnight without selection, and plated on YT medium with 10% sucrose to select for the loss of
pFLP2. Individual colonies were patch plated onto VBMM supplemented with 300 ︎g/ml
carbenicillin and PIA to ensure the loss of pFLP2. To confirm the presence of the fusion
constructs, PCR was performed using the forward primer used to construct the fusion and the
reverse primer lacZRforTF (Table 2.2). b-Galactosidase activity was deter- mined by incubating
cell extracts with o-nitrophenyl-b-D-galactopyranoside (4 mg/ml) as described by Miller (32). A
strain carrying the empty vector, miniCTXlacZ, was assayed, and the value for this background
(28 Miller units) was subtracted from all transcriptional fusions. All mucoid strains were
confirmed to be mucoid at the end of each experiment by plating on PIA plates and making sure
that all colonies were mucoid. Experiments were performed in triplicate at least three times.
Site-directed mutagenesis
Phosphorylated primers rsmASDMAlgUF and rsmASDMAlgUR were used in an inverse
PCR with the PE3-lacZ transcriptional fusions as the templates. The predicted AlgU-dependent
promoter in the -35 consensus sequence was mutated from GAACTT to GAATTC. The
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successful inverse PCR product was self-ligated, trans- formed into NEB5a cells (NEB, Ipswich,
MA), and screened by plasmid digestion with EcoRI digestion and sequencing. The constructs
obtained by site-directed mutagenesis were conjugated into Pseudomonas strains as described
above.
Western blot analysis
P. aeruginosa strains were grown in LB broth at 37°C for various times. The bacteria
were collected by centrifugation, resuspended in sterile phosphate-buffered saline, and lysed by
sonication. Total protein concentrations were quantified by the Bradford protein assay (Bio-Rad,
Carlsbad, CA). Cell extracts (5 mg) were separated by 12% SDS-PAGE and transferred to a
polyvinylidene difluoride membrane (Bio-Rad). The membranes were blocked and probed using
a 1:2,500 dilution of anti-HA monoclonal antibody (Thermo Fisher, Pittsburgh, PA), followed by
a 1:30,000 dilution of horseradish peroxidase-conjugated goat anti-rabbit immunoglobulin
antibody (33). Arbitrary units were determined by standardizing the Western blots to the
Coomassie- stained SDS-polyacrylamide gel of each strain using total protein analysis as
described previously (34, 35). Detection was performed using an ECL Plus kit (Thermo Fisher,
Pittsburgh, PA) and chemiluminescence detection (ProteinSimple, Santa Clara, CA). The blots
and Coomassie-stained SDS-polyacrylamide gels were analyzed with ImageJ software. All
Western blot analyses were repeated at least three times.
Primer extension
Total RNA (15 mg) from P. aeruginosa was isolated using a Pure-Link RNA minikit
(Life Technologies, Grand Island, NY). Radiolabeled primers rsmAPE1 and rsmAPE3 (Table
2.2) were used in a reverse transcription reaction in a ThermoScript reverse transcription43

detected using autoradiography. Primer extension results were confirmed using two different
primers a total of four times.
In vitro transcription and RPA
The rsmA probe for the RNase protection assay (RPA) was synthesized using a PCR
product generated with primers that incorporated a T7 promoter sequence at the 5= end and a
MAXIscript T7 kit (Life Technologies). The reverse primer containing the T7 promoter
sequence contained a nonhomologous sequence to discriminate between the full-length probe
and protected fragments. The primers rsmASDMAlgRF and rsmARPAR were used to produce
the PCR product. The probes were labeled with UTP by the use of biotin-16-UTP (Life
Technologies) at a ratio of 4:6 and were gel purified after in vitro transcription. Twenty
micrograms of total RNA from each P. aeruginosa strain was precipitated with 800 pg of labeled
probe and resuspended in hybridization buffer {80% formamide, 400 mM NaCl, 40 mM PIPES
[piperazine-N,N=-bis(2-ethanesulfonic acid); pH 6.4], 1 mM EDTA}, heated at 95°C for 5 min,
and incubated overnight at 42°C. Negative controls consisting of the probe incubated with 10 mg
Saccharomyces cerevisiae yeast RNA were also included. Digestion of unhybridized RNA was
performed using RNase A at 25 mg/ml and RNase T1 at 10 U/ml. A biotinylated RNA ladder
(Kerafast) was also used to deter- mine the size of the protected probe fragments. The products
of the reactions were run on a 5% acrylamide– 8 M urea gel, and the gels were transferred to a
positively charged membrane (Hybond N+; Amersham Biosciences) using a semidry blotting
system and 0.5M Tris-borate-EDTA buffer (Hoefer, Holliston, MA). Nucleic acid was UV crosslinked, and the probes were detected using a chemiluminescent nucleic acid detection module
(Thermo Scientific). After washing, the blot was incubated for 5 min and developed using a
FluoroChem M system (ProteinSimple). RNase protection assays were performed at least three
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times.
Overexpression/complementation studies.
In order to overexpress algU, the coding sequence was amplified (Table 2.2) and cloned
into the integrating vector pTJ1 for complementation or overexpression (36). Trimethoprimresistant colonies were picked, cultured overnight, and diluted 1,000-fold on the following day.
The presence of the gene of interest was confirmed using primers pTJ1R and either algUTJ1F2
or algRTJ1F2. Cultures requiring induction used 1% arabinose and were grown for 8 h in broth
or overnight on agar plates.
Statistical analyses.
Statistical analyses were performed using Graph- Pad Prism (version 6.0) software
(GraphPad Software, La Jolla, CA). The results of transcriptional and translational fusions and
densitometry analysis were compared using a one-way analysis of variance (ANOVA) with
Tukey’s posttest. ImageJ software was used for Western blot analysis.
RESULTS
AlgU hyperactivity significantly contributes to rsmA expression in mucA mutant strains.
Previous studies using an rsmA translational fusion and/or Western blot analyses found
that RsmA levels increase throughout the growth phases (5, 21, 28), which suggests a role of the
stationary-phase sigma factor RpoS (37). Another study using a transcriptional fusion indicated
that a mucA strain has increased rsmA expression (14). Because the alternative sigma factor
AlgU is available in strains lacking functional MucA, AlgU has increased activity in this
background, and we postulated that AlgU might play a role in rsmA expression. To further
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Figure 2.1 Depiction of the rsmA genomic region, the promoters controlling rsmA
expression, and the reagents used in this study. (A) Schematic representation of the rsmA
genomic region. The sequences below the schematic represent those of the two potential
promoters. The bent arrows above the sequence indicate the transcriptional start sites identified
by primer extension analysis. The primers used in the primer extension experiments are
identified by bent arrows below the genomic schematic. The potential promoters are indicated
by a line underneath the sequence and are in bold. Potential sigma factor consensus sequences
are indicated below the sequence. The probe used for RNase protection assays is indicated
below, and position numbers are relative to the rsmA translational start site. (B) The rsmA-lacZ
transcriptional fusions constructed are indicated. Arrows indicate the primers used in the
construction of the transcriptional fusions. The position numbers above the arrows are in
relation to the rsmA translational start codon. The X indicates the site-directed mutagenesis of
the putative AlgU -35 consensus sequence.
understand rsmA regulation at a transcriptional level, an rsmA transcriptional fusion, TF1-lacZ,
was constructed by cloning the entire intergenic region between rsmA and lysC in the
transcriptional fusion vector miniCTXlacZ (Fig. 2.1) (38).
Due to posttranscriptional rsmA autoregulation (39), it was important that only
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transcription be monitored. The miniCTXlacZ vector allows insertion of single- copy lacZ fusion
integrants and contains an RNase III processing site to ensure that transcription is uncoupled
from posttranscriptional effects (38, 40). In wild-type strain PAO1, the TF1-lacZ fusion had bgalactosidase activity of 380 Miller units at 8 h (Fig. 2.2A). This result indicates that rsmA was
expressed at low levels at this time point. The fusion was also tested at additional time points,
including 16 h, and there was little change in TF1-lacZ activity (data not shown). In a ∆algU
strain, the TF1-lacZ transcriptional fusion had no decrease in TF1-lacZ activity at 8 h (Fig.
2.2A). A ∆rpoS mutant was constructed and assayed for rsmA expression. There was no
significant decrease in b-galactosidase activity at either 8 or 16 h (Fig. 2.2A). A ∆algU ∆rpoS
strain was constructed, and the TF1-lacZ transcriptional fusion was assayed. No change in TF1lacZ activity was seen in the double mutant. A ∆algR mutant had significantly increased rsmA
expression at 8 h (Fig. 2.2A). A previous study indicated that AlgR activates rsmA expression
(14), but the strain used, PA103, and the growth conditions differed from those used in our study.
Our results suggest that rsmA is expressed at low levels in wild-type strain PAO1 and its mutant
derivatives.
To further investigate the role of AlgU in controlling rsmA expression, the level of TF1lacZ fusion expression was measured in a mucA22 strain as well as the isogenic mucA22 ∆algU
nonmucoid derivative. As shown in Fig. 2.2A, a mucA22 strain had a ~3- fold increase in rsmA
expression compared to that in wild-type strain PAO1. In the mucA22 ∆algU strain, rsmA
transcriptional activity was reduced to the levels in wildtype strain PAO1 (Fig. 2.2A), confirming
that AlgU does control rsmA expression. The analysis of the TF1-lacZ transcriptional fusion
suggests that AlgU does play a role in regulating rsmA expression, but this effect is seen only
when mucA is mutated and not able to sequester AlgU. In addition, RpoS does not regulate rsmA
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Figure 2.2 AlgU activates rsmA expression in mucA mutants. (A) Analysis of TF1- lacZ
in mutant strains at 8 h of growth in LB broth. The TF1-lacZ transcriptional fusion was
inserted into the attB site in the chromosomes of the indicated strains. Transcriptional fusion
values are indicated as β-galactosidase activity. The values are the result of subtraction of the
value for PAO1 containing the vector (miniCTXlacZ) alone (28 Miller units) from all test
values. Fusion assays were all conducted at least three times. Determination of all significant
differences from the results for the wild type was performed using a one-way analysis of
variance and Tukey’s posttest. **, P < 0.01; ***, P < 0.001. (B) (Top) Western analysis of
RsmA in algU mutant strains. An rsmA-HA allele was constructed and introduced into
various strains via homologous recombination, the strains were grown for 8 h, and whole-cell
lysates were probed with anti-HA antibody. A single band was detected in all Western blots
using the strains containing the rsmA-HA allele. A representative Western blot is shown.
Western blot analysis was completed at least three times. The strains assayed are listed below
the bottom panel. PAO1 without the rsmA-HA allele was run as a negative control (data not
shown). (Bottom) Densitometry analysis was performed for each strain. Densitometry values,
determined using ImageJ software, were standardized by dividing the intensity of the band in
the Western blot by the intensity of the total protein in each lane stained with Coomassie. The
result for PAO1 was set equal to 1, and the values for the other strains were normalized using
the value for PAO1 as a reference. A one-way ANOVA with Tukey’s posttest was used to
determine statistical significance. ***, P < 0.0001.
48

under these conditions.
To determine if RsmA protein levels mirrored the findings of rsmA expression analysis,
we constructed a hemagglutinin (HA)- tagged rsmA allele that was introduced into strains by
allelic exchange. As shown in Fig. 2.2B, the mucA22 mutant had significantly higher RsmA
levels than wild-type strain PAO1. Densitometry analysis indicated that there was a significant
decrease in RsmA levels in the ∆algU mutant compared to those in wild-type strain PAO1 (Fig.
2.2B). The mucA22 ∆algU mutant showed a drastic decrease in RsmA levels compared to those
in the mucA22 strain (Fig. 2.2B). The results of Western blot analysis suggested that AlgU is
required for increased rsmA expression in mucA mutant backgrounds.
Identification of a second rsmA promoter
Because the sigma factor AlgU played a role in rsmA expression, the upstream region of
rsmA was inspected for possible promoter sequences. A potential AlgU consensus sequence is
located upstream of rsmA (Fig. 2.1A). To determine if this AlgU promoter is functional, we performed primer extension analysis. Total RNA was reverse transcribed using a radiolabeled
primer (rsmAPE1) specific for a sequence located within the rsmA coding region, and extension
products were detected on a denaturing polyacrylamide gel. Primer extension indicated that there
were two transcriptional start sites (Fig. 2.3A), which suggests that rsmA has an additional
promoter. The start site most distal to the coding region was identified as an A residue located 86
bp upstream of the predicted rsmA translational start codon. The first and closest transcriptional
start site was a G residue located 40 bp upstream of the rsmA coding region. Primer extension
analysis with an additional radiolabeled primer, rsmAPE3, produced a single extension product
and confirmed the presence of the A residue identified to be a transcriptional start site 86 bp
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upstream of rsmA (data not shown). The second transcriptional start site was independently
identified four times. Primer extension analysis with a third primer, rsmAPE4, whose sequence
overlapped the most distal transcriptional start site, failed to produce an extension product,
suggesting that rsmA has only two active promoters under the conditions tested.
Sequences upstream of the identified transcriptional start sites were examined for
potential promoters (Fig. 2.1A). Three previous studies identified using transcriptome
sequencing (25, 26) and 5’ rapid amplification of cDNA ends (24) a transcriptional start site that
is 40 nucleotides upstream of the rsmA translational start codon. The sequence of the proximal
promoter identified by our primer extension analysis resembled a sigma70 (RpoD) promoter
sequence. Therefore, the proximal promoter that we identified was the same promoter previously
identified, validating the findings of our primer extension analysis.
The second transcriptional start site has two possible promoter consensus regions
upstream. A potential AlgU consensus sequence GAACTT in the -35 region (Fig. 2.1A) (11) and
a potential RpoS -10 region are located upstream of this transcriptional start site. The potential
RpoS consensus sequence CAATACT differs from the RpoS consensus sequence CTATACT by
1 nucleotide (41). E. coli RpoS promoters frequently have an extended structure, denoted by a
G/T residue directly upstream of the conserved -10 region (42). The potential RpoS promoter
upstream of rsmA also follows this extended structure (Fig. 2.1A). The potential RpoS -10 region
overlaps the potential AlgU -10 region (Fig. 2.1A). On the basis of the results of primer
extension and sequence analyses, rsmA has a second promoter that is controlled by AlgU and/or
RpoS.
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AlgU controls the distal rsmA promoter
Because two rsmA transcripts were detected by primer extension (Fig. 2.3A), this led us
to test whether rsmA has two promoters. Two transcriptional fusions were constructed using the
data generated by primer extension analysis (Fig. 2.1) to confirm the promoter activity of these
regions. The activity of PAO1 carrying the vector alone (28 Miller units) was subtracted from the
values obtained. A transcriptional fusion, TF2-lacZ, was constructed by deleting the putative
distal promoter. TF2-lacZ has the 5’ end at position -74 in relation to the rsmA translational start
site and extends 18 nucleotides into the rsmA coding region (Fig. 2.1B). The transcriptional
fusion TF3- lacZ was constructed using the intergenic region from lysC to the distal
transcriptional start site at position +1 as the 3’ end of the fusion and therefore contains only the
putative distal promoter (Fig. 2.3B). When these fusions were analyzed in wild-type strain
PAO1, both fusions produced b-galactosidase activity (Fig. 2.3B and C), but the level of
expression was very low. The values for both the TF2-lacZ and TF3-lacZ fusions were much
lower than the value for TF1-lacZ, suggesting that the entire region is necessary for optimal
rsmA expression.
The TF2-lacZ transcriptional fusion was constructed and tested to determine the activity
of the proximal promoter. The TF2-lacZ fusion did not have increased reporter activity in the
mucA22 strain (Fig. 2.4B). When algU was deleted in either background, no decrease in reporter
activity was detected, indicating that this promoter was constitutively active at low levels in the
strains analyzed (Fig. 2.4C).
To determine if AlgU affected the distal promoter that we identified, the TF3-lacZ fusion
was analyzed in wild-type strain PAO1 and a ∆algU mutant. The activity of the TF3-lacZ fusion
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Figure 2.3 Identification of a second rsmA promoter region controlled by AlgU. (A)
Primer extension analysis was performed to identify the transcriptional start sites of rsmA.
Total RNA was reverse transcribed using a radiolabeled primer, rsmAPE1 (Table 2), and run
alongside the products of the sequencing reactions on a denaturing polyacrylamide gel. Lanes
G, A, T, and C, the sequencing ladder generated using the same primer used in the reverse
transcription reaction; lane 1, a control lane with total RNA without reverse transcriptase; lane
2, reverse-transcribed PAO1 RNA. Arrows, extension products. (B) b -Galactosidase activity
of chromosomal transcriptional fusion TF2-lacZ in the indicated strains tested in triplicate
after incubation in LB broth for 8 h at 37°C as described in the legend to Fig. 2A. The value
for PAO1 carrying the vector alone was subtracted from the value for each strain. (C) b Galactosidase activity of chromosomal transcriptional fusions of TF3-lacZ in the indicated
strains tested in triplicate after incubation in LB broth for 8 h at 37°C. The value for PAO1
carrying the vector alone was subtracted from the value for each strain. Transcriptional fusion
assays were performed at least three times. All significant differences from the wild type were
determined using a one-way analysis of variance and Tukey’s posttest. ***, P < 0.001.
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in PAO1 was low, and no difference in activity was seen when it was tested in a ∆algU mutant at
8 h. However, when the activity of the TF3-lacZ fusion was tested in a mucA22 strain, there was
an ~8-fold increase (Fig. 2.3C). The activity of the TF3-lacZ transcriptional fusion in a mucA22
∆algU strain was significantly reduced ~8- fold (Fig. 2.3C). These results show that the promoter
contained in the TF3-lacZ fusion is AlgU dependent.
Overexpression and complementation of algU increase rsmA expression
For overexpression of algU, we used an arabinose- inducible promoter to control algU
expression (43). As shown in Fig. 2.4A, there was a statistically significant increase in TF3-lacZ
activity when algU was induced with arabinose in strain PAO1. The results suggest a role for
AlgU in activating rsmA expression.
Additionally, the ∆algU mutant containing the TF3-lacZ transcriptional fusion was
complemented with pAlgU. When 1% arabinose was used to induce algU expression, TF3-lacZ
activity was also increased (Fig. 2.4B). Complementation and overexpression resulted in an
increase in TF3-lacZ activity. From these results, we conclude that AlgU is necessary for increased rsmA expression.
To determine if RsmA protein levels matched those of the transcriptional fusions, we
used the PAO1 rsmA-HA strain containing epitope-tagged rsmA. When algU expression was
induced by the addition of arabinose, there was a significant increase in RsmA levels (Fig. 2.4C).
On the basis of this result, it was determined that algU overexpression is able to increase rsmA
transcription.
Site-directed mutagenesis of the putative AlgU-binding site in the distal promoter reduces rsmA
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expression
Site-directed mutagenesis was performed on the TF3-lacZ transcriptional fusion to

Figure 2.4 AlgU overexpression and complementation confirm the AlgU regulation of
rsmA. (A and B) β−Galactosidase activity of the TF3-lacZ (A) and ∆algU TF3-lacZ (B)
constructs. (A) The algU gene was cloned into the integrating vector pTJ1 and induced with
1% arabinose. Strains were grown in LB broth for 4 h and induced with arabinose for 4 h.
PAO1 with the vector alone (pTJ1) was used as a negative control. Data from triplicate
experiments were averaged after subtraction of the value for PAO1 carrying the vector alone
(28 Miller units). (B) Complementation of the ∆algU strain containing the transcriptional
fusion TF3-lacZ was performed as described in the legend to panel A. (C) Overexpression of
algU increased RsmA protein levels. PAO1-HA/pTJ1 was the PAO1 strain with the rsmA-HA
allele and the vector alone. PAO1-HA/pAlgU contained the rsmA-HA allele and
overexpressed algU when arabinose was added. ImageJ software was used for densitometry
analysis, as described in the legend to Fig. 2B. (Top) A representative Western blot. Western
blot analysis was performed at least three times. (Bottom) Densitometry results for the
Western blots.
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determine if the putative AlgU consensus sequence was required for increasing rsmA expression.
The putative AlgU -35 sequence GAACTT was converted to GAATTC (underlined nucleotides
indicate changes introduced) (Fig. 2.5). There was a ~3- fold decrease in the level of
transcription in the mucA22 strain with the mutagenized AlgU promoter (Fig. 2.5). The results of
the site-directed mutagenesis experiment demonstrate the necessity of the conserved AlgU -35
sequence and strongly suggest that AlgU directly controls rsmA transcription by binding the
distal rsmA promoter.

Figure 2.5 The potential AlgU-binding site is required for increased rsmA expression in
a mucA22 mutant. The TF3-lacZ transcriptional fusion was engineered with two mutations
in the potential AlgU -35 consensus sequence (indicated by asterisks above the indicated
nucleotides in the sequence above the graph). The transcriptional start site (the 3= end of the
TF3-lacZ fusion) is indicated in bold. USDM indicates the fusion containing the mutation of
the conserved AlgU -35 consensus sequence. β-Galactosidase activity was determined as
described in Materials and Methods. Data from triplicate experiments were averaged after
subtraction of the value for PAO1 carrying the vector (28 Miller units). A one-way ANOVA
with Tukey’s posttest was used to determine statistical significance. ***, P < 0.0001.
AlgU regulation of rsmA is conserved
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To determine if AlgU control over rsmA is a conserved mechanism in other P.
aeruginosa strains, we investigated the role of AlgU in the clinical strains 2192 and 383. These
strains were isolated from a longitudinal study (44) and have been determined to be isogenic
(45). Strain 2192 is mucoid and has a mucA mutation (46). We took a genetic approach and
assayed our transcriptional fusions TF1-lacZ and TF3-lacZ to determine the role of AlgU in
activating rsmA expression in these strains (Fig. 2.6). Strain 2192 had an ~3-fold increase in the
amounts of both the TF1-lacZ fusion and the TF3-lacZ fusion compared to those in nonmucoid
strain 383 (Fig. 2.6A and B). These results demonstrate that the AlgU-dependent promoter
activity is increased in strain 2192 compared to that in its nonmucoid counterpart, strain 383. A
2192 ∆algU mutant was constructed, and assays for the expression of the TF1-lacZ and TF3lacZ fusions were performed to confirm a role for AlgU in other P. aeruginosa strains. As shown
in Fig. 2.6A and B, there was a statistically significant decrease in the levels of TF1- and TF3lacZ expression, supporting the role of AlgU in regulating the distal promoter. To confirm the
transcriptional fusion results, the levels of RsmA in the clinical strains were determined using the
rsmA-HA allele. RsmA levels were increased in strain 2192 compared to those in the nonmucoid
383-parent strain (Fig. 2.6C), suggesting that AlgU activated rsmA expression in strain 2192.
The 2192 ∆algU mutant had a significant decrease in the amount of RsmA compared to that in
2192 (Fig. 2.6C). On the basis of these results, it is likely that AlgU activates rsmA expression in
multiple strains.
RpoS involvement in the control of rsmA
There are conflicting data regarding RpoS control of rsmA expression (9, 27). The
potential RpoS-binding site upstream of rsmA implicated RpoS in the control of rsmA (Fig.
2.1A). However, the TF1-lacZ transcriptional fusion analysis did not demonstrate a decrease in
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Figure 2.6 Clinical mucA mutant strains have increased rsmA expression. (A and
B) β-Galactosidase activities of the TF1-lacZ (A) and TF3-lacZ (B) transcriptional
fusions. (A) The β-galactosidase activity of the TF1-lacZ transcriptional fusion was
assayed in clinical isolates 383 and 2192 and a 2192 ∆algU strain after 8 h, as
described in the text. Data from triplicate experiments were averaged after subtraction
of the value for PAO1 carrying the vector alone (28 Miller units). (B) The βgalactosidase activity of the TF3-lacZ transcriptional fusion was analyzed in strains
383, 2192, and 2192 ∆algU at 8 h, as described in the text. Data from triplicate
experiments were averaged after subtraction of the value for PAO1 carrying the vector
alone (28 Miller units). A one-way ANOVA with Tukey’s posttest was used to
determine statistical significance. ***, P < 0.0001 (C) RsmA levels are also increased
in clinical mucA mutants. The rsmA-HA allele was exchanged for the wild-type rsmA
allele in clinical isolates 383 and 2192. Whole-cell lysates were produced and probed
with anti-HA antibodies. PAO1 was used as a negative control (data not shown). The
results for PAO1-HA and mucA22-HA are shown for reference. (Top) A
representative Western blot. (Bottom) Results of densitometry analysis of the blot
performed using ImageJ software. Data are in arbitrary units and were produced from
three Western blots. Densitometry analysis was performed as described in the legend
to Fig. 2B.
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rsmA

expression in a ∆rpoS mutant. Because sigma factor competition on the distal promoter could
have influenced our ability to detect RpoS activity on the rsmA promoter (47), we tested a

Figure 2.7 RpoS is not a significant regulator of rsmA expression. (A) β-Galactosidase
activity of the TF2-lacZ transcriptional fusion in the denoted strains. Data from triplicate
experiments were averaged after subtraction of the value for PAO1 carrying the vector
alone (28 Miller units). (B) β-Galactosidase activity of the TF3-lacZ transcriptional fusion
in the denoted strains. β-Galactosidase activity was determined as described in the text.
Data from triplicate experiments were averaged after subtraction of the value for PAO1
carrying the vector alone (28 Miller units). Significant differences from the results for the
wild type were determined using a one-way analysis of variance and Tukey’s posttest.
***, P < 0.001.
double mutant, the ∆algU ∆rpoS mutant (Fig. 2.1A). No further decrease in TF1-lacZ activity in

58

the ∆algU ∆rpoS mutant was detected. To further define the role of RpoS in controlling rsmA
expression, we tested the TF2- and TF3-lacZ fusions for activity in either ∆rpoS strains or ∆algU
∆rpoS strains (Fig. 2.7). Interestingly, both a ∆rpoS mutant and a ∆algU ∆rpoS mutant had
significantly higher levels of activity when the TF2-lacZ promoter was used (Fig. 2.7A),
suggesting that RpoS has a negative effect on transcription from the proximal rsmA promoter.
No significant change was found when the TF3-lacZ transcriptional fusion was used in the ∆rpoS
or ∆algU ∆rpoS mutant strains (Fig. 2.7B). From these results, the role of RpoS in regulating
rsmA is inconclusive.
RpoS and AlgU are necessary for rsmA expression from the distal promoter
RNase protection assays (RPAs) were performed using an RNA probe specific for a
region spanning the entire rsmA coding region and 129 bp upstream of the rsmA gene (Fig. 2.1A)
to more directly analyze rsmA transcripts and better understand the role of AlgU and RpoS in
controlling rsmA expression. The probe also includes non-template-encoded nucleotides to
distinguish the full-length probe from protected fragments. As shown in Fig. 2.8, the RPAs
confirmed the findings of our primer extension and transcriptional fusion analysis by detecting
two rsmA transcripts in wild-type strain PAO1. The expected fragments were 281 bp and 235 bp,
on the basis of the probe used. This matched what was seen in the RPAs (Fig. 2.8). Interestingly,
the ∆algU mutant contained the same two transcripts as wild-type strain PAO1. When the ∆rpoS
mutant was analyzed, both transcripts were detected, with the amount of the first transcript
resulting from the amount of the proximal promoter being increased. A ∆algU ∆rpoS strain was
also analyzed, and the larger transcript resulting from the distal promoter completely
disappeared, demonstrating that both AlgU and RpoS contribute to transcription from the distal
promoter (Fig. 2.8). The mucA22 strain had both transcripts as well, with both transcripts having
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Figure 2.8 RPAs confirm the presence of two rsmA transcripts. RPAs of the
indicated strains were performed after RNA was harvested from cultures grown in LB
broth for 8 h at 37°C. Twenty micrograms of total RNA from the indicated strains was
hybridized with 800 pg of biotinylated probe and subjected to RNase treatment. After
RNase inactivation, RNA was precipitated from the samples and run on a 5% denaturing
polyacrylamide gel, transferred to a nylon membrane, UV cross-linked, and developed
using chemiluminescent detection. The undigested probe is indicated by the large arrow
at the top. The protected rsmA probe is indicated by the three smaller arrows. Shown is a
result representative of results from three RNase protection assays. Ladder, molecular
size markers.

greater intensities. The highest band in the ∆rpoS and mucA22 strains was likely undigested
probe.
Three controls were included in the RPA. Two of the controls were the probe incubated
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with yeast RNA; one of these was treated with RNase, and the other was not. As shown in Fig.
2.8, RNase treatment completely degraded the probe, which indicates that the probe did not bind
nonspecifically. The intact probe can be seen at ~330 bp in the lane in Fig. 2.8 labeled “probe
alone -RNase,” which is consistent with the additional nucleotides that are non-template
encoded. A ∆rsmA mutant was constructed and used as an additional control. In the ∆rsmA
mutant, there was only one discernible protected probe fragment at ~150 bp. On the basis of how
the ∆rsmA mutant was constructed, a protected fragment of 144 bp was expected. The results
obtained with the ∆rsmA strain support the suggestion that there are only two rsmA transcripts, at
least under the conditions used. Altogether, the results of the RPA suggested that there are two
rsmA transcripts and that both AlgU and RpoS are involved in controlling the distal promoter
region, suggesting overlapping promoters.
AlgU control of rsmA expression is responsible for RsmA activity in a P. aeruginosa mucA22
strain
Because AlgU increased RsmA levels, we hypothesized that RsmA activity was also increased in a mucA22 strain. We analyzed a variety of mutant strains, including strains that should
alter the activity of RsmA on the basis of the current RsmA paradigm (5). RetS interferes with
GacA phosphorylation, and mutation of retS should lead to increased production of the small
RNAs RsmY and RsmZ (18, 48). Therefore, the level of RsmA activity should be reduced. In
contrast, mutation of gacA should lead to a reduction in the amounts of the small RNAs RsmY
and RsmZ (49). In this case, increased RsmA activity should be observed. Mutants with
mutations in the gacA and retS genes were constructed in both the PAO1 and mucA22 strain
backgrounds.
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Figure 2.9 AlgU activation of rsmA leads to changes in tssA1 expression. (A) Schematic of
the genomic region of the RsmA-controlled genes tssA1 and fha1. Below the genomic
schematic is a depiction of the leader fusion that was constructed. The position numbers
above the fusion construct indicate those of the primers used relative to the tssA1 translational
start codon. (B) Analysis of a TssA1 leader translational fusion driven by the lacUV5
promoter in wild-type and mutant derivative strains. All assays were repeated at least three
times in triplicate. Data were normalized to the mean for PAO1. PAO1 activity with the
lacUV5-tssA1-lacZ fusion was 12 Miller units. A one-way ANOVA with Tukey’s posttest
was used to determine statistical significance. ***, P < 0.0001.
RsmA has previously been shown to affect the production of the exopolysaccharide genes
pel and psl (9, 16, 50). However, no studies have investigated the involvement of RsmA in
alginate production. We hypothesized that if RsmA inhibits biofilm formation, then RsmA would
inhibit alginate production. Interestingly, the mucA22 ∆gacA, mucA22 ∆retS, and mucA22
∆rsmA mutants still overproduced alginate (data not shown), and we conclude that RsmA does
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not affect alginate production.
RsmA posttranscriptional activity was tested using a tssA1 leader/translational fusion
containing the lacUV5 promoter and the tssA1 untranslated sequence, based on the study of
Brencic and Lory (5) (Fig. 2.9A). Due to the low level of activity of this reporter, the data are
presented as a percentage of the wild-type activity, where the values were normalized to those
for the PAO1 strain (12 Miller units). The mucA22 strain had fusion activity decreased ~3-fold
compared to that of PAO1 (Fig. 2.9B). There was no difference in activity between PAO1 and a
∆algU strain when the leader fusion was used (Fig. 2.9B). In the case of a mucA22 ∆algU strain,
there was a 5.5-fold increase in leader fusion activity compared to that in the mucA22 strain (Fig.
2.9B). These results suggest that RsmA is active in the mucA22 strain background and this is due
to AlgU regulation of rsmA.
Further confirmation of RsmA activity in the mucA22 strain was carried out using
mutants with mutations in gacA and retS, as described above. While the differences in activity
were not significant by statistical analysis, there was no activity from a mucA22 ∆gacA strain,
even after the reaction was allowed to proceed overnight. This result would be expected if RsmA
activity were increased due to the absence of the small RNAs RsmY and RsmZ (49). As there
was an increased amount of RsmA in the mucA22 strain due to AlgU activation of the distal
promoter, the difference between the mucA22 strain and the mucA22 ∆gacA strain should not be
so different if our hypothesis is correct (Fig. 2.10). The leader fusion also had increased activity
in both the mucA22 ∆rsmA and the mucA22 ∆retS strains compared to that in the mucA22 strain
(3-fold and 7-fold, respectively) (Fig. 2.9B). These results also indicate the RsmA activity in
the mucA22 strain background. The increased activity of the leader fusion indicates that the
absence of RsmA or an abundance of RsmY and RsmZ due to the absence of RetS allows greater
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Figure 10. Model depicting the expression and activity of rsmA and the protein that it
encodes, RsmA, in mucA mutant strains. Two transcripts of different sizes are produced.
AlgU and RpoS control the longer transcript originating from the distal promoter. In the mucA
strain background, AlgU increases the level of transcription from the distal promoter, but both
transcripts are increased in amount either by transcription initiation at both promoters or by
posttranscriptional processing of the longer message. Due to increased rsmA transcription,
there is an increased amount of RsmA in mucA mutants. Transcriptional start sites are
represented by bent arrows. The left and right bent arrows indicate the distal and proximal
promoters, respectively. The +1 indicates the putative translational rsmA start site. RsmA
levels increase, preventing translation of tssA1 and therefore production of the HSI-I T6SS.
The dashed curved arrow on the left side indicates that AlgU either directly or indirectly leads
to the activation of the tssA1 operon. RetS and GacA are depicted on the right to show how
they are incorporated in the RsmA scenario. GacA, when phosphorylated by GacS, activates
the expression of two small RNAs, RsmY and RsmZ, that bind and prevent RsmA from
performing posttranscriptional regulation. RetS interferes with GacA phosphorylation by
physically binding GacS and allows RsmA to regulate expression of mRNAs. The small
RNAs RsmY and RsmZ bind and prevent RsmA activity.

expression from the leader fusion. Altogether, these data suggest that RsmA activity is present in
a mucA22 strain.

64

DISCUSSION
RsmA is considered an important posttranscriptional regulator involved in the positive
regulation of acute virulence factors, such as the type III secretion system and motility (5, 14).
Little is known of the transcriptional regulation of rsmA. Initially, we undertook studies to
determine how rsmA was regulated in P. aeruginosa. We demonstrate that AlgU activates rsmA
expression and increases RsmA levels in a mucA22 mutant and a clinical isolate. Analysis of a
leader fusion to assess the posttranscriptional activity of the RsmA target, tssA1 (5), led us to
discover RsmA activity in the mucA22 strain. To our knowledge, this is the first demonstration
of RsmA activity in a mucA mutant strain of P. aeruginosa. Our work demonstrates that
increased rsmA expression due to AlgU activation leads to changes in the RsmA regulon. We
hypothesize that RsmA plays an important role during P. aeruginosa chronic infection and that
there are additional RsmA targets in mucA mutant strains.
One of the goals of this study was to determine how rsmA expression is regulated.
Previous studies have raised questions about how rsmA is regulated in P. aeruginosa (9, 14, 24).
In E. coli, five promoters control csrA (the orthologue of rsmA) expression (51). Only one rsmA
promoter was previously identified in P. aeruginosa (24–26), and a previous study indicated that
AlgR plays a role in regulating rsmA expression (14). Using primer extension, a new
transcriptional start site was identified, indicating a second rsmA promoter (Fig. 2.2). Both
transcriptional fusion analysis and RPA confirmed the presence of a second promoter (Fig. 2.3
and 2.8). Overexpression and Western blot analyses support a role of AlgU in controlling rsmA
expression (Fig. 2.1E and 2.4). However, when MucA is functional, such as in PAO1, it is
difficult to detect changes in rsmA expression. This explains the low levels of activity of the
transcriptional reporters (Fig. 2.1A and 2.2). The role of RpoS in controlling rsmA expression is
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somewhat less clear. While we were not able to detect RpoS regulation of rsmA by
transcriptional fusion analysis (Fig. 2.7), the results of RPA suggested that RpoS does play a role
(Fig. 2.8). Further studies are needed to determine the significance of RpoS in controlling rsmA
expression. A previous study identified AlgR to be a regulator of rsmA, rsmY, and rsmZ (14). It
is possible that AlgR and AlgU work together in regulating rsmA in mucA mutant strains. It is
clear that rsmA regulation is complex, but this work solidifies the role of AlgU as an rsmA
activator.
Our finding that AlgU controls rsmA expression is bolstered by the analysis of rsmA in
the clinical strains 2192 (mucoid) and 383 (nonmucoid) (45). These data indicate higher levels of
RsmA in the mucA mutant strain 2192 (Fig. 2.6). The findings of our regulation studies are
consistent with a previous observation that a mucA mutant had increased levels of rsmA
expression (14). Thus, our work implicates RsmA to be necessary for the persistence of P.
aeruginosa during chronic infections, because mucA mutants are found at later time points
during infection. This is consistent with the requirement of Helicobacter pylori, which requires
CsrA (the RsmA orthologue) for persistence in the stomach (52). Whether RsmA participates in
regulating virulence factors in mucA mutant strains is currently not known and is an unexplored
area.
After finding that AlgU, an important sigma factor in chronic infections (7), regulates
rsmA expression, we asked if the increased RsmA levels have activity in mucA mutant strains.
Our results support a model (Fig. 2.10) where RsmA activity in the mucA mutant background is
due to AlgU. First, using the tssA1 leader fusion, the mucA22 strain showed decreased activity,
indicating in- creased posttranscriptional regulation compared to that in PAO1. Second, the
mucA22 ∆algU strain had increased leader fusion activity compared to that of the mucA22 strain,
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which supports our conclusion that increased rsmA expression leads to increased RsmA activity.
This result also demonstrates the importance of AlgU control of rsmA expression. Third, the
increase in the fusion activity in the mucA22 ∆rsmA strain compared to that in the mucA22 strain
was greater than the increase in the ∆rsmA mutant of PAO1. Further support for RsmA activity
in mucA mutant strains comes from the increased leader fusion activity of the mucA22 ∆rsmA
and mucA22 ∆retS strains compared to that of the mucA22 strain. An alternative explanation of
our data is that some other form of posttranscriptional regulation occurs independently of RsmA.
However, the gacA and retS mutants are known to regulate RsmA activity, even though rsmA is
expressed in these strains (data not shown). We do not favor this alternative hypothesis, as
previous studies have determined that GacA controls only rsmY and rsmZ expression (21, 49).
Another posttranscriptional regulator, RsmF/RsmN, is also known to control tssA1 expression
(24, 53). This could possibly have affected the fusion results found in the present study as well
and may explain the increased expression of the tssA1 leader fusion in the mucA22 ∆retS strain.
Regardless, the results still indicate increased posttranscriptional regulation of tssA1 in a mucA22
strain.
The results of a proteomic study of the isogenic clinical strains 383 and 2192 also support
our findings. In this study, the mucoid strain 2192 has decreased amounts of HSI-I T6SS
components, whereas the nonmucoid strain has increased HSI-I T6SS components (54). If the
level of RsmA was increased due to AlgU in mucoid strain 2192, as presented here (Fig. 2.6),
then the proteomic analysis suggests that RsmA is responsible for the decreased amounts of HSII T6SS components in mucoid strain 2192. We are currently examining RsmA activity in other
clinical isolates.
However, a previous study did not find that RsmA posttranscriptionally regulates tssA1 in
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a mucA mutant (14). A possible reason for the discrepancy between the findings of that study and
those of our study is that different strains and growth conditions were used. In addition, the
previous study found that rsmY and rsmZ expression are increased in a PA103 mucA mutant (14).
We analyzed rsmY and rsmZ expression using transcriptional fusions and also found the same
result (data not shown). It is not known how RsmA functions if RsmY and RsmZ levels are
increased, and this requires further investigation. One possibility is that the promoter fusions do
not accurately monitor the levels of the small RNAs. We are directly measuring RsmY and
RsmZ levels in a mucA mutant strain to determine if this is the case. If RsmY and RsmZ levels
are increased and there is still RsmA activity, then we speculate the higher-affinity target
mRNAs present compete with RsmY and RsmZ. Alternatively, other factors that appropriately
direct RsmA to its targets, even in the presence of RsmY and RsmZ, exist.
The P. aeruginosa mucA mutant strains provide a snapshot of some of the bacteria found
in the lungs of patients with cystic fibrosis during chronic infection. The use of mucA mutant
strains may help provide an understanding of the factors required for persistence and adaptation
in the lung environment. For instance, the overproduction of alginate by mucA mutant strains
provides a competitive advantage by sequestering free radicals, preventing complement attack,
and inhibiting phagocytosis (55). Our data suggest that RsmA also plays a role in chronic
infections, such as those that occur in the lungs of cystic fibrosis patients. The RsmA regulon
may have additional targets in mucA mutant backgrounds that have not yet been discovered. An
understanding of RsmA in both acute and chronic infections may provide new ways to combat P.
aeruginosa.
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ABSTRACT
Pseudomonas aeruginosa is an important pathogen of the immunocompromised, causing
both acute and chronic infections. In cystic fibrosis (CF) patients, P. aeruginosa causes chronic
disease. The impressive sensory network of P. aeruginosa allows the bacterium to sense and
respond to a variety of stimuli found in di- verse environments. Transcriptional regulators,
including alternative sigma factors and response regulators, integrate signals changing gene
expression, allowing P. aeruginosa to cause infection. The two-component transcriptional
regulator AlgR is important in P. aeruginosa pathogenesis in both acute and chronic infections.
In chronic infections, AlgR and the alternative sigma factor AlgU activate the genes responsible
for alginate production. Previous work demonstrated that AlgU controls rsmA expression. RsmA
is a posttranscriptional regulator that is antagonized by two small RNAs, RsmY and RsmZ. In
this work, we demonstrate that AlgR directly activates rsmA expression from the same promoter
as AlgU. In addition, phosphorylation was not necessary for AlgR activation of rsmA using algR
and algZ mutant strains. AlgU and AlgR appear to affect the antagonizing small RNAs rsmY and
rsmZ indirectly. RsmA was active in a mucA22 mutant strain using leader fusions of two RsmA
targets, tssA1 and hcnA. AlgU and AlgR were necessary for posttranscriptional regulation of
tssA1 and hcnA. Altogether, our work demonstrates that the alginate regulators AlgU and AlgR
are important in the control of the RsmA posttranscriptional regulatory system. These findings
suggest that RsmA plays an unknown role in mucoid strains due to AlgU and AlgR activities.
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IMPORTANCE
P. aeruginosa infections are difficult to treat and frequently cause significant mortality in
CF patients. Understanding the mechanisms of persistence is important. Our work has
demonstrated that the alginate regulatory system also significantly impacts the
posttranscriptional regulator system RsmA/Y/Z. We demonstrate that AlgR directly activates
rsmA expression, and this impacts the RsmA regulon. This leads to the possibility that the
RsmA/Y/Z system plays a role in helping P. aeruginosa persist during chronic infection. In
addition, this furthers our understanding of the reach of the alginate regulators AlgU and AlgR.
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INTRODUCTION
The opportunistic pathogen Pseudomonas aeruginosa possesses multiple virulence
factors for causing disease. This allows P. aeruginosa to cause both acute and chronic infections.
Acute infecting strains are characterized by the presence of type IV pili (T4P), flagella, and a
type III secretion system (T3SS) (1–3). In contrast, chronic infecting strains diversify (4, 5) and
frequently do not express T3SS, T4P, or flagella (6, 7). Chronic infecting strains often form
biofilms composed of exopolysaccharides, such as alginate, and signal a decline in lung function
in CF patients (8–11). Alginate biosynthesis requires activation of the alternative sigma factor
AlgU (12, 13) and the two-component transcriptional regulator AlgR (12, 14, 15).
Two-component signal transduction systems are important in regulating the bacterial
response to environmental conditions. AlgR controls both acute and chronic virulence genes
(16–18). In the case of acute infections, AlgZ phosphorylates AlgR and activates the fimU
operon encoding minor pilins important in pilus biogenesis (19–21). The production of alginate,
indicative of chronic infection, does not require AlgR phosphorylation (22). This fact has been
demonstrated by deletion of the histidine sensor kinase gene algZ (23) and by the expression of
an algR mutant allele encoding an asparagine in place of the conserved aspartate (22).
In chronic P. aeruginosa infections, the bacteria frequently acquire spontaneous mucA
mutations that free the alternative sigma factor AlgU (12, 14, 24–26). AlgU and AlgR regulate
the alginate biosynthesis genes producing mucoid colonies (12). In addition, AlgR decreases the
expression of acute virulence factors, such as the T3SS in chronic infections when mucA
mutations occur (7, 27). Therefore, AlgR has multiple roles depending on the type of infection
and the phosphorylation state of AlgR: phosphorylated in acute infections activating the fimU
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operon and unphosphorylated in chronic infections activating alginate biosynthesis.
Previous work implicated the AlgZ/R system in the control of rsmA expression (28), but
a mechanism for AlgR activation of rsmA was not investigated. RsmA is considered a global
regulator that controls the expression of many P. aeruginosa genes by binding to mRNAs (29).
Two noncoding RNAs, RsmY and RsmZ, counteract RsmA (29, 30). In this study, we sought to
determine how AlgR activates rsmA and further investigate the role of RsmA in P. aeruginosa
strains containing an mucA mutation. We further examined rsmY and rsmZ expression in algR
mutant strains.
We demonstrate that AlgR directly activates rsmA expression in a phosphorylationindependent manner and that both AlgR and AlgU are important in activating rsmA expression in
mucoid strains. The activity of RsmA is not thought to be significant in chronic infecting strains,
such as mucA mutants. However, we also provide evidence that RsmA is active in mucoid P.
aeruginosa. Altogether, our work shows that the two-component regulator AlgR can affect gene
expression through RsmA, providing another mechanism for how AlgR impacts virulence gene
regulation. We postulate that AlgR and RsmA likely function as a rheostat, as opposed to a
switch, and suggest that RsmA plays a role in chronic infections.

MATERIALS AND METHODS
Strains, plasmids, and media.
The strains used in this study are presented in Table 1. Escherichia coli strains were
maintained on LB (Difco) plates or broth without or with antibiotics as appropriate.
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Pseudomonas aeruginosa strains were grown on Pseudomonas isolation agar (PIA), LB, or
Vogel-Bonner minimal medium (64) and supplemented with the appropriate concentration of
antibiotics. For E. coli, antibiotics were used at the following concentrations when appropriate:
10 µg/ml tetracycline, 15 µg/ml gentamicin, 100 µg/ml ampicillin, and 35 µg/ml kanamycin. For
Pseudomonas strains, antibiotics were used at the following concentrations: 150 µg/ml
gentamicin, 50 µg/ml tetracycline, and 300 µg/ml carbenicillin. For allelic exchange, sucrose
was supplemented at 10% in YT (1% tryptone and 0.5% yeast extract) medium.
Table 1. Strains and plasmids used in this study.
Strain or plasmid
Genotype or relevant propertiesa

Reference or
source

E. coli strains
NEB5α

fhuA2 Δ(argF-lacZ)U169 phoA
ø80Δ(lacZ)M15 gyrA96

New England
BioLabs

pRK2013

Helper strain

67

pEX18Tc

Allelic exchange vector

66

pEX18Gm

Allelic exchange vector

66

pEX18Tc ΔrsmA

31

pEX18Tc ΔalgR

Allelic exchange for rsmA nonpolar
deletion
Allelic exchange for algR nonpolar deletion

algZHSDM/pEX18Gm

Allelic exchange for making algZ mutant

This study

rsmAHA/pEX18Gm

Allelic exchange for rsmA HA allele

31

pGEX4T-3

GST fusion vector

GE Healthcare

Plasmids

81

31

pGEX4T-3 algR

GST fusion vector AlgR purification

This study

miniCTXlacZ

Transcriptional fusion vector

73

rsmATF1-lacZ

Transcriptional fusion

31

rsmATF3-lacZ

Transcriptional fusion

31

rsmATF2-lacZ

Transcriptional fusion

31

rsmYTF1-lacZ

Transcriptional fusion

This study

rsmYTF2-lacZ

Transcriptional fusion

This study

rsmYTF3-lacZ

Transcriptional fusion

This study

rsmZTF1-lacZ

Transcriptional fusion

This study

rsmZTF2-lacZ

Transcriptional fusion

This study

lacUV5CTXCP

Transcriptional fusion

This study

lacUV5 tssA-lacZ

Leader fusion vector

This study

lacUV5 hcnA-lacZ

tssA1 leader fusion

This study

PAO1

Wild type

74

ΔalgR mutant

algR mutant

75

D54N mutant

This study

algZ mutant

algR with asparagine instead of aspartate at
residue 54 algR
algR with glutamate instead of aspartate at
residue 54
algZ mutant

mucA22 mutant

mucA22 mutant
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mucA22 ΔalgR mutant

mucA22 ΔalgR mutant

This study

mucA22D54N mutant

mucA22 mutant strain with algR with
asparagine instead of aspartate at residue 54
mucA22 mutant strain with algR with
glutamate instead of aspartate at residue 54
mucA22 mutant strain, algZ mutation

This study

P. aeruginosa strains

D54E mutant

mucA22D54E mutant
mucA22 algZ mutant

82

This study
This study

This study
This study

ΔrsmA mutant

rsmA nonpolar deletion

31

mucA22 ΔrsmA mutant

rsmA nonpolar deletion in mucA22 strain

31

ΔrsmY mutant

rsmY nonpolar deletion mutant

This study

ΔrsmZ mutant

rsmZ nonpolar deletion mutant

This study

PAO1 rsmATF1-lacZ

rsmA transcriptional fusion strain

31

ΔalgR TF1-lacZ mutant

rsmA transcriptional fusion strain

31

D54N rsmATF1-lacZ mutant

rsmA transcriptional fusion strain

This study

D54E rsmATF1-lacZ mutant

rsmA transcriptional fusion strain

This study

mucA22D54N rsmATF1-lacZ

rsmA transcriptional fusion strain

This study

mutant mucA22D54E
rsmATF1-lacZ mutant

rsmA transcriptional fusion strain

This study

mucA22 algZ mutant

rsmA transcriptional fusion strain

This study

mucA22 TF1-lacZ mutant

rsmA transcriptional fusion strain

31

mucA22 ΔalgR rsmATF1-lacZ
mutant

rsmA transcriptional fusion strain

31

PAO1 rsmATF3-lacZ

rsmA transcriptional fusion strain

31

ΔalgR rsmATF3-lacZ mutant

rsmA transcriptional fusion strain

31

mucA22 TF3-lacZ mutant

rsmA transcriptional fusion strain

31

mucA22 ΔalgR rsmATF3-lacZ
mutant

rsmA transcriptional fusion strain

This study

PAO1 rsmATF2-lacZ

rsmA transcriptional fusion strain

This study

ΔalgR rsmATF2-lacZ mutant

rsmA transcriptional fusion strain

This study
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mucA22 rsmATF2-lacZ mutant

rsmA transcriptional fusion strain

This study

mucA22 ΔalgR rsmATF2-lacZ
mutant

rsmA transcriptional fusion strain

This study

PAO1 rsmYTF1-lacZ mutant

rsmY transcriptional fusion strain

This study

ΔalgR rsmYTF1-lacZ mutant

rsmY transcriptional fusion strain

This study

algZ rsmYTF1-lacZ mutant

rsmY transcriptional fusion strain

This study

mucA22 rsmYTF1-lacZ mutant

rsmY transcriptional fusion strain

This study

mucA22 ΔalgR rsmYTF1-lacZ
mutant

rsmY transcriptional fusion strain

This study

mucA22 algZ mutant

rsmY transcriptional fusion strain

This study

PAO1 rsmYTF2-lacZ

rsmY transcriptional fusion strain

This study

ΔalgR rsmYTF2-lacZ mutant

rsmY transcriptional fusion strain

This study

mucA22 rsmYTF2-lacZ mutant

rsmY transcriptional fusion strain

This study

mucA22 ΔalgR rsmYTF2-lacZ
mutant

rsmY transcriptional fusion strain

This study

84

PAO1 rsmYTF3-lacZ

rsmY transcriptional fusion strain

This study

mucA22 rsmYTF3-lacZ mutant

rsmY transcriptional fusion strain

This study

PAO1 rsmZTF1-lacZ

rsmZ transcriptional fusion strain

This study

ΔalgR rsmZTF1-lacZ mutant

rsmZ transcriptional fusion strain

This study

algZ rsmZTF1-lacZ mutant

rsmZ transcriptional fusion strain

This study

mucA22 mutant

rsmZ transcriptional fusion strain

This study

mucA22 ΔalgR rsmZTF1-lacZ
mutant

rsmZ transcriptional fusion strain

This study

mucA22 algZ rsmZTF1-lacZ
mutant

rsmZ transcriptional fusion strain

This study

PAO1 rsmZTF2-lacZ

rsmZ transcriptional fusion strain

This study

mucA22 rsmZTF2-lacZ mutant

rsmZ transcriptional fusion strain

This study

PAO1HA

PAO1 with epitope-tagged RsmA

31

ΔalgRHA mutant

ΔalgR mutant with epitope-tagged RsmA

This study
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mucA22HA mutant

mucA22 mutant with epitope-tagged RsmA

31

mucA22 ΔalgRHA mutant

mucA22 ΔalgR mutant with epitope-tagged
RsmA

This study

PAO1 lacUV5 hcnA-lacZ
mutant

PAO1 with hcnA leader fusion

This study

mucA22 lacUV5 hcnA-lacZ

mucA22 mutant with hcnA leader fusion

This study

mucA22 ΔrsmA lacUV5 hcnAlacZ mutant

mucA22 ΔrsmA mutant with hcnA leader
fusion

This study

mucA22 ΔalgU lacUV5 hcnAlacZ mutant

mucA22 ΔalgU mutant with hcnA leader
fusion

This study

mucA22 ΔalgR lacUV5 hcnAlacZ mutant

mucA22 ΔalgR mutant with hcnA leader
fusion

This study

PAO1 lacUV5 tssA1-lacZ

PAO1 with tssA1 leader fusion

This study

mucA22 lacUV5 tssA1-lacZ
mutant

mucA22 mutant with tssA1 leader fusion

This study

mucA22 ΔrsmA lacUV5 tssA1lacZ mutant

mucA22 ΔrsmA mutant with tssA1 leader
fusion

This study

mucA22 ΔalgU lacUV5 tssA1lacZ mutant

mucA22 ΔalgU mutant with tssA1 leader
fusion

This study

mucA22 ΔalgR lacUV5 hcnAlacZ mutant

mucA22 ΔalgR mutant with tssA1 leader
fusion

This study
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Mutant construction
All PCR products were amplified from P. aeruginosa PAO1, unless otherwise noted,
using Q5 polymerase (New England BioLabs). Crossover PCR (SOE’ing) (65) was used to
construct deletion mutations and to clone into the suicide vector pEX18Tc or pEX18Gm (66).
All cloned constructs were confirmed via sequencing. P. aeruginosa strains were conjugated
with E. coli as a donor strain and the pRK2013-containing helper strain (67). Conjugations were
performed overnight on LB plates at 30°C, and conjugations were plated for single-crossover
mutants on the appropriate selective media. Merodiploids were grown without selection and then
screened for sucrose sensitivity on YT–10% sucrose plates. Mutations were confirmed using
PCR with primers containing the suffix intF and intR shown in Table 3.2 and sequencing of the
resulting PCR fragment. Hemagglutinin (HA) tagging of proteins was accomplished using
primers containing the HA tag at the 3’ end of the gene and introduced as described above using
the suicide vector pEX18Gm.
Table 2. Primers used in this study.
Primer Name
algRTJ1F2

Sequence
GCGCCCATGGGAATGAATGTCCTGATTGTCG
ATGAC
GCGCAAGCTTTCAGAGCTGATGCATCAGAC
GC
GCAACTGGACTGGCAGGTGC
CGCGACTGGTCATCGGCAG
GCGCGGATCCGTCAGAGCTGATGCATCAGA
CG

Use
Overexpression

algZHindIIIF

GCGCAAGCTTCTCTCGCTGCAACAAGAAAC
GG

Mutant

algZSDMcheckF
algRD54XbaIF

CAGCTGGGCGGAGAACTGAC
AACATCCGCATGCCCGGTCTAGACGGC

Mutant
Mutant

algRTJ1R
algRintF
algRintR
algRBamHIR
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Overexpression
Mutant
Mutant
Mutant

algRD54NR
algRD54EF
algRD54ER
algZHSDMF
algZHSDMR
rsmARXbaI
rsmAFHindIII
rsmASDMcheckF
rsmAHAF
rsmAHAR
rsmASDMAlgUF
rsmASDMAlgUR
rsmYRPART72
rsmYRPAF
rsmYT7RPAR
rsmZRPAT72
rsmZRPAF
rsmZRPART7
rsmYTFFEcoRI
rsmYTFRBamHI
rsmYTFFUAS
rsmYshortEcoRIF
dnrTFRBamHI
rsmZKpnIF
rsmZXbaIR
rsmZSOEF
rsmZSOER
rsmZIntF
rsmZintR
rsmYKOF
rsmYKOR
rsmYSOEF

CAGCAGGACGATATCGGGCTTGA
GTCCTTCTAGAGATCCGCATGC
GATATCGGGCTTGAGGCTGTCG
GAATTCCTGTTCAACAGCCTGAACAG
CGGGCGAATCCGCGCCTGCA
GCGCTCTAGAGCACGGTGATCCTGCAGACC
GCGCAAGCTTCGGCAACATCACCACGCTGG
G
GCCAAGGTTTCCATCGTCGG
TACCCATACGATGTTCCAGATTACGCTTA
ATTTTTATCTAATTTTCCCTTTGC
TTAAGCGTAATCTGGAACATCGTATGGGT
AATGGTTTGGCTCTTGATCTTTCTC
CAGAATTCTTCATTCCGGCGGGACTG
CCAAACGGTCAAAAACGACAAAAG
ATGCTAATACGACTCACTATAGGGAGACTG
ACATCCGTGCTACGCCAC
CTTGGACGTCAGGACATTGCGCAGGAAG
TAATACGACTCACTATAGGGAGACAATAAA
AAACCCCGCCTTTTGGG
ATGCTAATACGACTCACTATAGGGAGAGTAT
TACCCCGCCCACTCTTCA
GGGCCCCACTCCTGCGTACAGGGAACAC

Mutant
Mutant
Mutant
Mutant
Mutant
Mutant
Mutant
PCR check
HA allele
HA allele
SDM
SDM
RPA
Northern
Northern
RPA
Northern

TAATACGACTCACTATAGGGAGACAAAAAA
AAGGGGCGGGGTATTAC
GCGCGAATTCGTGTTGCCGTCGGTCCGGC
GCGCGGATCCTTCCTGCGCAATGTCCTGACG
GCGCGCGGCCGCCAGCGTGTAAGCCAAGGC
TTAC
GCGCGAATTCAAACGGCGGTGGTTTTGGCTG
GCGCGGATCCCCATGCTGGGAAGGCTCGC
GCGCGGTACCCGTCTGGCGCAGAAGGGCG
GCGCTCTAGAGAGCGAAACCGCCAACATCC
GTTTTCTGGCAGGTTGCGGGATTTGCCTGCC
GTTTTACTCGTC

Northern

GACGAGTAAAACGGCAGGCAAATCCCGCAA
CCTGCCAGAAAAC
GCGCGCGGCCGCACCGATCCGTGCGAGCTG
CATGCAGGAATTCATCGAGCTG
CGCGGAGCTCCTGTTCACTCGAAGCACTCCA
G
CGCGTCTAGATTCGCCAACTCCGCTATTTCG
GCGTAATCTTCAAACCGTCAGGATCCTGCGG

Mutant
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TF
TF
TF/RPA
TF
TF
Mutant
Mutant
Mutant

Mutant
Mutant
Mutant
Mutant
Mutant

rsmYSOER
rsmYintF
rsmYintR
tssA1annealF
tssA1annealR
5SrRNAI

CCCGAGGAAAACCGCGTCG
CGACGCGGTTTTCCTCGGGCCGCAGGATCCT
GACGGTTTGAAGATTACGC
CCTGGAGCTGGACGGGAG
GGAATTCAGGAAGGTGTCCC
GATCCTTCGATGATAGGGAGATCGTCACCGT
GCTG
CAGCACGGTGACGATCTCCCTATCATCGAAG
TTGGACAGGATGGGGTTGGA

Mutant
Mutant
Mutant
Leader fusion
Leader fusion
Northern

5SrRNA2T7

TAATACGACTCACTATAGGGA
GACGATTGTGTGTTGTAAGG

Northern

lacZScaIF

GCTATGACCATGATTAGTACTGATTCACTGG
CCGTC
CCCCTCGAGCAGACATGGCCTGCCCGGTTAT
TA
GATGTGCTGCAAGGCGATTAAG
ATCGCAACTCTCTACTGTTTCTC
GAATTCGGCAGGAACTTTCATTCCGGC
TAATACGACTCACTATAGGGAGAGATAAAA
ATTAATGGTTTGGCTCTTG
CCTTTTGTCGTTTTTGAGAATTCGGCAGGAA
CTTTCATTC
GAATGAAAGTTCCTGCCGAATTCTCAAAAAC
GACAAAAGG
CGCCTCCTGGCGCTACCGTTCGTCCCTCCGA
CACCCCTGCTGCGTCGC

TLF vector

algDBS1R

GCGACGCAGCAGGGGTGTCGGAGGGACGAA
CGGTAGCGCCAGGAGGCG

Gel Shift

rsmARBS1F

GCGCCTTTTGTCGTTTTTGACCGTTTGGCAG
GAACTTTCATTCCG
CGGAATGAAAGTTCCTGCCAAACGGTCAAA
AACGACAAAAGGCGC

Gel Shift

CGGCTGGGTGTTGCCGTCGGTCCGGCGAGCG
GAACTATTACAGCG
CGCTGTAATAGTTCCGCTCGCCGGACCGACG
GCAACACCCAGCCG
GCTGGCGGAGTGTCGCCGGGAACTGGCCAG
AGG

Gel Shift

lacZRXhoI
lacZRforTF
pHERDSF
rsmASDMAlgRF
rsmARPAR
rsmARSDMF
rsmARSDMR
algDBS1F

rsmARBS1R

rsmYRBS1F
rsmYRBS1R
pscFRBSF

89

TLF vector
SEQ
SEQ
RPA
RPA
Gel Shift
Gel Shift
Gel Shift

Gel Shift

Gel Shift
Gel Shift

pscFRBSR
rsmYEMSAR2
rsmZEMSAR2
rsmAPE1F
rsmAPE3F
rsmAPE3R

CCTCTGGCCAGTTCCCGGCGACACTCCGCCA
GC
GGGCGGGGTTTTGCAGACCT
GTATTACCCCGCCCACTCTTCA
GCGCGGTACCAAGGATCGCGCTCTTGATTTC
TGCGGATCCGCCGCCATTTCTT
GCGCGGTACCGCTGACAGGCGAAAGGCG
GCGCGGATCCTCACCCAGTATTGACCAGTCC

Gel Shift
Gel Shift
Gel Shift
Gel Shift
Gel Shift
Gel Shift

rsmAEcoRIR

GCGCGAATTCACGAGTCAGAATCAGCATTCC
Gel shift
TTTC
rsmAR1SDMannealF CCGCGGAATTCGTCGTTTTTGACCGTTTGGC
Gel Shift
AGGAACTTTC
rsmAR1SDMannealR GAAAGTTCCTGCCAAACGGTCAAAAACGAC
Gel Shift
GAATTCCGCGG
rsmAR2SDMannealF CCGCGGAATTCGTCGTTTTTGAGAATTCGGC
Gel Shift
AGGAACTTTC
rsmAR2SDMannealR GAAAGTTCCTGCCGAATTCTCAAAAACGAC
Gel Shift
GAATTCCGCGG
rsmAGSWTannealF CCGCGCCTTTTGTCGTTTTTGACCGTTTGGCA
Gel Shift
GGAACTTTC
rsmAGSWTannealR
GAAAGTTCCTGCCAAACGGTCAAAAACGAC
Gel Shift
AAAAGGCGCGG
Abbreviations: TF, transcriptional fusion, TLF, translational fusion, LF, leader fusion, SEQ,
sequencing primer; RPA, RNase protection assay
algR mutant construction
The wild-type algR genomic region was amplified using Q5 (NEB) and primers
algRXbaIR and algRHindIIIF and cloned into pEX18Tc. Site-directed mutagenesis was
performed using the algRD54XbaIF/algRD54NR primers for the D54N allele or the
algRD54EF/algRD54ER primer pair for the D54E mutation. The algZ mutant was constructed
using the algZHSDMF/algZHSDMR primers. The primers were phosphorylated and used in sitedirected mutagenesis, in accordance with the manufacturer’s instructions, using Q5 (NEB).
Constructs were analyzed by restriction enzyme analysis and sequencing. Mutant strains were
constructed using homologous recombination, as described above, and were checked using PCR
and the algRintF/algRintR primer pair and digestion with the appropriate restriction enzyme.
90

Additional PCR amplicons were sequenced to confirm the mutation in each strain using the same
primers. Further confirmation of mutants was done using phenotypic assays.
Transcriptional and translational leader fusion analysis
Upstream DNA fragments containing promoter regions were generated by using primers
listed in Table 1 in conjunction with Q5 polymerase (New England BioLabs). PAO1 genomic
DNA was used as the template. PCR products were cloned into pMiniT (NEB) and then
subcloned into miniCTXlacZ using the restriction enzymes HindIII and BamHI, HindIII and
EcoRI, or KpnI and BamHI (NEB). The rsmA transcriptional fusions have been previously
described (31). To construct rsmY and rsmZ transcriptional fusions, the
rsmYTFFEcoRI/rsmYTFR and rsmZTFF/rsmZTFR primer pairs, respectively, were used. PCR
products were purified, cut with restriction enzymes, and inserted into the EcoRI and BamHI
sites of miniCTXlacZ using T4 DNA ligase (NEB). The leader fusion vector was constructed by
annealing the lacUV5NotI/lacUV5BamHI primer pair together and cloning into the NotI/BamHI
site of CTXCP (31). Translational/leader fusions were constructed using the tssA1annealF/R and
hcnAannealF/R primer pairs (Table 1) and were cloned into the ScaI/BamHI site of the leader
fusion vector. Fusion constructs were confirmed by sequencing and conjugated into P.
aeruginosa strains by triparental conjugation. Strains were selected for tetracycline resistance
and then conjugated with pFLP2 to remove vector sequences (66). Strains were selected for
carbenicillin resistance, grown overnight without selection, and plated on YT medium with 10%
sucrose to select for the loss of pFLP2. Individual colonies were patch-plated onto VBMM
CB300 and PIA to ensure the loss of pFLP2. To confirm the presence of the fusion constructs,
PCR was performed using the forward primer used to construct the fusion and the reverse primer
lacZRforTF (Table 1). b -Galactosidase activity was determined by incubating cell extracts with
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o-nitrophenyl- b -D-galactopyranoside (ONPG) (4 mg/ml), as described by Miller (68). A strain
carrying the empty vector miniCTXlacZ was also conjugated into PAO1 and assayed, and this
background (28 Miller units) was subtracted from all transcriptional fusions. The
translational/leader fusion backbone CTXCPlacUV5 had no background activity. All mucoid
strains were confirmed mucoid at the end of each experiment by plating on PIA plates to ensure
all colonies were mucoid. Three biological replicates were reproduced for all assays.
AlgR purification
The algR gene was PCR amplified using Q5 (NEB) and PAO1 chromosomal DNA using
oligonucleotides algRSal1F and algRNot1R (Table 1). A 754-bp SalI/NotI fragment was cloned
into pGEX-4T-3 (Novagen) to be expressed as a glutathione S-transferase–AlgR (GST-AlgR)
fusion protein. The resulting plasmid (pGEX-4TAlgR) was transformed into E. coli BL21(DE3)
(NEB) cells and incubated overnight. The colonies from this transformation were collected,
inoculated into LB supplemented with 100 µg/ml ampicillin, and grown to an optical density at
600 nm (OD600) of 0.6; 0.2 mM isopropyl-b-D- galactopyranoside (IPTG) was added to induce
AlgR expression for 4 h at 15°C. The cells were collected by centrifugation (6,740 x g, 15 min),
washed once in 20 ml of phosphate-buffered saline (PBS), and resuspended in 1 ml of PBS
containing protease inhibitors (Thermo Fisher). AlgR was purified from this supernatant using
the GST spin purification kit (Thermo Fisher). After binding of the fusion protein and washing
the column, AlgR was cleaved away from GST with 10 U of thrombin/column overnight at
22°C. Purified protein was dialyzed using a Slide-A-Lyzer (Thermo Fisher) and storage buffer
(20% glycerol, 20 mM Tris [pH 7.5], 5 mM MgCl2, and 1 mM dithiothreitol [DTT]) overnight at
22°C. The identity of the purified protein was determined by mass spectrometry. The purity of
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AlgR was visually determined in a Coomassie-stained 7.5% electrophoresis gel (SDS-PAGE).
EMSAs
Purified AlgR was used in electrophoretic mobility shift assays (EMSAs) using either
PCR amplicons or annealed primers using the LightShift kit, in accordance with the
manufacturer’s instructions (Thermo Fisher Scientific). For rsmA, the rsmAPE3F/rsmAPE3R,
rsmAPE1F/rsmAEcoRIR, or rsmAPE3F/ rsmAEcoRIR primer pair was used to produce PCR
amplicons using Taq polymerase (NEB). Amplicons were gel extracted and biotinylated using
the 3’ biotinylation kit (Thermo Fisher Scientific). Annealed primers were heated to 95°C for 5
min and cooled to room temperature. The annealed primers were biotinylated and incubated with
purified AlgR. Purified AlgR was incubated at increasing concentrations to determine the
suitable concentrations to be used. The nonspecific competitor poly(dI-dC) at 25 ng/µl was used
for all gel shift reactions. DNA and protein were electrophoresed through 5% or 10% native
polyacrylamide gels, transferred to a nylon membrane using a semidry apparatus (Hoefer), UV
cross- linked, developed using the chemiluminescence detection kit (Thermo Fisher Scientific),
and visualized using a charge-coupled-device (CCD) camera (ProteinSimple). The gel shift
assays were repeated at least two times.
Western blot analysis
P. aeruginosa strains were grown in LB at 37°C for 8 h. The bacteria were collected by
centrifugation, resuspended in sterile PBS, and lysed by sonication using a Branson sonifier.
Total protein concentrations were determined by the Bradford protein assay (Bio-Rad, Carlsbad,
CA). Cell extracts (5 to 10 µg) were separated by 15% SDS-PAGE gels and transferred to a
polyvinylidene difluoride membrane (Bio-Rad). The membranes were blocked and probed using
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a 1:2,500 dilution of anti-HA monoclonal antibody in blocking buffer (Thermo Fisher,
Pittsburgh, PA), followed by a 1:30,000 dilution of horseradish peroxidase-conjugated goat antirabbit antibody (69). Densitometry of Coomassie-stained SDS-PAGE gels was used to
standardize the Western blots using total protein analysis, as described previously (70, 71).
Detection was performed using the ECL Plus kit (Thermo Fisher) and chemiluminescence
detection (ProteinSimple, Santa Clara, CA). The blots and Coomassie-stained SDS-PAGE were
analyzed using ImageJ analysis. All Western blotting was repeated at least four times.
Primer extension
Total RNA (15 µg) from P. aeruginosa was isolated using the PureLink RNA minikit
(Life Technologies, Grand Island, NY). Radiolabeled primers rsmYPE1 and rsmZPE1 (see Table
1) were used in a reverse transcription reaction using ThermoScript (Life Technologies). A
temperature of 42°C was used for the extension. The same primer used for primer extension was
also used in a sequencing reaction with the rsmY or rsmZ upstream sequence in pGEM-T
(Promega, Madison, WI) using the Sequenase 7-deaza-deoxy-GTP (7-deaza-dGTP) kit
(Affymetrix, Cleveland, OH). Both primer extensions and sequencing reactions were run on a
6% acrylamide-8 M urea gel. The gel was dried and extension products detected using
autoradiography.
In vitro transcription and RPA
The rsmA, rsmY, and rsmZ probes for RNase protection assay (RPA) were synthesized
using a PCR product generated with primers that incorporated a T7 promoter sequence at the 5=
end and using the MAXIscript T7 kit (Life Technologies) (Table 1). The reverse primer
containing the T7 promoter sequence contained a nonhomologous sequence to discriminate
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between the full- length probe and protected fragments. The primers rsmASDMAlgRF and
rsmARPAR were used to produce the PCR product for rsmA. The rsmYRPAT&R/rsmYRPAF
primer pair for rsmY or rsmZRPAT7RPAF/ rsmZRPAF primer pair for rsmZ was used to
produce probes for the appropriate target. Probes were labeled by biotin-11-UTP (Life
Technologies) at a ratio of 4:6 with UTP and were gel purified after in vitro transcription. Five
micrograms of total RNA from each P. aeruginosa strain was precipitated with 800 pg of labeled
probe and resuspended in hybridization buffer [80% formamide, 400 mM NaCl, 40 mM
piperazine-N,N=-bis(2-ethanesulfonic acid) (PIPES) (pH 6.4), 1 mM EDTA], heated 95°C for 5
min, and incubated overnight at 42°C. Negative controls using the probe incubated with 10 µg of
yeast RNA were also included. Digestion of unhybridized RNA was performed using RNase A
at 25 mg/ml and RNase T1 at 10 U/ml. A biotinylated RNA ladder (Kerafast) was also used to
determine the size of protected probe fragments. The reactions were run on a 5% acrylamide-8 M
urea gel for rsmA and a 10% acrylamide-8 M urea gel for rsmY and rsmZ. RNA was transferred
to a positively charged membrane (Hybond N+; Amersham Biosciences) using a semidry
blotting system and 0.5X Tris-borate-EDTA (TBE; Hoefer, Holliston, MA). Nucleic acid was
UV cross-linked and probes detected using the chemiluminescent nucleic acid detection module
(Thermo Scientific). After washing, the blot was incubated for 5 min and developed using a
FluorChem M (ProteinSimple). RNase protection assays were performed at least three times.
Northern blot analysis
Total RNA was extracted from strains using the PureLink RNA minikit (Thermo Fisher).
RNA was quantitated using a NanoDrop (Thermo Fisher). Two to 5 µg of total RNA was
electrophoresed through a 10% acrylamide-8 M urea gel using formaldehyde-loading buffer.
After electrophoresis, RNA was transferred using a semidry blotter (Hoefer, Holliston, MA) at
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300 mAmp for 45 min and the membranes cross-linked using UV light (Bio-Rad). Probes
produced by in vitro transcription were biotin labeled and hybridized to the membrane using
ULTRAhyb buffer (Thermo Fisher) at 65°C overnight. The primers used to make probes for
rsmY and rsmZ are listed in Table 2. For rsmY, the rsmYRPAF/rsmYT7RPAR primer pair was
used. For rsmZ, the rsmZRPAF/rsmZRPART7 primer pair was used. Membranes were washed
with two 5-min low-stringency washes at room temperature and 2 high-stringency washes for 15
min at 65°C. Blots were developed using the chemiluminescence detection kit (Thermo Fisher),
in accordance with the manufacturer’s instructions. For normalization, 5S RNA probes (Table 2)
made by in vitro transcription were used using primers 5SrRNAI and 5SrRNA2T7. Northern
blotting was repeated more than three times.
Statistical analyses
Statistical analyses were performed using Graph- Pad Prism (version 6.0) software
(GraphPad Software, La Jolla, CA). The results of transcriptional and translational fusions and
densitometry analysis were compared using a one-way analysis of variance (ANOVA) with
Tukey’s posttest. ImageJ software was used for Western blot analysis.
RESULTS
mucA mutant strains require AlgR for increased rsmA expression
Previous studies suggested that AlgU and AlgR control rsmA expression (28, 31).
However, whether both AlgZ and AlgR were involved in the control of rsmA expression was not
tested. We constructed and assayed an rsmA transcriptional fusion (Fig. 3.1A) that contains both
rsmA promoters (rsmATF1-lacZ). The rsmATF1-lacZ fusion was analyzed in the wild-type
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Figure 3.1 AlgR, but not AlgZ, is necessary for increased rsmA expression in mucoid
strains. (A) Schematic of rsmA genomic region. The sequence below the genomic schematic
indicates the AlgU-dependent promoter region. Underlined sequences are potential AlgRbinding sites. The bent arrow and bold nucleotide indicate the transcriptional start sites. The
rsmA transcriptional fusion rsmATF1-lacZ used in this study is listed below. Arrows indicate
the primers used and the numbers indicate the primer locations relative to the translational
start site. (B) The transcriptional fusion rsmATF1-lacZ (Fig. 1A) was assayed in the indicated
strains after growth for 8 h in LB broth. Significant differences from the wild type were
determined using a one-way analysis of variance and Tukey’s posttest. Asterisks indicate P
values of 0.01 (*) and <0.0001 (***). (C) Western blot analysis of the indicated strains
containing an HA-tagged rsmA allele. PAO1 without the rsmAHA allele was run as a negative
control. Densitometry analysis was performed using a duplicate gel and staining for total
protein using Coomassie blue, and all strains were normalized to PAO1 containing the
rsmAHA allele. Western blotting was performed four times, and densitometry analysis is
indicated below the Western blot. A representative Western blot is shown above the
densitometry. A one-way ANOVA with Tukey’s posttest was used to determine statistical
significance. **, P <0.001; ***, P < 0.0001.
strain P. aeruginosa PAO1, ΔalgR and algZ mutants, and in the corresponding mucA22 mutants.
The algZ mutant has a mutation in the conserved histidine residue, which prevents AlgZ-
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mediated phosphorylation of AlgR (19, 32) but does not disrupt the internal algR promoter (33).
As shown in Fig. 1B, there was a slight increase in rsmATF1-lacZ activity in a ΔalgR mutant.
When the rsmATF1-lacZ fusion was assayed in an algZ mutant strain, there was also a slight
increase in reporter activity (Fig. 3.1B). The modest increase in reporter activity suggests that
AlgZ and AlgR have a minor role in rsmA regulation in strain PAO1.
As previous studies also indicated a role for AlgU in regulating rsmA expression, the
rsmATF1-lacZ transcriptional fusion was assayed in a mucA22 strain, where AlgU is most
active. Reporter activity was increased ~3-fold in a mucA22 strain, as previously described (31)
(Fig. 3.1B). However, in the mucA22 ΔalgR double mutant, there was a drastic decrease (~3fold) in rsmATF1-lacZ activity (Fig. 3.1B). The mucA22 algZ mutant strain had rsmATF1-lacZ
activity almost identical to that of the mucA22 mutant strain (Fig. 3.1B). These data implicate
AlgR but not AlgZ in rsmA regulation in a mucA22 mutant strain and suggest that AlgR
phosphorylation is not necessary for rsmA activation.
To confirm that AlgR affected rsmA expression, an epitope-tagged rsmA allele was
introduced into the wild-type strain (PAO1), mucA22 mutant, and respective algR mutant strains
and analyzed by Western blot analysis. As shown in Fig. 3.1C, a slight decrease in RsmA levels
in the ΔalgR mutant strain was detected compared to the wild-type strain PAO1. As reported
previously (31), a mucA22 mutant strain had drastically increased RsmA levels (Fig. 3.1C). The
mucA22 ΔalgR mutant strain had significantly decreased RsmA compared with the mucA22
mutant strain (Fig. 3.1C). The Western blot analysis confirmed the transcriptional fusion analysis
and supported a significant role for AlgR activating rsmA in the mucoid mucA22 mutant strain
but not in the nonmucoid strain PAO1.
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Figure 3.2 AlgR phosphorylation is not required for rsmA activation. Mutants containing
either a mutated aspartate to asparagine (D54N) or aspartate to glutamate (D54E) were
constructed in both the wild-type background PAO1 and the mucA22 mutant background. The
rsmA transcriptional fusion rsmATF1-lacZ was introduced into the strains indicated, resulting
in single-copy chromosomal transcriptional fusions. The indicated strains were grown for 8 h
in LB broth and assayed for b-galactosidase activity. Values indicate the actual b galactosidase activity minus the vector control (~28 Miller units). Differences from the wildtype strain PAO1 or mucA22 mutant were determined using a one-way analysis of variance
and Tukey’s posttest. Triple asterisks indicate P values of <0.0001.
AlgR phosphorylation is not required for activation of rsmA expression
To further investigate the role of AlgR phosphorylation in the regulation of rsmA, algR
site-directed mutants were constructed that mimic either the unphosphorylated (D54N) or
phosphorylated form of AlgR (D54E). The algRD54N and algRD54E mutant alleles were also
constructed in the mucA22 mutant background to confirm a phosphorylation- independent mode
of AlgR activation of rsmA. Both the mucA22 algRD54N and the mucA22 algRD54E mutant
strains were mucoid (data not shown), supporting the notion that phosphorylation is not
necessary for alginate production and that the mutant AlgR proteins produced in these strains
were still functional. The mucA22D54N mutant had increased rsmA reporter activity compared
to a mucA22 mutant strain (Fig. 3.2). The mucA22 algRD54E strain had decreased rsmATF199

lacZ activity compared to the mucA22 mutant (Fig. 3.2). Because the mucA22 algRD54N and the
mucA22 algZ mutant strains had elevated and similar levels, respectively, of rsmATF1-lacZ
activity (Fig. 3.2 and 3.1B, respectively) compared to the mucA22 mutant strain, this suggests
that phosphorylation of AlgR is not required for rsmA activation.
AlgR regulates the distal rsmA promoter
Previous work determined that rsmA has two promoters (31). An RNase protection assay
was performed using a probe spanning the upstream region of rsmA (Fig. 3.3A) to determine
which rsmA message AlgR affected. As we previously reported (31), two rsmA messages were
seen in both the wild-type strain PAO1 and the mucA22 mutant strain, with the longer transcript
increased in the mucA22 mutant strain (Fig. 3.3B). There was little difference in the rsmA
transcripts between PAO1 and the ΔalgR mutant (Fig. 3.3B). In contrast, there was a substantial
decrease in the longer rsmA transcript in the mucA22 ΔalgR mutant strain compared to the
mucA22 parent strain (Fig. 3.3B). The specificity of the rsmA probe was confirmed using the
probe incubated with yeast tRNA (-RNase) and using a ΔrsmA mutant (Fig. 3.3B). These results
suggest that AlgR is most important for rsmA control in the mucA22 background and that AlgR
controls the distal rsmA promoter that is also under control by AlgU.
To confirm that AlgR regulates the distal rsmA promoter, transcriptional fusions
containing individual rsmA promoters were used (Fig. 3.3A; see also Fig. 3.S1A in the
supplemental material). The transcriptional fusion rsmATF2-lacZ contains only the proximal
rsmA promoter (Fig. 3.S1A). The transcriptional fusion rsmATF3-lacZ (Fig. 3.3A) contains only
the distal promoter that has been shown to be controlled by AlgU (31). The deletion of algR had
no effect in the rsmATF2-lacZ transcriptional fusion in the wild-type or a mucA22 background
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Figure 3.3 AlgR controls the distal AlgUdependent rsmA promoter. (A) Schematic of the
RNase protection assay probe used. Numbers indicate
distances from the rsmA translational start site. The
transcriptional fusion rsmATF3-lacZ is indicated at
the bottom. Arrows indicate the primers used and
their location in reference to the rsmA translational
start site. (B) A representative RNase protection
assay performed on the indicated strains after 8 h
of growth in LB broth. Total RNA was isolated
from each strain and hybridized to 800 pg of
biotinylated rsmA probe. After treatment with
RNase A/RNase T1, protected probe fragments
were detected after electrophoresis through a
denaturing polyacrylamide gel and transfer to a
nylon membrane. Protected probe fragments are
indicated by solid arrows. The broken arrow
indicates a full-length probe. Biotinylated molecular
size markers are indicated to the left. RNase
protection assays were performed three times.
(C) The rsmA transcriptional fusion rsmATF3-lacZ
was introduced into the indicated strains to
generate strains containing single-copy
chromosomal fusions. The strains were grown for
8 h in LB broth and assayed for b -galactosidase
activity minus the vector control. Differences
from the wild-type strain PAO1 or mucA22 mutant
were determined using a one-way analysis of
variance and Tukey’s posttest. Triple asterisks
indicate P values of <0.0001. Fusion analysis
was performed in triplicate three times.
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(Fig. 3.S1B). The transcriptional fusion rsmATF3-lacZ had increased reporter activity in a
mucA22 mutant strain compared to that in PAO1 (Fig. 3.3C). Compared to PAO1, no change in
rsmTF3-lacZ activity was seen in a ΔalgR mutant strain (Fig. 3.3C). However, algR deletion in a
mucA22 mutant strain (mucA22 ΔalgR) resulted in a significant decrease in rsmATF3-lacZ
activity (Fig. 3.3C), supporting the RNase protection assay. Taking these results together, we
conclude that AlgR activates the distal rsmA promoter, and this further suggests that AlgU and
AlgR both are required to activate rsmA transcription from the distal promoter.
AlgR directly binds the distal rsmA promoter
We hypothesized that AlgR directly activated the distal rsmA promoter. In support of this
idea, two potential AlgR-binding sites are located upstream of rsmA. One of the potential AlgRbinding sites is 2 nucleotides away from the AlgU -35 consensus promoter (Fig. 3.4A). Purified
AlgR was tested in gel shift studies with biotinylated rsmA promoter fragments (Fig. 3.4A). A
biotinylated pscF gene, a component of the T3SS (34, 35), was used as a negative control and
did not shift when incubated with purified AlgR (Fig. 3.4B to D). A PCR fragment representing
the entire rsmA upstream region containing both promoters was dramatically shifted using
purified AlgR (Fig. 3.4B), suggesting that AlgR directly binds to at least one of the AlgRbinding sites upstream of rsmA. To further define the region upstream of rsmA that was bound by
AlgR, PCR amplicons that corresponded to the transcriptional fusion constructs containing
individual rsmA promoters (Fig. 3.4A) were biotinylated and tested via gel shift analysis. A
biotinylated probe containing the proximal promoter (TF2) and upstream sequence to the more
distal transcriptional start site did not shift when incubated with purified AlgR (Fig. 3.4B). This
result suggested that AlgR does not bind the proximal rsmA promoter. As shown in Fig. 3.4B,
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Figure 3.4 AlgR directly binds the AlgU-dependent rsmA promoter and requires both
AlgR-binding sites. Purified AlgR was incubated with either biotinylated PCR products or
annealed primers. (A). Schematic of the rsmA genomic region. Below are fragments or
annealed primers and the approximate location upstream of rsmA. Promoters are indicated
above as bent arrows and are denoted by PAlgU or PRpoD. The arrowheads indicate the
approximate location of the putative AlgR-binding sites. (B) Analysis of biotinylated PCR
fragments in gel shift studies. The PCR fragment TF1 represents the entire rsmA upstream
region (see panel A). Fragments TF2 and TF3 correspond to the separated rsmA promoters
(see Fig. 1). TF2 corresponds to the proximal rsmA promoter, and TF3 corresponds to the
distal AlgU-dependent promoter. A minus sign indicates probe alone. A plus sign indicates
AlgR concentration of 2.5 µM. pscF was used as a negative control. Shaded arrowheads
indicate shifted fragments. White arrowheads indicate unbound probe. (C) Titration and
competition assay using purified AlgR and the TF3 fragment corresponding to the distal rsmA
promoter. The pscF fragment was used as a negative control. TF3 was incubated with
different concentrations of AlgR (indicated by the graded triangle; 0.05, 0.25, 1.25, and 2.5
µM). TF3 was also used in a competition assay using unlabeled TF3 as a competitive
inhibitor. Ratios below indicate the ratio of labeled to unlabeled probe. Shaded arrowheads
indicate shifted fragments. White arrowheads indicate unbound probe. A minus sign indicates
probe alone. (D) Two AlgR-binding sites are upstream of the distal rsmA promoter. Annealed
primers containing either wild-type or two different mutated AlgR-binding sites were tested in
gel shift experiments. The pscF fragment was used as a negative control. The rsmA lanes
indicate the probe using annealed primers with both AlgR-binding sites intact. M1 indicates
the same as rsmA, except that the furthest upstream AlgR-binding site was mutated. M2
indicates the same as rsmA, except that the further downstream AlgR-binding site is mutated.
Shaded arrowheads indicate shifted fragments. White arrowheads indicate unbound probe.
Minus signs indicate probe alone. Plus signs indicate an AlgR concentration of 2.5 µM.
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AlgR bound the distal promoter sequence fragment, TF3, containing the AlgU-dependent
promoter and potential AlgR-binding sites. The TF3 fragment containing the AlgU promoter was
tested in a competition assay using increasing concentrations of AlgR and unlabeled probe. A 1:1
ratio of labeled to unlabeled probe was capable of decreasing the shift of the TF3 probe (Fig.
3.4C). Competition with the unlabeled specific probe in a 1:5 or 1:10 ratio was able to compete
for AlgR binding, as indicated by severe reduction of the probe shift (Fig. 3.4C). These data
suggest that AlgR specifically binds the AlgU- dependent promoter region and strongly suggests
that AlgR binds at least one of the AlgR consensus sequences located in this promoter region.
AlgR has previously been shown to bind an 11-bp consensus sequence, with nucleotides
2 to 10 being the most conserved (36). To determine if one, or both, of the putative AlgR-binding
sites were required for AlgR binding, we used annealed primers upstream of the distal promoter
in gel shift analyses. Approximately 30-bp primers were annealed and biotinylated that contained
the predicted AlgR-binding sites. AlgR was able to shift the annealed biotinylated primers
containing the two predicted AlgR-binding sites (Fig. 3.4D). The first putative AlgR-binding
site, CCTTTTGTC, was mutated, and this mutation resulted in a loss of AlgR binding (Fig.
3.4D), suggesting that the first AlgR-binding site is required for AlgR binding to the rsmA
promoter. The second putative AlgR-binding site, CCGTTTGGC, is located 7 bp downstream
and directly adjacent to the AlgU -35 consensus sequence. When the second AlgR-binding site
was mutated, AlgR was no longer able to bind to the annealed primers (Fig. 3.4D). These data
suggest that AlgR binds both of the consensus sequences in order to activate rsmA expression.
AlgR regulates rsmY expression indirectly
A previous study indicated that rsmY and rsmZ expression was also increased in a mucA
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Figure 3.5 AlgR indirectly increases rsmY expression in a mucA22 mutant strain. (A)
Primer extension analysis performed on total RNA from strain PAO1. GATC indicates the
sequencing ladder. -C is a control without reverse transcriptase. PAO1 is reverse-transcribed
PAO1 mRNA. Below is the sequence of the rsmY promoter region. The asterisk denotes the
transcriptional start site identified. (B) Schematic of the rsmY genomic region. The UAS is
indicated between the numbers from the transcriptional start site. The bent arrows above
indicate the primers used for the transcriptional fusions, and the numbers correspond to the
distance from the transcriptional start site. P and the bent arrow indicate the start site of
transcription. The arrowheads represent potential AlgR-binding sites. The bent arrow below
indicates the primer used in the primer extension experiment. Indicated below is the probe
generated by in vitro transcription for Northern analysis. Transcriptional fusions are indicated
below. Numbers above the arrows indicate the distance from the transcriptional start site. (C)
Transcriptional fusion rsmYTF1-lacZ was introduced into the indicated strains in single copy,
grown for 8 h in LB broth, and assayed for b -galactosidase activity. Significant differences
from the wild type were determined using a one-way analysis of variance and Tukey’s
posttest. Asterisks indicate P values of 0.001 (**) and <0.0001 (***). (D) Northern blot
analysis of RsmY in the indicated strains after growth for 8 h in LB broth. The ΔrsmY mutant
was used as a control. The top half is a membrane probed with the RsmY probe, and the
bottom portion is a second independent blot of the loading control probed with a 5S rRNA
probe. Northern blotting was performed at least three times. (E) Transcriptional fusion
rsmYTF2-lacZ was introduced into the indicated strains in single copy, grown for 8 h in LB
broth, and assayed for b -galactosidase activity. Significant differences from the wild type
were determined using a one-way analysis of variance and Tukey’s posttest. Triple asterisks
indicate P values of <0.0001. All transcriptional fusion analyses were performed at least three
times.
mutant background and required AlgR (28). The transcriptional start site of rsmY was determined
in Pseudomonas fluorescens using 5’ rapid amplification of cDNA ends (RACE), and this
information was used to deduce the transcriptional start site in P. aeruginosa (30, 37). To
confirm the P. aeruginosa rsmY transcriptional start site, we performed primer extension. As
indicated in Fig. 3.5A, a single extension product was obtained after reverse transcription of total
RNA that confirmed the rsmY transcriptional start site assigned using P. fluorescens.
A transcriptional fusion, rsmYTF1-lacZ (Fig. 3.5B), was constructed and assayed in algR
and algZ mutants in both the PAO1 (wild-type) and the mucA22 background. When a ΔalgR or
algZ mutant was tested for rsmY reporter activity, there was no decrease compared to PAO1
(Fig. 3.5C). There was a ~3-fold increase in rsmYTF1-lacZ activity in a mucA22 mutant strain
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compared to PAO1 (Fig. 3.5C). When tested in a mucA22 ΔalgR mutant strain, the increased
activity in the mucA22 mutant strain was reduced to PAO1 levels (Fig. 3.5C). In the case of the
mucA22 algZ mutant strain, there was a slight but statistically significant decrease in rsmYTF1lacZ activity (Fig. 3.5C). Overall, the fusion results suggest that AlgR affects rsmY expression,
but only in the mucA22 background.
To confirm that the rsmY levels decreased, Northern blotting was performed on the same
strains. Two bands hybridized to the rsmY probe, as has been seen previously (Fig. 3.5D) (30,
38). Little difference was seen between a ΔalgR mutant strain and the wild-type PAO1 (data not
shown). However, an increase in both hybridizing RNAs was seen in a mucA22 mutant strain
(Fig. 3.5D). The mucA22 ΔalgR and mucA22 algZ mutant strains had decreased hybridizing
fragments (Fig. 3.5D). The loading control used (5S rRNA) was consistently uneven upon
repeated attempts, but the Northern blotting does confirm the transcriptional fusion analysis. A
second probe using proC was also used and gave similar results. A ΔrsmY strain had no
hybridizing RNA, confirming the specificity of the rsmY probe. Overall, these results support
AlgR control of rsmY expression in the mucA22 strain.
Both rsmY and rsmZ contain upstream activating sequences (UAS) that GacA con- trols
(39). A potential AlgR-binding site is located 23 nucleotides upstream of the UAS for rsmY. An
additional AlgR-binding site is present further upstream on the opposite strand (Fig. 3.5B). Two
additional transcriptional fusions, rsmYTF2-lacZ and rsmYTF3-lacZ (Fig. 3.5B and 3.S2A),
were constructed to determine the sequences required for AlgR control. The rsmYTF2-lacZ
transcriptional fusion deletes the AlgR-binding sites but retains the UAS sequence (Fig. 3.5B).
When assayed in the algR mutant strains in both PAO1 and mucA22 backgrounds, a difference
was only seen in the mucA22 background (Fig. 3.5E). This result suggests that the potential
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AlgR-binding sites are not necessary for increased rsmY reporter activity.
An additional rsmY reporter, rsmYTF3-lacZ, was constructed that does not contain the
UAS sequence. This fusion had very low activity in both PAO1 and mucA22 (Fig. 3.S2B). This
result suggests that the UAS is required for increased rsmY reporter activity in a mucA22 mutant
strain as well as PAO1. Overall, the data suggest that AlgR and AlgU indirectly affect rsmY
expression.
AlgR regulates rsmZ expression indirectly
The regulation of rsmZ is more complex than rsmY and includes regulators other than
GacA (38, 40, 41). Primer extension analysis confirmed the location of the transcriptional start
site in P. aeruginosa that was predicted from P. fluorescens (Fig. 3.6A) (42, 43). A
transcriptional fusion, rsmZTF1-lacZ, was assayed in the algZ and algR mutants (Fig. 3.6B).
There was no difference in the rsmZ reporter in the ΔalgR or algZ mutant compared to PAO1
(Fig. 3.6C). There was a 5-fold increase in rsmZTF1-lacZ activity in the mucA22 mutant strain
compared to PAO1 (Fig. 3.6C). In a mucA22 ΔalgR mutant strain, there was a significant
decrease in rsmZTF1-lacZ activity. In a mucA22 algZ mutant strain, there was a significant but
slight decrease in rsmZTF1-lacZ activity compared to the mucA22 mutant (Fig. 3.6C). In all,
these results suggest that AlgR plays a major role and AlgZ plays only a minor role, if any, in
terms of rsmZ expression in the mucA mutant background.
To confirm the transcriptional fusion results, we again wanted to monitor the actual RNA
levels. Using Northern blot analysis, a trend was seen similar to that in the transcriptional
fusions. As shown in Fig. 3.6D, there were two bands detected, with the larger fragment being
the most intense. Previous studies utilizing Northern blotting suggested that the smaller
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Figure 3.6 AlgR increases rsmZ expression in a mucA22 mutant strain indirectly. (A)
Primer extension analysis using total RNA isolated from PAO1. GATC indicates the
sequencing ladder. -C is a control without reverse transcriptase. PAO1 is reverse-transcribed
PAO1 mRNA. Below is the sequence of the rsmZ promoter region. The asterisk denotes the
transcriptional start site identified. (B) Schematic of the rsmZ genomic region. The bent arrow
on top indicates the primer used for transcriptional fusion construction. The bent arrow
indicated by a “P” indicates the transcriptional start site. The bent arrow below indicates the
primer used in primer extension. (C) Transcriptional fusion ZTF1-lacZ was introduced into
the indicated strains in single copy, grown for 8 h in LB broth, and assayed for b galactosidase activity. Significant differences from the wild type were determined using a
one-way analysis of variance and Tukey’s posttest. Asterisks indicate P values of 0.001 (**)
and <0.0001 (***). Transcriptional fusion analysis was performed in triplicate three times.
(D) Northern analysis of the indicated strains grown for 8 h in LB broth and total RNA probed
with and rsmZ probe. A ΔrsmZ mutant strain was used to denote the specificity of the probe.
A separate blot of the same strains was probed using a 5S rRNA probe (shown below).
Northern blotting was performed three times.
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hybridizing fragment represents the small RNA lacking the stem-loop found at the 3’ end of the
small RNA (30). Therefore, the smaller hybridizing bands may represent the small RNAs lacking
a transcriptional terminator. A ΔrsmZ mutant was used as a negative control. The mucA22
mutant strain had increased RsmZ compared to PAO1 (Fig. 3.6D). The mucA22 ΔalgR mutant
strain had the most drastic decrease in RsmZ levels, and there was a slight decrease in RsmZ
levels in the mucA22 algZ mutant (Fig. 3.6D). Altogether, these results suggest that AlgR plays a
role in increasing the RsmZ small RNA in the mucA22 background.
We hypothesized that like rsmY expression, AlgR indirectly affects rsmZ expression. An
additional transcriptional fusion, rsmZTF2-lacZ (Fig. 3.S3A), was constructed and assayed in the
wild-type strain PAO1 and a mucA22 mutant strain, which lacks the UAS sequence. Both strains
had drastically decreased reporter activity (Fig. 3.S3B). Interest- ingly, the mucA22 mutant strain
had significantly decreased activity compared to PAO1 (Fig. 3.S3B). Further support for an
indirect mechanism of AlgR activation was obtained using gel shift analysis of a PCR amplicon
of the rsmZ upstream region (Fig. 3.S3A). Purified AlgR was not able to shift the rsmZ upstream
region tested (Fig. 3.S3C), suggesting AlgR does not directly activate rsmZ expression. These
results suggest that the UAS is required for increased rsmZ expression, and we conclude that
AlgR affects rsmZ expression indirectly.
AlgR is necessary for RsmA activity in a mucA mutant background
To ascertain whether AlgR control of rsmA was significant in a biological context, the
direct RsmA targets hcnA and tssA1 were used to assess RsmA activity (29). A new integrating
vector was constructed that contains the lacUV5 promoter and lacks a ribosome-binding site or a
start codon for lacZ. When tested in the wild-type strain PAO1, there was no activity of the
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vector alone.
The hcnA gene encodes part of the hydrogen cyanide synthase enzyme that is implicated
in virulence (44, 45). RsmA was shown to previously negatively affect a leader fusion using the
tac promoter and the ribosome-binding site region of hcnA (45). An hcnA leader fusion was
constructed by annealing 33 nucleotides, including one of the predicted RsmA-binding sites, the
ribosome-binding site, and the translational start codon of hcnA. As shown in Fig. 3.7A, the
lacUV5 hcnA-lacZ fusion had activity in strain PAO1. When assayed in a mucA22 mutant strain,
there was an ~2.5-fold decrease in reporter expression (Fig. 3.7A), consistent with increased
RsmA levels in the mucA22 mutant strain. If rsmA expression requires AlgR and AlgU, mutating
algR and algU should result in increased fusion activity in the mucA22 background due to
decreased rsmA expression. Both the mucA22 ΔalgR and the mucA22 ΔalgU mutant strains had
at least a 3-fold increase in reporter expression compared to the mucA22 strain (Fig. 3.7A). The
mucA22 ΔrsmA mutant strain was assayed and had a 3.6-fold increase in reporter activity
compared to the mucA22 mutant (Fig. 3.7A). Overall, these results are consistent with the
conclusion that RsmA is active in the mucA22 strain and that AlgU and AlgR are important for
the decreased posttranscriptional regulation of hcnA.
Another RsmA target, tssA1, was also analyzed. The tssA1 gene encodes a portion of the
T6SS and is directly regulated by RsmA (29, 46). Previous studies have used a lacUV5 tssA1
construct containing 227 bp of tssA1 upstream sequence that had extremely low activity (28, 29,
31). However, this fusion was found to contain additional transcriptional controls that resulted in
low activity (data not shown). To more carefully assess RsmA activity using tssA1, we
constructed a new leader fusion by annealing 31 nucleotides, including the predicted RsmAbinding site, the ribosome-binding site, and the translational start codon of tssA1. The lacUV5
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Figure 3.7 RsmA is active in a mucA22 mutant strain. (A) Leader/translational fusion
lacUV5 hcnA-lacZ (above graph) was introduced into the indicated strains in single copy,
grown for 8 h in LB broth, and assayed for b -galactosidase activity. Significant differences
from the wild type were determined using a one-way analysis of variance and Tukey’s
posttest. Triple asterisks indicate P values of <0.0001. (B) Leader/ translational fusion
lacUV5 tssA1-lacZ (above graph) was introduced into the indicated strains in single copy,
grown for 8 h in LB broth, and assayed for b -galactosidase activity. Significant differences
from the wild type were determined using a one-way analysis of variance and Tukey’s
posttest. Triple asterisks indicate P values of <0.0001. All leader/translational fusions were
assayed in triplicate three times.
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tssA1-lacZ fusion had approximately 200 times the activity as the previously constructed lacUV5
tssA1-lacZ fusion containing 227 bp of upstream sequence in the wild-type strain PAO1 (Fig.
3.S4). There was no activity when this fusion was assayed in a mucA22 mutant strain (Fig. 3.7B
and 3.S4). The lacUV5 tssA1-lacZ fusion confirmed our previous result (31), demonstrating
increased activity in the mucA22 ΔalgU mutant strain, validating the use of this construct. When
a mucA22 ΔalgR mutant was tested, the fusion was also increased from the mucA22 mutant
strain to levels similar to those of the mucA22 ΔalgU mutant strain (Fig. 3.7B). A mucA22
ΔrsmA mutant strain also had statistically significant activity compared to that of the mucA22
mutant (Fig. 3.7B). These results demonstrate that AlgR and AlgU are necessary for
posttranscriptional regulation of tssA1. From these data, we conclude that AlgU and AlgR are
both required for increased rsmA expression in the mucA mutant background and that this leads
to posttranscriptional regulation on two known RsmA targets, most likely through RsmA.

DISCUSSION
AlgR is an important two-component regulator having roles in both acute and chronic
infections. In the case of acute infections, AlgR activates the fimU operon, enabling the
production of T4P (19, 21, 47). In chronic infections, AlgR, AlgU, and other transcriptional
regulators activate the production of alginate (22, 48–50). These and other virulence factors in P.
aeruginosa are often considered mutually exclusive, de- pending on whether there is an acute or
chronic infection (51–53). This work demonstrates that another effect of a mucA mutation is that
AlgR activity is directed at increasing the posttranscriptional regulator RsmA. AlgR activation of
rsmA may help explain how AlgR participates in the mutually exclusive production of some
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virulence factors depending on acute or chronic infection.
The initial description of AlgR as a regulator of rsmA (28) did not evaluate the contribution of
AlgR phosphorylation by AlgZ or a mechanism for AlgR activation of rsmA. Because AlgR is
part of a two-component system that is important for both acute and chronic infections (19, 32),
it was necessary to address the mechanism for AlgR activation of rsmA in order to create a
framework to understand how AlgR regulation of rsmA might impact virulence gene expression.
AlgR binds a consensus sequence CCGTTCGTC (21, 48, 49), and phosphorylation is thought to
enable AlgR to bind potential binding sites that deviate from this consensus, such as the sites
found in the fimU promoter (32, 47). However, the rsmA promoter deviates from the AlgRbinding consensus, and AlgR phosphorylation was not required for rsmA expression. This argues
against phosphorylation as the sole mechanism for AlgR binding less well-conserved consensus
sequences. The studies using the mucA22 mutant strain, the algZ mutant, and the D54N mutant
are consistent with the conclusion that AlgR phosphorylation is not required for rsmA activation.
As AlgR phosphorylation is not required for alginate expression (22), our results are consistent
with the conclusion that AlgR activates rsmA expression in mucoid strains.
The mechanism for AlgR activation of rsmA is by directly binding upstream of the AlgUdependent promoter, further supporting our model (Fig. 8). Gel shift studies determined that two
AlgR-binding sites are required for in vitro binding. The location of the AlgR-binding sites, the
in vitro gel shift analysis, transcriptional fusions, and RNase protection assay all support AlgR
binding the distal promoter region of rsmA and are in accord with the activation of the AlgUdependent promoter.
Our data suggest that AlgR plays a more important role in regulating rsmA expression in mucA
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mutant strains, such as those found in CF patients. If AlgU and AlgR activate rsmA expression,
as predicted by our model (Fig. 8), this would explain why AlgR did not appear to play a
significant role in regulating rsmA in the wild-type PAO1 strain (Fig. 1B and C, 2, and 3). From
this work, we conclude that AlgR and AlgU play a greater role in rsmA activation in mucA
mutant strains. However, it is possible that in vivo conditions differ and that nonmucoid wildtype strains also have increased regulation of rsmA under other conditions.
The mucA mutation leads to AlgU and AlgR activation of rsmA, suggesting that RsmA

Figure 3.8 Model for AlgR activation of rsmA and RsmA activity in mucoid strains. In
chronic infections, mucA mutants arise, leading to increased AlgU activity. In the case of
rsmA, AlgR and AlgU activate the distal rsmA promoter. The dark-shaded triangles indicate
the AlgR-binding sites located upstream of rsmA. The light-shaded triangle indicates the
AlgU-dependent promoter. The model predicts that increased expression of rsmA leads to
increased RsmA activity, as indicated by the negative regulation of the RsmA targets, hcnA
and tssA1.
may regulate specific targets in mucA mutant strains. RsmA is a posttranscriptional regulator that
binds mRNAs, in many cases, at or near the ribosome-binding site of targets (54). It is likely that
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RsmA has unknown targets in a mucA mutant background due to transcriptional differences
between nonmucoid and mucoid strains (55–59). Therefore, RsmA will bind only to targets that
are present at a given time, supporting RsmA working as a rheostat. An alternative explanation is
that our conditions of growth in the laboratory environment do not represent the conditions in the
CF lung. While this is quite obvious, it is known that the mutation in mucA leads to alginate
production in vivo (11, 60, 61). In addition, nonmucoid P. aeruginosa also has active AlgU and
AlgR during infection because of alginate secretion by nonmucoid P. aeruginosa from CF
patients (62, 63). Therefore, it is highly probable that AlgU and AlgR activity in vivo would
increase RsmA levels during infection. What role RsmA plays due to AlgU and AlgR regulation
in vivo is not known.
The significance of AlgU and AlgR control of rsmA is demonstrated by the analyses of
RsmA targets. The posttranscriptional activity of the RsmA targets, tssA1 and hcnA, was greater
in the mucA22 background than in the wild-type PAO1 strain (Fig. 7). We also observed a lack
of posttranscriptional activity on RsmA targets when algU or algR was inactivated in a mucA22
mutant strain (Fig. 7), due to the decreased expression of rsmA. Therefore, we conclude that
RsmA is active in an mucA22 mutant strain and that RsmA activity requires AlgU and AlgR to
increase rsmA gene expression in this back- ground. The correlation between increased AlgR
activity and increased RsmA activity in mucA mutants also supports these systems acting as a
rheostat to fine-tune gene expression, as opposed to an on/off switch. When AlgU and AlgR
increase RsmA levels, the indirect effects of these two regulators may be due to RsmA. Further
work is necessary to pursue this exciting discovery that could help explain the exclusive
expression of particular virulence genes in a given background.
The role of AlgU and AlgR on the RsmA-antagonizing small RNAs rsmY and rsmZ is
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likely indirect. While our Northern blot data were not strong, they did support our transcriptional
fusion analysis. Our transcriptional fusions mirrored what was seen in a previous study (28),
supporting the idea of AlgR indirectly controlling rsmY and rsmZ expression. We hypothesize
that AlgU and AlgR activities may coincide with factors that lead to increased GacA
phosphorylation, resulting in the increased expression of rsmY and rsmZ. Further work is
necessary to establish the mechanism for increased expression of the small RNAs in a mucA
background.
Another question raised by our study is how RsmA remains active when the antagonizing
small RNAs are increased. One possibility is that RsmA preferentially binds its targets in the
mucA mutant strains better than the antagonizing small RNAs. This might also result from other
regulators, either protein or other small RNAs that are currently unknown and affect the ability
of RsmA to interact with the antagonizing small RNAs RsmY and RsmZ.
Altogether, our work demonstrates that AlgR is required for increased rsmA expression in
mucA mutant strains. Phosphorylation of AlgR was not required for rsmA activation. The
increased RsmA levels in a mucA22 mutant strain result in increased RsmA activity, even though
the antagonizing small RNAs are also increased. What roles RsmA plays and how RsmA
functions in chronic infecting strains are not known. To better understand the role of RsmA, we
are currently investigating new possible RsmA targets in AlgU-active strains. A further
understanding of the RsmA regulon in mucA mutants may provide additional insight into how P.
aeruginosa becomes such a successful CF pathogen and has implications for the important role
of RsmA in all types of P. aeruginosa infections.
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SUPPLEMENTAL FIGURES

Figure 3. S1 algR deletion has no effect on the proximal rsmA promoter. (A) Schematic
of the rsmA genomic region and the transcriptional fusion rsmATF2- lacZ. Numbers
indicate distance from the rsmA translational start site. The translational start site is
indicated by a +1. The AlgU and RpoD promoters are indicated by bent arrows. The
transcriptional fusion rsmATF2-lacZ is indicated directly below and the arrows indicate the
primers and the numbers their location relative to the rsmA translational start site. (B) The
rsmA transcriptional fusion rsmATF2-lacZ was introduced into the indicated strains to
generate strains containing single-copy, chromosomal fusions. The strains were grown for 8
hours in LB broth and assayed for β-galactosidase activity minus the vector control.
Differences from the wild-type strain PAO1, mucA22, or ∆algR mutants, were determined
using a one-way analysis of variance and a Tukey’s post-test. Transcriptional fusions were
assayed in triplicate three times.
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Figure 3. S2. The GacA binding site is necessary for increased rsmY expression. (A)
Schematic of the rsmY genomic region and the transcriptional fusion rsmYTF3-lacZ.
Numbers indicate distance from the rsmY transcriptional start site. The transcriptional start
site is indicated by a bent arrow and +1. The UAS controlled by GacA is indicated with the
distances from the transcriptional start site indicated below. The transcriptional fusion
rsmYTF3-lacZ is indicated directly below and the arrows indicate the primers and the
numbers their location relative to the rsmY transcriptional start site. (B) Transcriptional
fusion rsmYTF3-lacZ was introduced into the indicated strains in single-copy, grown for 8
hours in LB broth and assayed for β-galactosidase activity. Significant differences from the
wild type were performed using a one-way analysis of variance and a Tukey’s post-test.
Transcriptional fusions were assayed in triplicate three times.
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Figure 3. S3. AlgR does not directly affect rsmZ expression. (A) Schematic of the rsmZ
genomic region and the transcriptional fusion rsmZTF2-lacZ and the PCR product used for
gel shift analysis. Numbers indicate distance from the rsmZ transcriptional start site. The
transcriptional start site is indicated by a bent arrow and +1. The UAS controlled by GacA
is indicated with the distances from the transcriptional start indicated below. The
transcriptional fusion rsmZTF2-lacZ is indicated directly below and the arrows indicate the
primers and the numbers their location relative to the rsmZ transcriptional start site. (B)
Analysis of rsmZTF2-lacZ in PAO1 and a mucA22 strain. The indicated strains were grown
for 8 hours and assayed for β-galactosidase activity. Assays were repeated three times.
Significant differences from the wild type were performed using a one-way analysis of
variance and a Tukey’s post-test. Asterisks indicate P values of 0.001 (**) to < 0.0001
(***). (C) Gel shift analysis of the rsmZ upstream region with purified AlgR. Open
arrowheads indicate probes alone. Blackened arrowheads indicate shifted probe. pscF is a
negative control. algD is a positive control. ZF1 is the rsmZ upstream region. The – symbol
means a probe with no added AlgR. The + symbol indicates 2.5µM of AlgR added with the
probe.
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Figure 3. S4. Comparison of tssA1 leader/translational fusions. The previously used
leader/translational fusion was based on a 5’ RACE study by Brencic and Lory (1) and
includes 227bp of upstream sequence of tssA1 that was previously used to investigate
posttranscriptional regulation of tssA1 (1-3). On the left is the original lacUV5tssA1-lacZ
fusion assayed in PAO1 and mucA22 at 8 hours. On the right is the new lacUV5tssA1-lacZ
leader/translational fusion using annealed primers of 31bp cloned into the same vector and
assayed at 8 hours in the indicated strains. Assays were repeated three times. Significant
differences from the wild type were performed using a one-way analysis of variance and a
Tukey’s post-test. Asterisks indicate P values of 0.001 (**) to < 0.0001 (***).
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ABSTRACT
Pseudomonas aeruginosa is an opportunistic pathogen able to colonize any host tissue.
When Cystic fibrosis (CF) patients are infected with P. aeruginosa, the bacteria can develop a
niche in the CF lung and establish a chronic infection. A majority of CF chronic infection
isolates contain a mutation in mucA that encodes an anti-σ factor that sequesters the σ factor
AlgU. AlgU regulates the chronic virulence factor alginate. Strains that overproduce alginate
are termed mucoid. We have shown that AlgU also regulates the gene for the posttranscriptional
regulator rsmA. Based on our previous data demonstrating that the alginate regulators AlgU and
AlgR activate rsmA expression, we hypothesize rsmA has increased expression due to AlgU and
AlgR in mucoid strains of P. aeruginosa and this in turn affects the RsmA regulon. First, we
wanted to characterize observed phenotypic variations in the mucA22 ∆rsmA strain and study
any effects on virulence. Due to increased RsmA levels in mucoid strains and blatant variation
in phenotypes between mucA22 and mucA22 rsmA, we expected to identify novel RsmA targets
in the mucoid background. Therefore the mucA22 and mucA22∆rsmA proteomes were analyzed
using 2D-gel electrophoresis and isobaric tagging by relative and absolute quantification
(iTRAQ). The mucA22∆rsmA strain showed increases in previously unidentified targets:
PA3866, AlgP, PasP, AhpC, and OprF. We constructed a pasP leader fusion with a
constitutively active lacUV5 promoter and compared PAO1, mucA22, and the mucA22 ∆rsmA
mutant strains to confirm the iTRAQ data. Next, we demonstrated a direct interaction of RsmA
with pasP. These data show that rsmA has increased expression in mucA mutant strains and
identified new RsmA targets. We also showed a significant increase in rsmA expression in
several mucoid clinical isolates compared to nonmucoid strains. Overall, RsmA regulation is
important not only in nonmucoid strains like PAO1, but also mucoid strains of P. aeruginosa.
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INTRODUCTION
Pseudomonas aeruginosa is a Gram-negative bacillus capable of growing in a wide
variety of environments. While P. aeruginosa is capable of causing an infection in any human
host, the bacterium is more widely known as an opportunistic pathogen, causing afflictions in
individuals with a compromised immune system (1) (2). P. aeruginosa is a major contributor to
morbidity and mortality in individuals with major burns, type II diabetes, HIV/AIDS, and cystic
fibrosis(CF) (3-6). In the case with CF, P. aeruginosa establishes a niche in the lung that can
develop into a chronic infection (7). P. aeruginosa chronic infection isolates often present a
variant phenotype from acute infection isolates and express less inflammatory virulence factors,
like flagella, allowing them to persist in the CF lung (8).
P. aeruginosa in the CF lung is targeted by neutrophils releasing reactive oxygen and
nitrogen species (7). This attack causes osmotic stress on the bacteria and affects the integrity of
membrane bound proteins. The anti-sigma factor, MucA, is an inner membrane bound protein
that sequesters the extracytoplasmic sigma factor, AlgU (9). The release of AlgU allows for a
phenotypic shift where P. aeruginosa begins to produce copious amounts of the
exopolysaccharide alginate. P. aeruginosa strains that overproduce alginate are termed mucoid.
This thick protective biofilm allows for P. aeruginosa to evade phagocytosis, secreted reactive
species, and antibiotics (7, 9, 10). The AlgU regulon has been shown to contribute to the
expression of virulence factors like proteases lasB and the metalloproteinase aprA (11). Our
previous work has also shown AlgU contributes to posttranscriptional regulation of virulence
factors by regulating the expression of rsmA (12).
RsmA regulates hundreds of targets by binding the ribosomal binding site of a messenger
RNA (mRNA) and inhibiting translation (13). RsmA is antagonized by two small noncoding
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RNA called RsmY and RsmZ (14). RsmA is also parth of the Gac/Rsm hierarchal system. The
two component system GacA/S activate rsmY/Z expression (15). GacS, the sensor, can also
dimerize with another sensor, RetS, which will inhibit the phosphorylation of GacA and
therefore not make the RsmA antagonists (15-17). The RsmA homolog, CsrA, has been more
characterized and shown to not only inhibit translation, but also positively influence the
translation of some targets (18). CsrA has also been shown to form protein-protein interactions
(19, 20). In P. aeruginosa RsmA has been shown to inhibit the production of virulence factors
like the Type VI secretion system and hydrogen cyanide synthase while positively influencing
other virulence factors like type IV pili (13). Originally, the function of RsmA was to regulate
as a switch from acute to chronic infection virulence factors (21). Most studies of RsmA targets
via microarray were investigated in acute/nonmucoid strains of P. aeruginosa like PAO1 or
PAK.
However, our work investigating AlgU controlling rsmA expression showed that more
RsmA was present in a chronic/mucoid strain where AlgU is not sequestered by MucA (12). Not
only was there more RsmA present in the mucA22 strain, but we also showed this abundance in
RsmA was inhibiting the translation of the type six secretion component, tssA1, and hydrogen
cyanide synthase, hcnA (12). Due to bacteria tightly controlling the regulation of their various
products, these data suggested an importance to the abundance of RsmA in mucoid chronic
infection strains. We also hypothesized from these results that there might be more RsmA
targets or different targets in mucoid strains.
In this study, we continue our understanding of RsmA in a mucoid chronic infection
model strain. We characterize a mucoid ∆rsmA strain in terms of virulence factor production and
also the effects on virulence of this mutation. Since RsmA is known to regulate hundreds of
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targets post-transcriptionally and previous works examined the transcriptome of P. aeruginosa,
we decided to compare the proteome of the mucoid mucA22 strain and its rsmA mutant. We
hypothesized proteomic analysis would produce a better representation of RsmA targets in the
mucoid background. Lastly, we demonstrated a direct interaction with RsmA and a previously
unknown target, pasP, a small protease. Overall, this work furthers the understanding of the
RsmA regulon in mucoid strains of P. aeruginosa.

METHODS
Strains, plasmids, and media
The strains used in this study are presented in Table 4.1. Escherichia coli strains were
maintained on LB (Difco) plates or broth without or with antibiotics, as appropriate.
Pseudomonas aeruginosa strains were grown on Pseudomonas isolation agar (PIA), LB medium,
or Vogel-Bonner minimal medium (VBMM) supplemented with the appropriate concentrations
of antibiotics. For E. coli, antibiotics were used at the following concentrations when
appropriate: 10 µg/ml tetracycline, 15 µg/ml gentamicin, 100 µg/ml ampicillin, and 35 µg/ml
kanamycin. For Pseudomonas strains, antibiotics were used at the following concentrations: 150
µg/ml gentamicin, 50 µg/ml tetracycline, and 300 µg/ml carbenicillin. For allelic exchange,
sucrose was supplemented at 10% in YT (1% tryptone and 0.5% yeast extract) medium.
TABLE 4.1
Strain or Plasmid

Genotype or Relevant properties

Reference
or Source

fhuA2 Δ(argF-lacZ) U169phoA, glnV44

New
England

E. coli strains
NEB5α
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Φ80Δ(lacZ)M15 gyrA96
pRK2013
Helper strain
rsmAHA pEX18Gm Allelic exchange for rsmA HA allele
TF3-lacZ miniCTX Transcriptional fusion
hcp1-lacZ
Transcriptional fusion
lacUV5-pasp-lacZ
Leader fusion
P. aeruginosa
strains
PAO1
Wild type
mucA22
mucA22 mutation
FRD1
Mucoid clinical isolate
PAO568
Mucoid clinical isolate
8830
Mucoid clinical isolate
383
Nonmucoid clinical isolate
2192
Mucoid clinical isolate
∆lasR ∆rhlR
Attenuated control strain
mucA22 ∆retS
Mucoid retS mutant
∆rsmA
rsmA nonpolar deletion
mucA22∆rsmA
rsmA nonpolar deletion in mucA22 strain
PAO1
rsmA transcriptional fusion strain
TF3-lacZ
mucA22
rsmA transcriptional fusion strain
TF3-lacZ
2192 TF3-lacZ
rsmA transcriptional fusion strain
383 TF3-lacZ
rsmA transcriptional fusion strain
FRD1 TF3-lacZ
rsmA transcriptional fusion strain
PAO568 TF3-lacZ
rsmA transcriptional fusion strain
8830 TF3-lacZ
rsmA transcriptional fusion strain
PAO1 hcp1-lacZ
hcp1 transcriptional fusion strain
mucA22 hcp1-lacZ hcp1 transcriptional fusion strain
mucA22∆rsmA
hcp1 transcriptional fusion strain
hcp1-lacZ
PAO1
PAO1 with pasP leader fusion
lacUV5-pasp-lacZ
mucA22
mucA22 with pasP leader fusion
lacUV5-pasp-lacZ
mucA22∆rsmA
mucA22∆rsmA with pasP leader fusion
lacUV5-pasp-lacZ
PAO1HA
PAO1 with epitope tagged RsmA
mucA22HA
mucA22 mutant with epitope tagged RsmA
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Biolabs
21d
12
12
This study
This study
50
51
52
53
54
55
55
56
12
12
12
12
12
12
12
This Study
This Study
This Study
This Study
This Study
This Study
This Study
This Study
This Study
This study
This study

Strain construction
All PCR products were amplified with DNA from P. aeruginosa PAO1, unless otherwise
noted, using Q5 polymerase (New England BioLabs [NEB], Ipswich, MA) and primers listed in
Table 4.2. Crossover PCR (splicing by overlapping extension PCR) (21b) was used to construct
deletion mutations and to clone sequences into the suicide vector pEX18Tc or pEX18Gm (21c).
All cloned constructs were confirmed via sequencing. P. aeruginosa strains were conjugated
with E. coli as a donor strain and the pRK2013-containing helper strain (21d). Conjugations were
performed overnight on LB plates at 37°C, and the conjugants were plated on the appropriate
selective medium to obtain single-crossover mutants. Merodiploids were grown without
selection and then screened for sucrose sensitivity on YT medium–10% sucrose plates.
Mutations were confirmed using PCR with primers containing the suffix intF and intR in Table
4.2 and sequencing of the resulting PCR fragment. Hemagglutinin (HA) tagging of the proteins
was accomplished using primers containing the HA tag at the 3’ end of the gene, and HA was
introduced as described above using the suicide vector pEX18Gm.
TABLE 4.2
Primer
Hcp1-lacZF

Sequence
GCGCGGATCCACACCGACTTCGCCGCCTTC

GATCCGGACGTTAAGGAGAATGTCCAT

Use
Transcriptional
fusion
Transcriptional
fusion
Leader fusion

AATTCATGGACATTCTCCTTAACGTCC

Leader fusion

Hcp1-lacZR GCGCAAGCTTCTTTCCTCCCGTGTGGCTC
lacUV5pasP
F
lacUV5pasp
R
Paspt7emsa
F
Paspt7emsa
R
rsmyemsaF

TGTAATACGACTCACTATAGGGACGTTAAGGAGAAT EMSA
GTCCAT
ATGGACATTCTCCTTAACGTCCCTATAGTGAGTCGT EMSA
ATTACA
TGTAATACGACTCACTATAGGGGTCAGGACATTGCG EMSA
CAGGAAG
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rsmyemsaR

AAAACCCCGCCTTTTGGGCGG

EMSA

Phenotypic Assays
Various virulence products were assayed in the P. aeruginosa strains in this study. All
strains were grown in LB broth at 37ºC for 16 hours. Biofilm production was assayed by using
Congo Red plates and a 96-well plate biofilm quantification (22, 23). Strains were spotted onto
agar plates in 10 µl drops and incubated at 37ºC overnight. For quantification, strains were
resuspended in M63 media per O’Toole and quantified using a spectrophotometer. Skim milk
agar (Difco) was used to observe any differences of casein digestion (24). Strains were spotted
onto the agar in 10 µl drops and incubated overnight at 37ºC. Pyocyanin was assayed by
centrifuging the culture and collecting the supernatant. Then 2 mL of chloroform was used to
extract any pyocyanin produced in the culture by vortexing vigorously and allowing to set for 10
minutes. The chloroform layer was removed and 1 mL of 0.1 N HCl was added and vigorously
vortexed and allowed to set for 10 minutes. 0.1 N HCl was used to blank the spectrophotometer
at OD562nm. Values were normalized to PAO1.
C. elegans Assay
Caenorhabditis elegans was maintained on NGM agar plates with OP50 E. coli (25).
Once plates were fully saturated with C. elegans eggs, eggs were harvested and worms were
synced via bleaching (26). The following day worms were put on NGM media with OP50 and
allowed to grow to L1 stage. P. aeruginosa strains were incubated at 37ºC on fast killing media
on 20 cm plates(27). C. elegans were harvested and cleaned of E. coli and 30-50 worms were
plated on P. aeruginosa strains (27). C. elegans viability was recorded every 12 hours for 2.5
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days. Experiments were performed in triplicate two times.
Macrophage Survival Assays
P. aeruginosa strains were incubated with ATCC J774a.1 macrophages to assess
macrophage survivability. Macrophages were grown in Corning cellgro DMEM with LGlutamine, 4.5g/L Glucose, and 10% fetal bovine serum and 100 I.U./ml penicillin 100 µg/mL
streptomycin. Cells were maintained in a 37ºC incubator with 5% CO2 and humidity. Cells were
counted and plated in 12-well plates at 1x10^6 cells per well in media without pen/strep.
Overnight LB cultures of P. aeruginosa strains were diluted to 1% and allowed to grow for 2
hours at 37ºC at 250 rpm. Cultures were then centrifuged and washed with 1X PBS. Strains
were then aliquot to an OD600nm of 0.1 and incubated with macrophages up to 6 hours. The
inoculum of bacteria was also measured in CFU/mL. Macrophages were collected at 2, 4, and 6
hour time points and 1 mL of culture was mixed with 100 µL of 0.4% trypan blue to measure
viability. Experiments were performed three times in triplicate (n=9).
Western blot analysis
P. aeruginosa strains were grown in LB broth at 37°C for various times. The bacteria
were collected by centrifugation, resuspended in sterile phosphate-buffered saline, and lysed by
sonication. Total protein concentrations were quantified by the Bradford protein assay (Bio-Rad,
Carlsbad, CA). Cell extracts (5 µg) were separated by 12% SDS-PAGE and transferred to a
polyvinylidene difluoride membrane (Bio-Rad). The membranes were blocked and probed using
a 1:20,000 dilution of anti-HA monoclonal antibody (Thermo Fisher, Pittsburgh, PA), followed
by a 1:20,000 dilution of horseradish peroxidase-conjugated goat anti-mouse immunoglobulin
antibody or a 1:20,000 dilution of anti-Hcp1 polyclonal antibody followed by a 1:20,000 dilution
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of horseradish peroxidase-conjugated goat anti-rabbit immunoglobulin antibody (27b). The
membrane was stripped per Abcam mild stripping protocol and then probed with RpoA primary
antibody (1:20,00 dilution) followed by 1:20,000 dilution of horseradish peroxidase-conjugated
goat anti-mouse immunoglobulin antibody. Detection was performed using an ECL Plus kit
(Thermo Fisher, Pittsburgh, PA) and chemiluminescence detection (ProteinSimple, Santa Clara,
CA). All Western blot analyses were repeated at least three times.
Two dimensional gel electrophoresis
Strains were started as overnight cultures and the following day diluted to a fresh LB
broth at 1% and grown for 8 hours at 37ºC at 250 rpm. The bacteria were collected by
centrifugation, resuspended in sterile phosphate-buffered saline, and lysed by sonication with 10
µL of lysozyme 20 mg/ml added. Samples were centrifuged for 10 minutes at 10,000 x g.
Samples were quantified using a BCA assay. Four hundred micrograms of each sample was then
acetone precipitated with ice-cold acetone and left at -20ºC overnight. Samples were then
centrifuged at 14K x g for 15 minutes at 4ºC, then washed with 80% cold acetone and
centrifuged at 14K x g for 15 minutes at 4ºC twice. Pellet was dried in a speed vac centrifuge
after aspirating off 80% acetone. Using the Invitrogen ZOOM 2D kit, 1X IEF rehydration buffer
was mixed per 400 µg (309 µl ZOOM 2D Protein Solubilizer 1.1, Ampholytes 6.4 µl, 7 µl 0.1%
bromophenol blue, 31.6 µl deionized water, 6 µl 1M DTT). 1X IEF rehydration buffer was
added to each pellet. Samples were incubated on over end rotator for 1 hr at room temp.
Centrifuged samples at 12K x g for 10 minutes at 4ºC. Each Novex ZOOM strip was rehydrated
with 155 µl of rehydration buffer and incubate cassette for at least 2 hours on rocker at room
temp. Strips were then run following the IPG Runner program protocol B (200 V for 20 min,
450 V for 15 min, 750 V for 15 min, 2000 V for 65 min). ZOOM trays were then reduced and
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alkylated before running second dimension. Strips were added to a Novex 4-20% Tris-glycine
ZOOM gel and run for 165 minutes at 125V. Gels were fixed and Coomassie Blue stained and
then analyzed with Dymension Software. Significant spots were in-gel trypsin digested and
cleaned up to run through a Thermofisher LTQ XL mass spectrometer for protein identification.
Experiments were performed in duplicate twice.
In-gel trypsin digestion
Gel pieces were added to a microcentrifuge tube. To shrink the pieces, 50 µl of
acetonitrile was added and incubated for 15 minutes at RT. Gel pieces were then dried using a
speed vac centrifuge. To digest, 75 µl of a 10 ng/µl stock of trypsin was added to cover the gel
pieces and incubated at 37ºC overnight. The solution was removed and added to a new
microcentrifuge tube. Elution buffer (0.1% formic acid, 50% acetonitrile, 49.9% water) was then
added to cover the gel piece and incubated for 15 minutes then added to the new microcentrifuge
tube. Using Zip Tips (µ-C18) purification to prepare the sample for mass spectrometry, samples
were run through the tip column and then eluted off with elution buffer. The sample was
pelleted and dried using speed vac centrifugation. Samples were resuspended in 8 µl of mass
spec buffer (0.1% formic acid in 100 µl of acetonitrile and 400 µl HPLC water). Samples were
then sent through the LTQ XL mass spectrometer and analyzed using Proteome Discover 3.1
software to determine protein identified in sample and identifying only high confidence peptides.
iTRAQ
Strains were started as overnight cultures and the following day diluted to a fresh LB
broth at 1% and grown for 8 hours at 37ºC at 250 rpm. The bacteria were collected by
centrifugation, resuspended in sterile phosphate-buffered saline, and lysed by sonication with 10
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µL of lysozyme 20 mg/ml added. Samples were centrifuged for 10 minutes at 10,000 x g.
Samples were quantified using a BCA assay. One hundred and ten micrograms of each sample
was then acetone precipitated with ice-cold acetone and left at -20ºC overnight. Samples were
then centrifuged at 14K x g for 15 minutes at 4ºC, then washed with 80% cold acetone and
centrifuged at 14K x g for 15 minutes at 4ºC twice. The Sciex iTRAQ labeling protocol was
followed for labeling peptides. After labeling trypsin digested peptides, SCX spin tips were used
to create a gradient to identify lower frequency peptides in the labeled samples. Samples were
fractionated over 20 concentrations of increasing ammonium formate (15 to 500 mM) and
decreasing amount of 10% acetonitrile (985 µl to 500 µl). Fractions were then speed vac
centrifuged and resuspended in 8 µl of mass spec buffer. iTRAQ Samples were analyzed using
Bioworks 3.3 software with peptide confidence threshold set to 10-3 for only high confidence
peptides that also had iTRAQ label quantification. The p-value of comparison between labels
was performed using Student’s t-test. Experiments were performed in duplicate twice.
Transcriptional and translational leader fusion analysis
Upstream DNA fragments containing promoter regions were generated by using the
primers listed in Table 4.2 in conjunction with Q5 polymerase (NEB, Ipswich, MA). PAO1
genomic DNA was used as the template. PCR products were cloned into pCR2.1 and then
subcloned into miniCTXlacZ using the restriction enzymes HindIII/BamHI, HindIII/EcoRI, or
KpnI/BamHI (New England BioLabs, Ipswich, MA). The translational fusion vector
CTXlacZCP was constructed by amplifying the lacZ gene using the primers listed in Table 4.2 in
order to delete the lacZ ribosome-binding site and the translational initiation codon. The fusion
constructs were confirmed by sequencing and conjugated into P. aeruginosa strains by
triparental conjugation. Strains were selected for tetracycline resistance and then conjugated with
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pFLP2 to remove vector sequences (21c). Strains were selected for carbenicillin resistance,
grown overnight without selection, and plated on YT medium with 10% sucrose to select for the
loss of pFLP2. Individual colonies were patch plated onto VBMM supplemented with 300 µg/ml
carbenicillin and PIA to ensure the loss of pFLP2. To confirm the presence of the fusion
constructs, PCR was performed using the forward primer used to construct the fusion and the
reverse primer lacZRforTF (Table 4.2). β-Galactosidase activity was deter- mined by incubating
cell extracts with o-nitrophenyl-β-D-galactopyranoside (4 mg/ml) as described by Miller (27c).
All mucoid strains were confirmed to be mucoid at the end of each experiment by plating on PIA
plates and making sure that all colonies were mucoid. Experiments were performed in triplicate
at least three times.
RsmA purification
The rsmA gene was PCR amplified using Q5 (NEB) and PAO1 chromosomal DNA using
oligonucleotides rsmASal1F and rsmANot1R (Table 4.2). A 186-bp SalI/NotI fragment was
cloned into pGEX-4T-3 (Novagen) to be expressed as a glutathione S-transferase–RsmA (GSTRsmA) fusion protein. The resulting plasmid (pGEX-4T-RsmA) was transformed into E. coli
BL21(DE3) (NEB) cells and spread on LB Amp100 agar. The colonies from this transformation
were PCR confirmed and struck for isolation. The confirmed isolate was inoculated into LB
Amp100 at 37ºC at 250 rpm overnight. A 1% dilution was added to 250 mL of LB Amp100 and
grown to an OD600nm of 0.6 at 37ºC at 250 rpm; 0.2 mM isopropyl-β-D- galactopyranoside
(IPTG) was added to induce RsmA expression for 6 h at the same conditions. The cells were
collected by centrifugation (7,000 g, 10 min) and frozen overnight. Pellets were thawed and
lysed using BPER with 4 µl of lysozyme 20 mg/mL and 2 µL of DNase I per mL of BPER along
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with a 1X concentration of protease inhibitors. RsmA was purified from this supernatant using
the GST spin purification kit (Thermo Fisher). After binding of the fusion protein and washing
the column, RsmA was cleaved away from GST with 10 U of thrombin/column overnight at
22°C on an end over rocker. Purified protein was dialyzed using a Slide-A-Lyzer (Thermo
Fisher) and storage buffer (20% glycerol, 20 mM Tris [pH 7.5], 5 mM MgCl2, and 1 mM
dithiothreitol [DTT]) for 2 hours at room temperature twice and overnight at 4°C. The identity of
the purified protein was determined by mass spectrometry. The purity of RsmA was visually
determined in a Coomassie-stained 15% electrophoresis gel (SDS-PAGE).
RNA EMSA
Annealed oligomers or PCR amplicons with T7 promoters on the forward primer were
used to construct RNA probes for electromobility shift assays with RsmA (Table 4.2).
Oligomers were either annealed or amplified using Taq polymerase from NEB and gel purified
using an NEB Monarch gel extraction kit. In vitro transcription was performed using the NEB
HiScribe T7 High Yield RNA synthesis kit. Upon completion, the Pierce RNA 3’ End
Biotinylation kit was used to generate probes. The kit control was also biotinylated as a control
for this step and the EMSA as it has an RsmA binding motif (AGGA). Purified RsmA was used
in this study. The Pierce RNA EMSA kit was used for the detection of protein-RNA
interactions. Reactions were run on a 15% native PAGE and transferred to a nylon membrane at
35 mA for 35 minutes. The membrane was then UV cross linked for 60 seconds. The membrane
was then treated using the Thermofisher LightShift Chemiluminescent detection kit. Membranes
were developed using chemiluminescence detection on a ProteinSimple developer.
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Statistical analyses.
Statistical analyses were performed using Microsoft Excel software (Microsoft,
Redmond, WA).

RESULTS
mucA22 ∆rsmA has variant phenotypes
In P. aeruginosa RsmA has been shown to regulate hundreds of targets through
posttranscriptional regulation (13, 28). Our lab has previously shown that in a mucA22 strain,
AlgU and AlgR increase the expression of rsmA (12, 29). The rsmA mutation did not affect the
ability for alginate to be produced and both rsmA and mucA22 rsmA both appeared bluish on PIA
Figure 4.1 Appearance of rsmA mutants appear similar on PIA and skim milk agar.

P. aeruginosa strains on PIA (A) or skim milk agar (B). PIA is standard growth
media for Pseudomonas strains and blue pigmentation is typical of rsmA mutants.
Skim milk plates are used to observe the ability of a strain to digest casein protein.

(Figure 4.1a). To investigate other simple phenotypic assays, the rsmA mutants were also
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Figure 4.2 mucA22 rsmA produces more biofilm.

A) A 96-well microtiter plate biofilm assay was performed to quantify amounts of biofilm
between P. aeruginosa strains. All strains were normalized to PAO1 or percent of wildtype.
***represents a p < 0.01. B) Photos of below and the side of wells with P. aeruginosa strains
stained with crystal violet. C) Colonies of P. aeruginosa strains grown on LB supplemented
with Congo Red and Bromophenol Blue. Experiments were performed in triplicate (n=9).
screened on skim milk agar (Figure 4.1b) and analyzed for biofilm production (Figure 4.2).
Skim milk agar looks specifically at the ability of the bacteria to digest the milk protein, casein
(24). The parent strains were able to generate clear zones of digested casein much more readily
than either rsmA mutant.
Biofilm production was quantified using a 96-well plate and visualized using
crystal violet and Congo Red agar (22, 30). rsmA mutants produce more of the secondary
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messenger cyclic di-GMP (31). This compound indirectly contributes to biofilm formation. The
transcriptional regulator, AmrZ, also contributes to biofilm formation and is regulated by AlgU
(32, 33). In the mucA22 rsmA strain both AlgU is active and RsmA does not repress cyclic diGMP production. The rsmA strain showed a slight decreased in the biofilm assay, but appeared
slightly darker than PAO1 on the Congo Red plate. This result has been previously reported
where rsmA has impaired binding on a plate (28). mucA22 showed an even more significant
decrease in biofilm production. P. aeruginosa produces three known exopolysaccharides:
alginate, pel, and psl (32, 34, 35). The mucA22 strain has an abundance of alginate and RsmA,
which can repress the ability for biofilm formation (36). The mucA22 rsmA strain showed the
most increase in biofilm production in the microtiter plate assay and was also starkly different on
the Congo Red plate. Congo Red is bound by the biofilm compounds of P. aeruginosa and
causes the visual difference (22). The difference between rsmA mutants suggests RsmA has
potential for regulation of other targets in the mucA22 background compared to the nonmucoid
PAO1 strain.
C. elegans more susceptible to mucA22 ∆rsmA pyocyanin levels
RsmA has been shown to regulate pyocyanin production through anthranilate levels
increasing in an rsmA mutant (28). Pyocyanin is a blue pigment produced by P. aeruginosa that
blocks the effects of reactive oxygen species from host immune cells and creates an observable
blue appearance during skin infections (2, 37). Pseudomonas on PIA media will appear bluer if
there is increased pyocyanin production. Both rsmA mutants appeared blue on PIA, but
pyocyanin can be quantified as well (Figure 4.3a). The parent strains, PAO1 and mucA22,
produced no difference in pyocyanin levels. The nonmucoid rsmA mutant showed the expected
increase has reported previously (28). Similarly to the biofilm assay, the mucA22 rsmA strain
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produced a four-fold increase in pyocyanin compared to mucA22. This significant increase
showed further importance of studying the effects of RsmA in the mucoid background.
To analyze the effects of increased pyocyanin on virulence, a fast killing assay with C.
elegans can be used to screen for viability(27). In Figure 4.3b the rsmA were more lethal to the

Figure 4.3 mucA22 rsmA mutant produces more pyocyanin and is more lethal in a fastkilling assay than mucA22.

A) Pyocyanin assay was used to quantify production of pyocyanin by P. aeruginosa strains.
Experiments were performed in triplicate (n=9). B) Fast-killing assays were used to confirm
production of pyocyanin. C. elegans is more susceptible to pyocyanin with this media. P.
aeruginosa strains were incubated with C. elegans for 2.5 days. A lasR rhlR strain produces little
if no pyocyanin and was used as a control. Experiments were performed in triplicate (n=6). ***
represents a p < 0.01.
C. elegans due to increased pyocyanin production. A lasR rhlR mutant was included due to this
strain being attenuated and also deficient in pyocyanin production (38). There was no difference
between the lethality of PAO1 with rsmA, however the four-fold increase in pyocyanin
production was significant after two days between mucA22 and mucA22 rsmA. The fast killing
assay with C. elegans showed increased lethality in the mucA22 rsmA strain. Pyocyanin is an
important factor in this assay and the mucA22 rsmA strain produces four times as much
compared to the attenuated mucA22 strain.
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Figure 4.4 mucA22 ∆rsmA kills fewer J774a.1 macrophages than PAO1 and mucA22 after 6 hour
incubation.

J774a.1 macrophages were incubated with PBS or P. aeruginosa strains for up to 6 hours in 12-well
plates. Macrophages were scraped and strained for viability with 0.4% Trypan blue strain. Experiments
were performed in triplicate (n=9). a represents p < 0.01 compared to PAO1. b represents p < 0.01
compared to mucA22.
Macrophages have increased survivability with mucA22 ∆rsmA
To investigate the effects of mucA22 rsmA virulence further on a level more relevant to
higher organisms, P. aeruginosa strains were assayed with J774a.1 macrophages (Figure 4.4). A
lasR rhlR strain was used as a negative control since this strain is attenuated for multiple
virulence factors(39). mucA22, rsmA, mucA22 rsmA were all attenuated compared to PAO1.
Even more interesting was the significant increase in macrophage viability in the mucA22 rsmA
compared to mucA22. Since RsmA regulates multiple virulence factors and indirectly promotes
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acute virulence factors an rsmA mutant has been shown to be attenuated with epithelial cell
infection, which explains the increase in survivability with macrophages(15). Pyocyanin
production has also been demonstrated to affect macrophage phagocytosis but due to incubation
time and the cell culture media used, pyocyanin production does not seem to effect this assay
(37). Overall, the role of RsmA in the mucoid background effects virulence factor regulation
and pathogenesis, as we show herein that the mucA22 ∆rsmA is less lethal to J774a.1
macrophages.
Proteomics approach reveals new targets of RsmA
RsmA targets had been studied in the nonmucoid background previously using PAO1 and
PAK via a transcriptomics approach (13, 28). RsmA is expressed throughout
the P. aeruginosa growth phases and most expression of RsmA in nonmucoid strains occurs
around 9 hours (13, 40). A time course western blot was performed to identify the optimally
expressed hour for investigating RsmA in the mucoid strain, mucA22 (Figure 4.5). While RsmA
is present even at 24 hours in mucA22, P. aeruginosa cultures were collected at 8 hours to be
consistent with nonmucoid studies.
Figure 4.5 RsmA levels are increased in mucA22 across all time points compared to
PAO1.

Western blot analysis of PAO1 and mucA22 strains at 4, 6, 8, 10, 12, and 24 hours. Blots
were probed for RsmA-HA with anti-HA monoclonal antibodies. A PAO1 strain lacking an
HA-epitope was used as a negative control. Experiments were performed twice.
Since RsmA regulates targets by inhibiting translation of mRNA, a better representation
of RsmA targets would be through a proteomics approach versus transcriptomics (15). In Figure
4.6a and b 2-dimensional gels were initially used to investigate the proteomes between mucA22
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and mucA22 rsmA. In this proteomic approach, a known target of RsmA, Hcp1, was shown to be
increased in the mucA22 rsmA background(13). In order to streamline the proteomic approach,
the P. aeruginosa strains were analyzed though iTRAQ
(isobaric tagging relative and absolute quantification). mucA22 rsmA was compared to mucA22
and an abbreviated list of proteins can be observed in Table 4.3. In the iTRAQ screen the
mucA22 rsmA strain showed increases in known RsmA targets, hcp1 and phnA (28, 41). The
small protease PasP was increased in not only the 2D gel but also 2-fold in the iTRAQ. PasP had
Figure 4.6 2D-gel analysis reveals new RsmA targets.

A) and B) 2D gels of mucA22 (green) and mucA22 rsmA (pink) overlaid using Dymension
software. Molecular weight markers are designated on the left side of the gels. Isoelectric
points are designated on the bottom of the gels. Increases in the mucA22 background (M) or
in the mucA22 ∆rsmA background (MR) were picked and in-gel trypsin digested. C) Table
identifying the proteins via mass spectrometry analysis present in the selected spots.
not shown up in any of the transcriptome studies of RsmA, and it has been implemented in
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Table 4.3. iTRAQ analysis between mucA22 and mucA22 rsmA

Abbreviated data of iTRAQ results. Green shows a > 1.5 increased protein abundance in
mucA22 rsmA compared to mucA22. Red shows a ≤ 0.76 decreased protein abundance in
mucA22 rsmA compared to mucA22. Bold lines outline previously identified targets, or
targets identified in 2D-gel analysis. Experiments were performed in biological duplicate
for each iTRAQ label. Thermofisher Bioworks software was used for determining peptide
confidence and iTRAQ label amounts. No proteins under a 10-3 peptide confidence were
included meaning peptides had 99.95% confidence of correct identification.
affecting P. aeruginosa virulence (42, 43). Interestingly, these proteomic experiments are more
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insight into RsmA’s regulon in the mucoid background.
RsmA targets hcp1 and pasP in mucA22
iTRAQ, just like an RNA-seq or microarray, has to be confirmed because effects can be
indirect results of a mutation. In the case of RsmA, this is especially necessary since it regulates
hundreds of targets. Since RsmA had been known to target hcp1 already, there was no need to
prove a direct interaction (41). The effects of hcp1 in the mucoid background had not been
investigated so transcription and western blot analysis was employed to confirm the 2D gel and
iTRAQ results. In Figure 4.7a hcp1 expression was no different between PAO1 and mucA22,
however expression was decreased in mucA22 rsmA. The decreased expression levels of hcp1 in
an ∆rsmA mutant was not expected as nonmucoid ∆rsmA mutant is known to have increased
levels of Hcp1. Western blot analysis was employed to look at whether RsmA was in fact
having a role in Hcp1 translation in the mucoid strain. A mucA22 retS strain was included as a
control since RetS has been shown to negatively affect the levels of type VI secretion system
(T6SS) protein (44). The mucA22 retS strain showed more Hcp1 compared to mucA22 as
expected. Both rsmA mutants showed increased Hcp1 levels compared to the parent strains. The
T6SS is used to fend off other foreign bacteria, but not thought to be expressed in mucoid strains.
A previous proteomic comparison between co-cultured nonmucoid and mucoid strains, 383 and
2192, showed 2192 had less Hcp1 (45). Because RsmA is in higher abundance in mucA22,
RsmA inhibits the translation of the T6SS in the mucoid background.
Since pasP has never been shown to be a target of RsmA, confirmation of the 2D gel and
iTRAQ had to also include a direct interaction. The posttranscriptional effect on pasP was first
investigated using a lacUV5 leader fusion for its intergenic region (Figure 4.8a). The fusion was
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Figure 4.7. RsmA represses T6SS component Hcp1 in mucA22.

A) Strains were assayed for hcp1 expression using a transcriptional fusion with lacZ reporter.
P. aeruginosa strains were grown in LB broth overnight and then a 1% inoculum was grown
for 8 hours. β-galactosidase assay was performed to measure expression using a LacZ reporter
per Miller. Experiments were performed in three technical triplicates with three biological
replicates (n=9). Student’s t-test showed no significant difference between PAO1 and
mucA22, however statistical analysis showed a decrease with p <0.001 in mucA22 rsmA
compared to mucA22 represented by ‡. B) Western blot analysis with antibodies to Hcp1 in
P. aeruginosa strains. P. aeruginosa strains were grown in LB broth overnight and then a 1%
inoculum was grown for 8 hours. Nonmucoid and mucoid rsmA mutants had increased Hcp1
levels compared to their respective parent strains. A retS mutation, known to suppress T6SS
production, is similar to a rsmA mutation and was used as a control in this analysis. ImageJ
software was used to analyze densitometry.
very active in PAO1, but in mucA22 where there is an abundance of RsmA, the fusion decreased
100-fold. When the rsmA allele was removed in mucA22, reporter activity went up 50- fold.
RsmA is known to target an AGGA motif that is usually presented in the loop of a stem-loop
structure (13). Using m-fold predictive software, Figure 4.8b shows the intergenic region of
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Figure 4.8. RsmA interacts directly with pasP in mucA22.

A) Constitutively active fusion with lacZ reporter constructed with lacUV5 promoter and
intergenic upstream region of pasP to quantify posttranscriptional activity of RsmA. . P.
aeruginosa strains were grown in LB broth overnight and then a 1% inoculum was grown
for 8 hours. β-galactosidase assay was performed to measure expression using a LacZ reporter
per Miller. Experiments were performed in three technical triplicates with three biological
replicates (n=9). Student’s t-test was performed to compare PAO1 and mucA22 as well as
mucA22 and mucA22 rsmA. Both showed statistical significance with p < 0.001 demonstrated by
‡. B) Predicted secondary RNA structure of the pasP upstream intergenic region between PA0422
and pasP. The RsmA binding motif “AGGA” is highlighted at the top of the stem loop structure.
C) and D) RNA electrophoretic mobility shift assay (EMSA) with purified RsmA to illustrate
direct interaction between RNA of rsmY (C) or pasP (D) and RsmA. Twice as much
unbiotinylated (cold) rsmY RNA was used to demonstrate specificity and outcompete the
biotinylated probe. IRE (iron responsive element) RNA provided in the Pierce 3’ OH RNA
biotinylation kit has no RsmA binding motif and was used as a negative control.
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PA0422 and pasP, which contains the AGGA motif in a stem-loop. To confirm a direct
interaction with pasP, RsmA was purified and first tested with its ncRNA antagonist RsmY
(Figure 4.8c). RsmA was then incubated with a biotinylated pasP probe to prove if pasP was a
previously unknown target of RsmA (Figure 4.8D). RsmA could also be competed away with
unlabeled RsmY transcript in both experiments confirming specificity of RsmA for the probe,
RsmY or PasP (Figure 4.8c and d).
Figure 4.9. Mucoid strains of P. aeruginosa express more rsmA through rsmA’s distal
promoter.

Strains of P. aeruginosa were assayed for rsmA expression using a transcriptional fusion
(TF3-lacZ) that is regulated by AlgU and AlgR. P. aeruginosa strains were grown in LB
broth overnight and then a 1% inoculum was grown for 8 hours. β-galactosidase assay was
performed to measure expression using a LacZ reporter per Miller. Experiments were performed in
three technical triplicates with three biological replicates (n=9). Student’s t-test was performed
between PAO1 and 383, which showed no significant difference. Student’s t-test was performed
between nonmucoid PAO1 and mucoid strains where ‡ represents p < 0.001.

Mucoid clinical isolates have increased rsmA expression
P. aeruginosa commonly undergoes phenotypic variation when exposed to the hostile
response of a host’s immune system (46). Isolates from cystic fibrosis patients commonly
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convert to the mucoid phenotype. In our previous work, we investigated rsmA expression in a
nonmucoid isolate 383 and a mucoid isolate 2192 that were co-cultured from the same cystic
fibrosis patient (12, 55). The mucoid 2192 strain had increased RsmA levels via western blot
analysis (12). Because our iTRAQ results showed new potential targets, more mucoid clinical
isolates were investigated for rsmA expression using the TF3-lacZ fusion which relies on the
AlgU promoter (12) (Figure 4.9). mucA22 has the most increased rsmA expression all of the
mucoid clinical isolates have at least 3-fold increased expression compared to the nonmucoid
strains, PAO1 and 383. The increase of rsmA levels in mucoid strains lends credence to the
importance of understanding the RsmA regulon in the mucoid background.

DISCUSSION
P. aeruginosa can cause many life threatening infections from acute to chronic. In the
case of cystic fibrosis, P. aeruginosa will establish an infection in the lung where it can evade
the host response and antimicrobials to persist and develop into a chronic infection (47, 48).
Some clinical isolates from cystic fibrosis patients produce the phenotype termed mucoid, which
is commonly indicative of a chronic infecting strain. The mucoid phenotype is produced by the
extracytoplasmic sigma factor AlgU which regulates the alginate operon along with other
transcription factors like AlgR(9, 49). Our previous work showed that AlgU and AlgR also
contribute to rsmA expression and that there is increased RsmA levels in mucoid strains (12, 29).
Most of the work on the RsmA regulon has been done in nonmucoid strains investigating the
transcriptome (13, 28). However when compared to the nonmucoid rsmA mutant, the mucoid
mucA22 rsmA varies phenotypically. The mucA22 rsmA strain produced more casein digestion,
more biofilm, and more pyocyanin than the rsmA strain. We hypothesized that these results
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would lead to increased virulence of the mucA22 rsmA strain. However, the mucA22 rsmA strain
was attenuated compared to mucA22 and rsmA with J774a.1 macrophages due to an unknown
mechanism.
These stark differences between rsmA mutants in virulence factor production and
attenuation with macrophages led us to hypothesize that the RsmA regulon in mucoid strains
would be different that previously reported targets from transcriptome analysis. Our proteomic
approach demonstrated a better representation of posttranscriptional regulation by RsmA in
comparison to past transcriptomics analyses. If RsmA was not present to inhibit the translation
of its targets, the proteins would appear in abundance. We initiated this screen with 2D-gel
electrophoresis and identified previously unknown targets as well as known targets. In order to
screen the potential hundreds of targets of RsmA, we streamlined this approach with iTRAQ.
Using iTRAQ we confirmed already known targets of RsmA like Hcp1 and PhnA but also
previously unknown targets (Figure 4.10). Unfortunately with all global experiments, results can
be indirect. Direct interactions of RsmA and iTRAQ targets must be confirmed. However, the
virulence factors that are repressed in the mucA22 rsmA have potential to be positively regulated
RsmA targets just like CsrA is known to do with flagellum synthesis proteins in E. coli (18).
One new target we were able to confirm a direct interaction with RsmA is the P.
aeruginosa small protease, PasP. PasP has been shown to aid in P. aeruginosa virulence in a
rabbit corneal infection model (42, 43). Purified PasP was shown to also digest type I and IV
collagens in these studies (42, 43). PasP has also been shown to be important in the infection
process of a cystic fibrosis patient (48). We were able to show a direct interaction between
biotinylated in vitro transcribed probes for RsmY and PasP with purified RsmA. By competing
the RsmA away with cold in vitro transcribed RsmY, RsmA was shown to have specificity for
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Figure 4.10. Model of RsmA in mucoid strains.

In mucoid strains of P. aeruginosa AlgR and AlgU co-regulated the distal promoter of
rsmA. This activity leads to increased expression of rsmA in the mucoid background. The
mucoid P. aeruginosa RsmA regulon is similar and different to the targets of RsmA in
nonmucoid P. aeruginosa strains, PAO1 and PAK. RsmA targets T6SS components by
blocking the ribosomal binding site and inhibiting translation, but also represses previously
unknown targets like pasP. RsmA affects pyocyanin in both nonmucoid and mucoid
backgrounds, however a complicated pathway produces pyocyanin and direct targets have
yet to be elucidated.
the pasP message. Further work on the role PasP plays on the infection of P. aeruginosa is
important to elucidate the purpose of RsmA in regulating this target so heavily in mucoid strains.
Overall, studying the RsmA regulon in mucoid strains can help explain the role RsmA plays in
the infection process especially with cystic fibrosis. Also, by knowing what targets will and will
not be expressed direct antivirulence compounds in concert with antimicrobials can lower the
morbidity and mortality in cystic fibrosis patients with P. aeruginosa infections.
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ABSTRACT
Pseudomonas aeruginosa is an opportunistic pathogen and causes the most complications
in hosts with compromised immune systems like diabetes, HIV/AIDS, and cystic fibrosis. P.
aeruginosa wreaks havoc with an armamentarium of virulence factors able to evade immune
defenses and thrive in these hosts. P. aeruginosa regulates multiple virulence factors via two
component systems (TCS). TCS are composed of a sensor histidine kinase that receives an
external signal, autophosphorylates, and then phosphorylates its response regulator, which
activates or represses target genes. One TCS, AlgZ/R, activates the expression of the minor pilin
operon (fimUpilVWXY1Y2E) important in type IV pili (TFP). Previous work has shown that
some minor pilins can cause increased expression of the minor pilin operon via a feedback loop,
but the mechanism is unclear. algZ and algR transcriptional fusions were analyzed in a pilW
mutant strain of PAO1 to see if activity was affected due to the increase of minor pilin
expression. A 10-fold increase in algZ expression was seen in the pilW mutant. A previous
work performed a transposon mutagenesis screen to identify the regulator of this increase in algZ
expression. In this study, we show that the increase in minor pilin expression in a pilW mutant is
due to increased algZR expression and that phosphorylated AlgR is required for this increase.
These results were confirmed with qPCR and western blot analysis. These effects were also
examined in a pilW, phospho-deficient algR mutant (pilW algRD54A) that restored algZR
expression to wildtype levels. The biological effects of increased phosphorylated AlgR levels
were assayed with phenotypic assays for pyocyanin, elastin, and rhamnolipids, all showing
significant decreases in a pilW strain, but restoring levels to wildtype in pilW algRD54A. Lastly,
due to decreases in these virulence factors in pilW, the survivability of J774a.1 and RAW264.7
macrophages were assayed in the presence of the pilW and pilW algRD54A strains. Overall the
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overexpression of algZR in a pilW mutant leads to decreased virulence and demonstrates an
Achilles’ heel for P. aeruginosa.
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INTRODUCTION
Pseudomonas aeruginosa is an opportunistic pathogen capable of infecting any host
tissue. P. aeruginosa mostly causes acute infections in individuals with HIV/AIDS, with burns
over a majority of their body, and with ventilator assisted respiration (1, 2). These acute
infections can lead to septicemia and eventually death (3, 4). P. aeruginosa compromises its
host and evades the host immune system with the help of an armamentarium of virulence factors
(1, 5). The bacterium contains a diverse network of sensors and regulators controlling the
expression of virulence factors as to efficiently establish a niche and fully reap the host’s
nutrients.
One simple mechanism that P. aeruginosa uses to sense environmental signals is a twocomponent system (TCS) (6). TCSs are composed of a membrane bound sensor histidine kinase
that autophosphorylates upon binding its signal and then transfers this phosphate to a specific
response regulator. While many pathogens use TCSs, there are more identified TCSs in P.
aeruginosa than any other studied pathogen (7). These TCSs contribute to P. aeruginosa
pathogenesis in multiple ways including: biofilm development, attachment, antibiotic resistance,
suppressing posttranscriptional regulation, cyclic di-GMP production, and motility (5).
While some TCSs can have specific control over a single virulence mechanism, there are
TCSs that contribute to regulation of multiple virulence factors. The TCS AlgZ/R has been
shown to regulate rhamnolipids, pyocyanin, small noncoding RNAs, and type IV pili (TFP) (8,
9). This system consists of the histidine kinase, AlgZ, and the response regulator, AlgR. AlgZ
and AlgR are located in an operon together, like most TCSs (6). AlgZ is bound to the inner
membrane and the environmental signal it receives has still not been elucidated. The histidine
residue at 175 transfers the phosphate to AlgR’s aspartate at residue 54. AlgR contains the same
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motifs of most response regulators including the helix-turn-helix DNA binding domain (10).
Interestingly, AlgR can activate its targets in the phosphorylated form, like the TFP, or in a
phosphorylation independent manner, like rsmA (8, 11).
AlgR contributes to the production of TFP by regulating the expression of the minor pilin
operon (fimUpilVWXY1Y2E). These minor pilins are incorporated into the TFP stalk along with
the major pilin, PilA, and allow for P. aeruginosa to attach to surfaces and also perform motility
in the form of twitching (12). The TFP structure has two ATPase motors at its base for extension
and retraction of the stalk, allowing the bacterium to move across a surface (13, 14). Previous
work has shed light on the fact that the TFP not only contribute to adhesion and motility, but that
the tip of the TFP stalk, PilY1, contributes to expression of other virulence factors by acting as a
mechano-sensory apparatus, proving to be important in initiating an infection (14). Luo et al.
also showed that by removing the minor pilin operon, it caused a significant increase in minor
pilin expression (14). However, the actual mechanism by which the TFP works on regulating
other virulence factors has not been elucidated.
In this study, we expand upon the master’s thesis of Danielle A. Williams where she
performed a transposon mutagenesis with a pilW mutant containing an algZ-lacZ transcriptional
fusion (30). Her master’s work identified that in this background algZ expression was elevated,
but was significantly decreased when algR was interrupted by the transposon (30). We
hypothesized due to AlgR regulating minor pilin in a phosphorylation dependent manner and by
removing a minor pilin allele like pilW caused a significant increase in minor pilin expression
that not only was this due to increased levels of phosphorylated AlgR, but also these levels of
AlgR were causing a significant increase in algZ expression. In order to confirm this hypothesis
a pilW phospho-deficient strain, pilW algRD54A, was used. We assessed the pilW strain for
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AlgZ and AlgR levels, production of virulence factors regulated by AlgR, and whether or not the
increase in algZ/R expression had an effect on virulence. Overall, our work shows that targeting
the TFP can lead to manipulating the AlgZ/R TCS to make P. aeruginosa less virulent and in
combination with antibiotics, more readily cleared by the immune system.

METHODS
Strains, plasmids, and media
The strains used in this study are presented in Table 5.1. Escherichia coli strains were
maintained on LB (Difco) plates or broth without or with antibiotics, as appropriate.
Pseudomonas aeruginosa strains were grown on Pseudomonas isolation agar (PIA), LB medium,
or Vogel-Bonner minimal medium (VBMM) supplemented with the appropriate concentrations
of antibiotics. For E. coli, antibiotics were used at the following concentrations when
appropriate: 10 µg/ml tetracycline, 15 µg/ml gentamicin, 100 µg/ml ampicillin, and 35 µg/ml
kanamycin. For Pseudomonas strains, antibiotics were used at the following concentrations: 150
µg/ml gentamicin, 50 µg/ml tetracycline, and 300 µg/ml carbenicillin. For allelic exchange,
sucrose was supplemented at 10% in YT (1% tryptone and 0.5% yeast extract) medium.
Table 5.1
Strain or Plasmid

Genotype or Relevant properties

Reference or
Source

fhuA2 Δ(argF-lacZ) U169phoA, glnV44
Φ80Δ(lacZ)M15 gyrA96
Helper strain
r
F , cya-99, araD139, galE15, galK16, rpsL1 (Str ),

New England
Biolabs
16
Euromedex

E. coli strains
NEB5α
pRK2013
BTH101
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hsdR2, mcrA1, mcrB1
algZHA
pEX18Gm
algZ-lacZ
miniCTX
pAlgRD54E
P. aeruginosa
strains
PAO1
algR
algZ
algZHSDM
pilA
lasR rhlR
pilW
pilY1
vfr pilW
pilW algR
pilW algRD54A
pilW algZHSDM
PAO1HA
pilWHA

Allelic exchange for algZ HA allele

30

Transcriptional fusion

30

Overexpression of AlgRD54E

This study

Wild type
algR mutant
algZ mutant
algZ mutant with histidine 175 replaced with glutamate
pilA mutant
Quorum sensing deficient strain
pilW mutant
pilY1 mutant
Double mutant
Double mutant
Double mutant
Double mutant
PAO1 with epitope tagged AlgZ
mucA22 mutant with epitope tagged AlgZ

32
33
30
11
30
29
31
30
30
30
30
30
This study
This study

Strain construction
All PCR products were amplified from P. aeruginosa PAO1, unless otherwise noted,
using Q5 polymerase (New England BioLabs [NEB], Ipswich, MA) and primers listed in Table
5.2. Crossover PCR (splicing by overhang extension PCR) (14b) was used to construct deletion
mutations and to clone sequences into the suicide vector pEX18Tc or pEX18Gm (15). All cloned
constructs were confirmed via sequencing. P. aeruginosa strains were conjugated with E. coli as
a donor strain and the pRK2013-containing helper strain (16). Conjugations were performed
overnight on LB plates at 37°C, and the conjugants were plated on the appropriate selective
medium to obtain single-crossover mutants. Merodiploids were grown without selection and then
screened for sucrose sensitivity on YT medium–10% sucrose plates. Mutations were confirmed
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Table 5.2
Primer
algZqPCRF
algZqpcrR
algRqPCRF
algRqpCRR
uvrDqpcrR
uvrDqpcrF
mreBqpcrR
mreBqpcrF
algZTSFF

Sequence
GACCTGTCCGACCTGTTCCGG
CCAGCAGCGGCTGCAAGGTC
GCGGCAGCGGTCCGCGAG
CTTGTGGTCGGCAATGAAG
GGCGTCCCTGGTTGTT
GCAGTTCAGCGACGAC
CGCCGCAACTACGGCAG
GGTTGCGGCCGCGGA
GCGCGGATCCGTTCATGTGCACGTCTTCCAGG

Use
qPCR
qPCR
qPCR
qPCR
housekeeper
housekeeper
housekeeper
housekeeper
Transcriptional
fusion
algZTSFR
GCGCAAGCTTCGACAGAGTTTCCGCAAGG
Transcriptional
fusion
AlgRR
GCGCGGTACCCAGAGCTGATGCATCAGACGC
BACTH
AlgRF
GCGCGGATCCGAATGTCCTGATTGTCGATGACG
BACTH
AlgZF
GCGCGGATCCGCCTATCCGATTCAAGCCCGG
BACTH
AlgZR
GCGCGGTACCCAGGCTTCCTGCATGAGTCGC
BACTH
AlgZTruncR GCGCGGTACCGCGCGTGCCGCAGATACAG
BACTH
using PCR with primers containing the suffix intF and intR in Table 5.2 and sequencing of the
resulting PCR fragment. Hemagglutinin (HA) tagging of the proteins was accomplished using
primers containing the HA tag at the 3’ end of the gene, and HA was introduced as described
above using the suicide vector pEX18Gm.
Site-directed mutagenesis
Phosphorylated primers algRD54AF/algRD54EF and algRD54AR/algRD54ER were
used in an inverse PCR with the algR allele in pEX18Gm as the templates. The aspartate at
residue 54 of the algR allele was mutated into either an alanine with an NheI restriction site or a
glutamate with an XbaI site. The successful inverse PCR product was self-ligated, transformed
into NEB5α cells (NEB, Ipswich, MA), and screened by plasmid digestion with respective
restriction enzyme digestion and sequencing. The constructs obtained by site-directed
mutagenesis were conjugated into Pseudomonas strains as described above.
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BACTH
Bacterial adenylate cyclase two-hybrid system from Euromedex was used to test for
protein-protein interactions (17). The algR, algZ, and a truncated form of algZ were amplified
from PAO1 with primers listed in Table 5.2. These genes were cloned into the BACTH vectors.
For algR and the truncated C-terminus algZ either N-terminus or C-terminus fusions were used.
For the full-length algZ allele, only the C-terminus fusion was used. These vectors were
transformed into NEB5α cells and selected for on their respective antibiotic LB media, Amp100
or Kan50. After colony PCR confirmation, the strain was struck for isolation, frozen down and
set up for a plasmid precipitation using NEB Monarch plasmid prep kits. These plasmids were
than digested with the respective restriction enzymes and confirmed on a 1% agarose gel.
BTH101 cells were then transformed with the appropriate control vectors: empty Kan and Amp
vectors for negative control, leucine zipper positive controls, and the alleles to be investigated.
Cells were spread on MacConkey agar (Difco) with 1% Maltose, Amp100, and Kan50 or
LB/IPTG/XGal, Amp100, and Kan50 per Euromedex protocol. Colonies were PCR confirmed
for inserts before assaying. Assaying consisted of measuring β-galactosidase activity per Miller.
qPCR
P. aeruginosa strains were grown in LB broth at 37ºC overnight and then a 1% dilution
of the overnight culture was grown for 6 hours. The bacteria were collect by centrifugation
following the ZymoResearch Direct-zol RNA kit protocol. Upon elution from the column, RNA
was treated with DNase-I from NEB for 30 minutes at 37ºC. RNA was then precipitated with
200 proof EtOH and frozen overnight. The following day, the samples were centrifuged at 15k x
g for 10 minutes at 4ºC. The EtOH was aspirated off, 1 mL of 70% EtOH was added , and
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centrifugation repeated. EtOH was again aspirated off and samples were left to air dry. Pellets
were resuspended in 40 µl of Nuclease free water and quantified using a Thermofisher
NanoDrop. To generate cDNA, 5 ng of RNA was used with 2.5 ng random hexamers/µL (New
England Biolabs, Ipswitch, MA), 0.5 mM dNTPS, and followed Invitrogen superscript IV
reverse transcriptase protocol. A no RT control was generated. For qPCR NEB Luna was used
with a BioRad CFX96 Real-Time PCR detection system to quantify amplicons. Primers listed
in Table 5.2 were designed for inside the coding region of the target. Two house-keeping genes,
UvrD and RpoS, were used as controls along with no RT wells and wells for dilution of a PCR
amplicon of the gene of interest. Data analysis was performed using the CFX Manager software.
Experiments were repeated four times (n=12).
Western blot analysis
P. aeruginosa strains were grown in LB broth at 37°C overnight and then a 1% dilution
of the overnight culture was grown for 6 hours. The bacteria were collected by centrifugation,
resuspended in sterile phosphate-buffered saline, and lysed by sonication. Total protein
concentrations were quantified by the Bradford protein assay (Bio-Rad, Carlsbad, CA). Cell
extracts (5 µg) were separated by 12% SDS-PAGE and transferred to a polyvinylidene difluoride
membrane (Bio-Rad). The membranes were blocked and probed using a 1:20,000 dilution of
anti-HA monoclonal antibody (Thermo Fisher, Pittsburgh, PA), followed by a 1:20,000 dilution
of horseradish peroxidase-conjugated goat anti-mouse immunoglobulin antibody (18)or 1:20,000
dilution of AlgR antibody followed by 1:20,000 dilution of horseradish peroxidase-conjugated
goat anti-rabbit immunoglobulin antibody. The membrane was stripped per Abcam mild
stripping protocol and then probed with RpoA primary antibody (1:20,00 dilution) followed by
1:20,000 dilution of horseradish peroxidase-conjugated goat anti-mouse immunoglobulin
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antibody. Detection was performed using an ECL Plus kit (Thermo Fisher, Pittsburgh, PA) and
chemiluminescence detection (ProteinSimple, Santa Clara, CA). All Western blot analyses were
repeated at least twice.
Phenotypic Assays
Various virulence products were assayed in the P. aeruginosa strains in this study. All
strains were grown in LB broth at 37ºC for 16 hours. Pyocyanin was assayed by centrifuging the
culture and collecting the supernatant. Then 2 mL of chloroform was used to extract any
pyocyanin produced in the culture by vortexing vigorously and allowing to set for 10 minutes.
The chloroform layer was removed and 1 mL of 0.1 N HCl was added and vigorously vortexed
and allowed to set for 10 minutes. 0.1 N HCl was used to blank the spectrophotometer at
OD562nm. Values were normalized to PAO1. Elastase was assayed using Elastin-Congo Red
(ECR) from Sigma Aldrich. Strains were centrifuged and 100 µL taken from the supernatant.
This was mixed with 900 µL of ECR solution ( 100 mM Tris, 1 mM CaCl2, pH 7.5, 20 mg/mL)
and incubated at 37ºC for 4 hours at 250 rpm. The negative control used to blank the
spectrophotometer was 1 mL of ECR solution with no strain supernatant. Values were
normalized to PAO1. Rhamnolipid production was assayed using the orcinol method listed in
Morici et al. (19). All experiments were performed in triplicate (n=9).
Macrophage Survival Assays
P. aeruginosa strains were incubated with ATCC J774a.1 or Raw 264.7 macrophages to
assess macrophage survivability. Macrophages were grown in Corning cellgro DMEM with LGlutamine, 4.5g/L Glucose, and 10% fetal bovine serum and 100 I.U./ml penicillin 100 µg/mL
streptomycin. Cells were maintained in a 37ºC incubator with 5% CO2 and humidity. Cells were
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counted and plated in 12-well plates at 1x10^6 cells per well in media without pen/strep.
Overnight LB cultures of P. aeruginosa strains were diluted to 1% and allowed to grow for 2
hours at 37ºC at 250 rpm. Cultures were then centrifuged and washed with 1X PBS. Strains
were then aliquot to an OD600nm of 0.1 and incubated with macrophages up to 6 hours. The
inoculum of bacteria was also measured in CFU/mL. Macrophages were collected at 2, 4, and 6
hour time points and 1 mL of culture was mixed with 100 µL of 0.4% trypan blue to measure
viability. Experiments were performed in triplicate (n=9).
Overexpression/complementation studies.
In order to overexpress algD54E, the coding sequence was amplified (Table 5.2) and
cloned into the integrating vector pTJ1 for complementation or overexpression(20).
Trimethoprim-resistant colonies were picked and patched on trimethoprim-irgasan media and
0.1% arabinose PIA. The presence of the gene of interest was confirmed using primers
pHERDSF and algRTJ1R. Cultures requiring induction used 0.1% arabinose and were grown for
overnight in broth or on agar plates.
β-galactosidase Assay
β-Galactosidase activity was determined by incubating cell extracts with o-nitrophenyl-βD-galactopyranoside

(4 mg/ml) as described by Miller (20b). Experiments were performed in

triplicate (n=9).
Statistical analyses.
Statistical analyses (Student’s t-test) were performed using Microsoft Excel software
(Microsoft, Redmond, WA).
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RESULTS
AlgZ interacts with AlgR and AlgR dimerizes
The response regulator AlgR has been thoroughly studied and also implicated to affect
virulence in P. aeruginosa (4, 10). While AlgR and its cognate sensor histidine kinase have been
shown to be in an operon together, they have never been shown to actually interact (21). It is
important to demonstrate this interaction to complete a portion of P. aeruginosa knowledge.
With TCSs the sensor will share a phosphate with the response regulator at specific amino acid
residues, however they also have protein-protein interaction domains. In the case of AlgZ and
AlgR the C-terminus region of AlgZ is proposed to interact with AlgR. By using a BACTH
system, AlgZ and AlgR were shown to interact (Figure 5.1). In this analysis, appropriate
controls consist of empty vectors (T18 or T25), which produce pieces of adenylate cyclase, but
do not interact. The positive controls consisted of a leucine zipper (Zip) that is known to
dimerize and allow adenylate cyclase to make cyclic AMP (cAMP). Positive results consist of
700 to 7000 miller units with a β-galactosidase assay and colorimetric indication by pH indicator
phenol red on MacConkey agar or cleavage of X-gal on LB/IPTG/Xgal agar.
Since the AlgZ protein is incorporated into the inner membrane of the bacteria, the
fusion was placed on the C-terminus, so that the adenylate cyclase portion on AlgR had greater
potential to interact. An empty vector and leucine zipper-containing vector were co-transformed
with AlgZ carrying vector to test for any aberrant interactions. While the full-length AlgZ and
AlgR interaction did show positive results, some reporter activity was observed with our
negative controls. One possible explanation for these results is the fact that the structure of AlgZ
has not been elucidated and this could lead to arbitrary interactions. To combat this result, a
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truncated form of AlgZ was cloned into the BACTH vector, which just included the C-terminus
Figure 5.1 AlgZ and AlgR interact.

BACTH assay for AlgZ or truncated AlgZ interacting with AlgR using T18 or T25
portions of adenylate cyclase. β-galactosidase assay, MacConkey agar supplemented
with 1% maltose, and LB agar supplemented with IPTG/X-Gal were screened for
interaction between AlgZ, AlgZ C-terminus, and AlgR. * signifies beta-galactosidase
activity units between 700 – 7000, the significance threshold for the BACTH. . βgalactosidase assay was repeated in triplicate (n=9).
region (AlgZTrunc). The truncated form of AlgZ did not interact with the leucine zipper,
however the same reporter activity was observed with the truncated form of AlgZ and AlgR-T25.
Response regulators are commonly known to dimerize to activate their genetic targets.
AlgR has been shown to activate the minor pilin operon and the posttranscriptional regulator
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rsmA with two binding sites (8, 11). This consistent motif led us to also analyze the ability for
Figure 5.2 AlgR dimerizes.

BACTH assay for AlgR-AlgR interaction using T18 or T25 portions of adenylate
cyclase. β-galactosidase assay, MacConkey agar supplemented with 1% maltose, and
LB agar supplemented with IPTG/X-Gal were screened for interaction between AlgR
and AlgR (T18-AlgR, AlgR-T25). * signifies beta-galactosidase activity units between
700 – 7000, the significance threshold for the BACTH. β-galactosidase assay was
repeated in triplicate (n=9).
AlgR to dimerize using the BACTH system. The same controls were repeated in this experiment
except with AlgR. No activity with the empty vectors or the leucine zipper was reported with
AlgR (Figure 5.2). However, when both vectors containing AlgR were transformed, around
4000 units of β-galactosidase activity was observed as well as increased colorimetric reporter.
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Confirming the interactions of AlgZ with AlgR and AlgR dimerizing demonstrates the AlgZ/R
TCS truly interacts.
AlgZ levels are increased in pilW strain
When studying the effects of a pilY1 mutation, Luo et al. showed that the increase in
minor pilin expression was due to AlgR and not the known regulator of algZ, Vfr (14).
However, this group never investigated the effects on algZ expression; considering if AlgR needs
to be phosphorylated to activate the minor pilin operon then there might be an increase in algZ to
cause more phosphorylation. Williams identified that not only was there increased algZ
expression in a pilW strain but that this was dependent on AlgR (30). Since Williams only
investigated these effects with lacZ reporter fusions, algZ levels were examined with qPCR and
western blot (Figure 5.3a). Williams reported expression of algZ was maximal at 6 hours with
an algZ-lacZ transcriptional fusion (30). An algZ strain was used as a negative control in our
experiment. The pilW mutant had a 8-fold increase in algZ expression compared to the PAO1
wildtype strain. Interestingly, the phospho-deficient AlgR pilW strain showed algZ expression
levels less than PAO1. These results further asserted that there was a phosphorylated AlgR
dependent phenomenon causing the increase in algZ expression.
AlgZ levels between PAO1 and pilW were studied using a HA-epitope tagged algZ allele
(Figure 5.3b). These strains were also grown in LB and collected after 6 hours to mimic the
qPCR experiments. Western blot analysis also showed a significant increase in AlgZ levels in
the pilW background. The lower levels of AlgZ protein versus algZ transcript might be due to
posttranscriptional regulation or the fact that cell lysates were assayed instead of membrane
fractions also.

179

Figure 5.3 AlgZ levels are increased in a pilW mutant.

A) qPCR analysis of algZ expression. pilW has a significant increase while the phosphodeficient pilW was less than wildtype. Values were normalized to housekeeper genes (uvrD
and mreB) and compared to PAO1. *** signifies p < 0.01. Experiments performed in
triplicate (n=12). B) Western blot analysis of AlgZ in PAO1HA and pilWHA from 6 hour
cultures using anti-HA monoclonal antibodies. PAO1* is lacking the HA epitope. RpoA
was used as a loading control.
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Figure 5.4 AlgR levels are increased in a pilW mutant.

A) qPCR analysis of algR expression. pilW has a significant increase while the
phospho-deficient pilW was less than wildtype. Experiments were performed in
triplicate at least three times. Values were normalized to housekeeper genes (uvrD and
mreB) and compared to PAO1. *** signifies p < 0.01. Experiments performed in
triplicate (n=12). B) Western blot analysis of AlgR in PAO1, algR, pilW,pilW vfr, and
pilW algRD54A from 6 hour cultures using anti-AlgR serum. RpoA was used as a
loading control.
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AlgR levels are increased in pilW strain
Since the AlgZ/R TCS is genetically organized in an operon, algR expression and protein
levels were investigated. Depending on which regulators are active, algR can be expressed as a
message with algZ or the extracellular sigma factor AlgU can activate expression of algR with a
promoter in the algZ coding region (14, 22). Williams studied the effects of the AlgU dependent
promoter in pilW and showed no increase in algR expression compared to PAO1. The AlgZ
levels were increased in the pilW strain as well as Williams confirming the Luo et al. data that
minor pilin expression also significantly increased, which is an effect of phosphorylated AlgR.
To see if algR mRNA was increased, algR expression was also investigated via qPCR (Figure
5.4a). This time the algR mutant was the negative control and the algZ mutant showed no
difference in expression compared to PAO1. The pilW strain showed an increase in expression
levels similar to the algZ expression (Figure 5.3a). Just like algZ expression, the phosphodeficient AlgR pilW strain showed wildtype levels. This datum showed more evidence of algZ/R
co-transcription due to phosphorylated AlgR, but were AlgR protein levels also decreased?
Western blot analysis showed significant increases in pilW and in the pilW vfr in AlgR levels
(Figure 5.4b). Luo et al. reported that while significant, the pilX vfr mutant still had increased
levels of minor pilin expression compared to wildtype (14). Williams also reported this same
result with a pilW vfr mutant and transcriptional fusion analysis. However, the phosphodeficient AlgR pilW strain showed little AlgR protein present, further arguing the importance of
phosphorylated AlgR on activating the expression of the algZ/R operon.
pilW has decreased AlgR-regulated virulence factor production
AlgR has been show to regulate multiple virulence factors including pyoverdine,
rhamnolipids, and TFP in a phosphorylation dependent manner (8, 9). Since the pilW strain
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showed increases in the AlgZ/R TCS, then were the same increases in virulence targets of AlgR
present in this background? Pyocyanin is known to be regulated by AlgR in a phosphorylation
Figure 5.5 Virulence factor production is decreased in pilW.

A) Pyocyanin assay from overnight LB cultures. Circles underneath the strain represent color
taken from image of culture tube. B) Rhamnolipid assay from overnight LB cultures. C)
Elastase assay using Elastin-Congo Red (ECR), and values were normalized to PAO1.
Overnight LB cultures were pelleted and 100 µL of supernatant was incubated with ECR for
four hours. * represents p < 0.05 *** represents p < 0.01. All experiments were repeated in
triplicate (n=9).
independent manner (9). Little et al. showed that in a phospho-deficient AlgR strain, pyocyanin
production was increased while in the phosphomimetic strain, pyocyanin levels were much lower
than wildtype (9). Pyocyanin production was assessed in minor pilin mutants (pilY1 and pilW) as
well as strains lacking the ability to phosphorylate AlgR in a pilW (algR, algRD54A,
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algZH175E) (Figure 5.5a). A lasR rhlR strain was used for a negative control as these regulators
are known to contribute to pyocyanin production (23). Bohn et al. and Siryaporn et al. have both
characterized the effects of pilY1 mutations and how they mimic lasR mutations. Both minor
pilin mutants showed decreases in pyocyanin production compared to wildtype (24, 25).
However, loss of the algR allele in the pilW mutant or inability for this mutant to phosphorylate
AlgR showed significant increases in pyocyanin levels. Next, rhamnolipid production was
assayed in pilW and pilW algRD54A (Figure 5.5b). A similar pattern of decrease in pilW and
increase in the phospho-deficient strain was observed. The literature in this case is conflicting.
Morici et al. states that AlgR represses the Rhl quorum sensing (QS) system and rhlA expression
where an algR mutant has increased rhamnolipid production, while Okkotsu et al. demonstrate
the opposite and AlgR actually activates rhlA. Both also show AlgR binding upstream. The
results in Figure 5.5b were performed in a broth instead of collected from a biofilm on a plate
and may explain the lack in distinct significance. Also, the western blot analysis from Figure
5.4b shows more AlgR present in pilW and less in pilW algRD54A, which supports the argument
from Morici et al. that AlgR would be repressing rhamnolipid production. Lastly, the quorum
sensing target, elastase, was quantified. Due to the effects of decreases in QS targets because of
increased AlgR, an elastase assay was used to study the effects pilW had on elastase activity
(Figure 5.5c). Since elastase is a direct target of the Las and Rhl QSs, the lasR rhlR mutant again
was used as a negative control. Again, the same pattern of decrease in pilW and increase in pilW
algRD54A was observed. Further arguing the work of Morici et al. that increased AlgR levels
are repressing the QS response. These data also argue that minor pilin mutants can affect the QS
response via AlgR’s ability to influence the Rhl quorum system.
Increased macrophage survivability in pilW strain
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To find out if the decreases in virulence factors had any effect on virulence in the pilW
mutant, macrophage survival was assayed (Figure 5.6). Strains were incubated up to 6 hours
Figure 5.6 Macrophages have increased survivability with pilW.

A) J774a.1 and B) Raw 264.7 macrophages were incubated with PAO1, pilW, and pilW
algRD54A for viability with 0.4% Trypan blue stain at 2, 4, and 6 hours. * represents p <
0.05 and *** represents p < 0.01. All experiments were performed in triplicate (n=9).

with either J774a.1 (Figure 5.6a) or Raw 264.7 cells (Figure 5.6b). PBS inoculated wells were
used as a negative control in both experiments. Both cell lines had increased survivability with
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the pilW strain. There was also no significant difference between PAO1 and the pilW algRD54A
strains. Siryaporn et al. demonstrated that both pilY1 and pilW mutants were attenuated in killing
the amoeba Dictyostelium discoideum (25). These results were more visible in the incubation
with the Raw 264.7 macrophages. The major difference between J774a.1 and Raw 264.7 cells is
the production of interleukin-1β (IL-1β) by J774a.1. This overproduction of IL-1β with the pilW
strain may be causing the lesser significance as compared to the Raw 264.7 cells. However, due
to overall decreased virulence products produced in the pilW mutant, the pilW mutant is
attenuated when incubated with macrophages. But when AlgR is unable to be phosphorylated in
the pilW background, virulence factor production is equal to wildtype if not increased and this
effect leads to macrophage death.
Overexpression of phosphomimetic AlgR mimics pilW strain
The pilW strain not only has increased levels of AlgR but that these are increased levels
of phosphorylated AlgR due to increases in AlgZ also. The pilW strain also had decreased
virulence factors and was attenuated with two lines of macrophages. To further drive home the
fact that this is due to increased levels of phosphorylated AlgR, an inducible phosphomimetic
AlgR (pAlgRD54E) was constructed and put it in a strain that could not phosphorylate AlgR
(algZH175E). The pAlgRD54E construct was induced in all scenarios with 0.1% arabinose.
This strain was first analyzed with the algZ-lacZ transcriptional fusion to confirm the increased
algZ expression in the pilW was phosphorylated AlgR dependent (Figure 5.7a). Upon induction,
the expression of algZ increased by ~100 fold. The algZH175E strain cannot phosphorylate
AlgR due to the mutated histidine. Due to the increase of algZ expression, pyocyanin was
quantified in uninduced and induced strains (Figure 5.7b). PAO1 was also incubated with 0.1%
arabinose to show no effects of the added compound. algR and algZH175E strains were also
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Figure 5.7 Overexpression of phosphomimetic AlgR mimics pilW mutant and shows
decreased virulence.

A) β-galactosidase assay of algZ expression of uninduced and induced AlgRD54E in
algZH175E strain that cannot phosphorylate AlgR. B) Pyocyanin assay of uninduced and
induced AlgRD54E. PAO1† represents wildtype with 0.1% arabinose. C) Macrophage
survivability assay with J774a.1. PBS† represents macrophages inoculated with PBS and
0.1% arabinose. All experiments were performed in triplicate (n=9). * represents p < 0.05
and *** represents p < 0.01.
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used as controls in the comparison to the algZH175E pAlgRD54E strain. The induced
algZH175E pAlgRD54E strain had levels of pyocyanin similar to the lasR rhlR strain. Lastly,
this strain was assayed for macrophage survivability to see if increased levels of AlgRD54E had
a decrease in virulence like pilW (Figure 5.7c). An algRD54A strain was also assayed to show a
similarity with the phospho-deficient strain algZH175E when pAlgRD54E was not induced. The
induced pAlgRD54E strain had significantly increased levels of macrophage survivability. At
the 6-hour time point, around 50% of macrophages survived which again mimics the lasR rhlR
mutant strain (data not shown). The overexpression of the phosphomimetic AlgR construct
further suggests that the same activation of algZR expression and decrease in virulence occurs in
the pilW mutant due to the increase in phosphorylated AlgR via autoregulation.

DISCUSSION
The response regulator AlgR is used by P. aeruginosa to control the expression of
multiple virulence factors and aid in establishing an infection and persisting in a compromised
host a (8-10, 26). While genetically arranged in an operon with algZ, no evidence to this date
has demonstrated that AlgZ is the sensor histidine kinase to AlgR except for bioinformatic
prediction. We demonstrated using a BACTH system that AlgZ and AlgR do in fact interact.
While more information can be determined from studying the 3D structure with X-ray
crystallography of AlgZ and AlgR, overall this interaction proves a wide-held belief with this
TCS in P. aeruginosa. AlgR has also been proposed to have DNA binding sites that require two
AlgRs (8, 11). In activating these AlgR targets, AlgR would dimerize and bind the DNA
consensus sequence. By using the BACTH system we demonstrated that AlgR is capable of
interacting with itself. This datum affirms that like other response regulators, AlgR can, at least,
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dimerize (27). In the case with AlgZ and AlgR, a phosphotransfer assay would be more
pertinent to show that actual exchange between these members of this TCS. However, AlgR has
the ability to autophosphorylate and could prove to be difficult to visualize unless studied in a
time dependent manner(8, 13).
Confirming the interaction with AlgZ and AlgR is important for understanding the
increase in algZR expression in a pilW mutant. Williams demonstrated that not only did a pilW
mutant have increased minor pilin expression confirming the Luo et al. work, but there was also
increased algZ expression. Autoregulation is common amongst TCSs that are arranged in an
operon (6, 23). We confirmed that there was increased algZR message and also increased levels
of AlgR protein in pilW. When AlgR was mutated to a phospho-deficient algRD54A these levels
dropped. Lastly, because AlgR regulates the expression of the minor pilin operon in a
phosphorylation dependent manner and by overexpressing the AlgR phosphomimetic,
pAlgRD54E, showed the same increase in algZ expression; we theorize that the pilW mutant has
no way of turning off the algZR autoregulation mechanism. Marko et al. demonstrated using the
BACTH system that four minor pilin proteins, PilVWXY1, form a complex in the
innermembrane/periplasmic space and interact with AlgZ(28). This interaction would be a
mechanism for AlgZ to “turn off” the phosphorylation of AlgR and decrease expression of minor
pilins. However, when one of these prominent minor pilins is missing, the off-switch is
nonfunctional and the AlgZ/R autoregulation mechanism (Figure 5.8) increases algZ expression
and minor pilin expression. This mechanism would also explain the effects on the Rhl quorum
sensing system virulence factors all being decreased. Since the pilW strain is also producing
more AlgR and Morici et al. showed that increased levels of AlgR repress this QS mechanism,
naturally pyocyanin, rhamnolipid, and elastase production would also decrease (19).
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Many groups have shown that pilY1 mutations or pilW mutations lead to attenuation with
amoebae and C. elegans (25, 28). in vivo studies and global knowledge experiments, like
Figure 5.8 Model of pilW mutation and the effects on algZR expression.

We show with this work herein that minor pillin mutants, in this case pilW, that the AlgZ/R
TCS is no longer regulated in P. aeruginosa. algZ/R expression increases greatly, therefore
increasing minor pilin expression. The effects of this increase also influence other
phosphorylated AlgR dependent targets besides TFP and decreases virulence when incubated
with J774a.1 macrophages.
transcriptomics or proteomics, would allow for better understanding and the coordination
between the AlgZ/R TCS, TFP, and the Rhl QS network in P. aeruginosa virulence. To this
point, we showed that a pilW mutant and a strain overexpressing phosphomimetic AlgR were
attenuated with macrophages. These results lead the TFP of P. aeruginosa to be targeted as an
Achilles’s heel to compromise the bacterium’s virulence capabilities. Since the TFP are crucial
for twitching motility and attaching to surfaces; by targeting this apparatus, a pilicide would not
only render the bacterium unable to attach and twitch, but also decrease the production of
virulence factors. This effect in concert with an additional antimicrobial could allow for
clearance of an infection, preventing the development of septicemia in acute infections or
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persister cells in chronic infections.
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CHAPTER 6
CONCLUSIONS
P. aeruginosa is a versatile opportunistic pathogen capable of infecting any tissue in the
human body (Winstanley et al. 2016; Moradali et al. 2017). P. aeruginosa has always posed the
most threat to immunocompromised individuals with HIV, type II diabetes, or cystic fibrosis
(Bahemia et al. 2015; Winstanley et al. 2016; Stefani et al. 2017). P. aeruginosa is the leading
cause of morbidity and mortality in people with cystic fibrosis (Salunkhe et al. 2005). However,
over time P. aeruginosa infections are becoming more difficult to treat as the bacteria become
more resistant to antibiotics, specifically carbapenem-resistant strains (Woodworth et al. 2018).
New tactics for treating P. aeruginosa acute and chronic infections are necessary for increasing
the quality of life for people susceptible to this pathogen.
Because P. aeruginosa has become resistant to multiple antibiotics and adapts to newly
developed antibiotics, researchers have started looking for alternative means to clear bacterial
infections. In the case with uropathogenic E. coli (UPEC) the Hultgren lab has investigated
crippling the pathogen by targeting the Fim pathway (Chorell et al. 2012). This group has
generated a compound called a pilicide that outcompetes the affinity for UPEC to bind host and
instead inactivates the attachment mechanism clearing the pathogen from the bladder (Chorell et
al. 2012; Greene et al. 2014). Similar work is occurring with P. aeruginosa. Multiple groups are
investigating virulence targets of P. aeruginosa like: inhibiting the quorum sensing system,
disrupting biofilms, and interfering with two component systems and adhesins (Fothergill et al.
2014). Antivirulence studies require understanding of genetic regulation and regulation of
virulence factors in order to compromise the infectious pathogen. This work investigates the
multifactorial components of virulence factor regulation in both acute and chronic infections of
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P. aeruginosa. The regulation of the post-transcriptional regulator, rsmA, by two known
regulators of virulence AlgU and AlgR, the RsmA regulon of virulence targets in the mucoid
background, and the role of minor pilins of the type IV pili in regulating the algZ/R twocomponent system.
RsmA has mainly been studied in nonmucoid strains of P. aeruginosa like PAO1 and
PAK (Burrowes et al. 2006; Brencic and Lory 2009). RsmA is studied in this background
because RsmA has always been assumed to regulate virulence factors associated with
establishing infections and repressing virulence factors known to be expressed in a chronic
infection (Lapouge, Schubert, et al. 2007; Valentini et al. 2018). With a P. aeruginosa infection
in the cystic fibrosis lung, the bacteria face osmotic stress from reactive oxygen and nitrogen
species (ROS and RNS) from the host immune system (Palmer et al. 2015). This immune cell
assault causes the release of the extracytoplasmic sigma factor, AlgU, which then activates the
expression of its regulon(Schnider-Keel et al. 2001). The most well known AlgU directed target
is the alginate operon that produces a copious amount of exopolysaccharide (Hershberger et al.
1995). The alginate biofilm can protect P. aeruginosa from ROS and RNS, phagocytosis, and
antibiotics (Firoved et al. 2002). The overproduction of alginate allows for P. aeruginosa to
persist in the cystic fibrosis lung and develop into a chronic infection. The most common
phenotype isolated from cystic fibrosis chronic infections are alginate overproducers of P.
aeruginosa (Boucher et al. 2000; Winstanley et al. 2016).
Interestingly we identified a predicted AlgU consensus sequence upstream of the
previously identified RpoD promoter for rsmA (Stacey and Pritchett 2016). This work went
against the paradigm that RsmA only had a role in regulating acute virulence factors and RsmA
activity was repressed by the small RNA antagonists RsmY and RsmZ in later phases of growth
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(Brencic and Lory 2009). We showed that there was more RsmA present in a mucoid mutant of
PAO1, mucA22 and the mucoid cystic fibrosis isolate, 2192. The increase in RsmA was a result
of AlgU activity in these mucoid strains. AlgU’s role was confirmed via site directed mutation
of the -35 consensus sequence and deletion of the algU allele. While there was no direct
interaction demonstrated between AlgU and this promoter, an electromobility shift assay to show
protein-DNA interaction or interferometry between AlgU and RpoS to identify which sigma
factor has a greater affinity of the distal rsmA promoter. However, this discovery proved that
RsmA has a role in mucoid strains and still contributes to virulence factor regulation in chronic
infection strains.
In mucoid strains, AlgU is known to work in concert with the response regulator AlgR.
Together they are known as the alginate regulators and contribute to expression of the algD
operon that produces alginate (Salunkhe et al. 2005). Our next study investigated if this coregulation occurred on the distal rsmA promoter. Bioinformatics showed two possible AlgR
binding sites upstream of the AlgU binding sites. An algR mutant mucA22 showed decreases in
RsmA levels and increases in RsmA targets hcnA and tssA1. AlgR was shown to directly bind
this distal rsmA promoter and both AlgR binding sites were required, a common feature of AlgR
(Morici et al. 2007; Okkotsu et al. 2013). AlgR also binds the rsmA promoter independent of
phosphorylation, further arguing this is a mucoid strain phenomenon. To reiterate not only is
there more RsmA in mucoid strains but the increase is due to the alginate regulators, AlgU and
AlgR. These works demonstrated a new dimension to RsmA in P. aeruginosa virulence
regulation and had importance in relation to pathogenesis in cystic fibrosis where the alginate
regulators give way to chronic infections.

197

The RsmA regulon has been studied in PAO1 and PAK by using global transcriptome
experiments (Burrowes et al. 2006; Brencic and Lory 2009). These strains are nonmucoid and
are used as acute infection model strains. These studies found that RsmA positively influences
motility genes for flagellum synthesis and type IV pili, alginate and biofilm production, and the
type III secretion system (Burrowes et al. 2006; Brencic and Lory 2009). These virulence factors
are used by P. aeruginosa for establishing an infection and creating a niche inside the host.
RsmA was also found to repress the type VI secretion system, a multidrug efflux pump system,
and genes involved in iron regulation(Burrowes et al. 2006; Brencic and Lory 2009). These
virulence factors are commonly found expressed in chronic infecting strains of P. aeruginosa,
where the bacteria have to dominate other pathogens and acquire the valuable nutrient iron. It is
easy to see why RsmA would be associated with initiating a P. aeruginosa infection and be
repressed in the chronic infection phase of growth.
However, due to the fact that RsmA is in abundance in mucoid strains, the RsmA regulon
is more complex than believed. Our proteomic approach of studying the RsmA regulon was
more indicative of whether or not translation had occurred versus the transcriptome approach.
The transcriptome approach will give better results to repressed targets, which will show
increases in fold change, while targets positively influenced by RsmA are potentially indirect. In
our iTRAQ study, we identified similar targets that were repressed by RsmA like hcp1.
However, some of our targets also differed in previously reported results. AlgD , the protein
regulated by AlgU and AlgR which generates alginate, was increased in the mucA22 rsmA strain
while the rsmA mutant was reported to show a -3 fold change compared to wildtype (Burrowes et
al. 2006). Lastly, our study identified previously unknown targets. We were able to confirm a
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direct interaction with the P. aeruginosa small protease, PasP. We can now argue that not only

Figure 6.1 Schematic of RsmA production in nonmucoid (PAO1) and mucoid
(mucA22) strains of Pseudomonas aeruginosa. In mucoid strains, the alginate
regulators, AlgU and AlgR, activate the distal promoter of rsmA, which causes
an increase in RsmA levels in this background. In the mucoid background,
there is a previously unidentified target, the P. aeruginosa small protease, pasP.

is RsmA important in the P. aeruginosa chronic infection, but it regulates multiple virulence
factors not previously known (Figure 6.1). This work has opened a door for further
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understanding of the RsmA regulon and its role in infecting the cystic fibrosis lung, which has
potential to lead to antivirulence drug targets.
Like CsrA in E. coli, RsmA has potential to positively interact with some of the products
that were repressed in the mucA22 rsmA strain (Wei et al. 2001). Using m-fold predictive
software, alignments of known targets and these RsmA “positive targets” could show the
possibility of the AGGA stem-loop motif. These positive targets that present the RsmA binding
motif would then be tested with purified RsmA. P. aeruginosa RsmA has never been shown to
interact with other proteins too, unlike CsrA in Campylobacter jejuni and Bacillus subtillis
(Mukherjee et al. 2011; Dugar et al. 2016). The interaction between CsrA and mRNA positively
influences motility, which RsmA is known to contribute to also. To identify possible proteinprotein interactions of RsmA a simple bait-prey experiment with the bacterial adenylate cyclase
two-hybrid system could be performed. The most important experiment to be performed to
understand RsmA in mucoid strains is in vivo experiments. Because RsmA influencing virulence
factor regulation in mucoid strains is still relatively new, the mucA22 rsmA strain should be
screened in a higher organism than C. elegans or macrophages. If the mucA22 rsmA strain were
attenuated in a respiratory infection in a mouse, rat, or cystic fibrosis mouse, then an
antimicrobial compound targeting RsmA would be of the utmost importance in clearing P.
aeruginosa infections.
Another important vulnerability in P. aeruginosa is the type IV pili. Pili are commonly
used for attachment, motility, mechanosensory mechanisms(Giltner et al. 2010; Luo et al. 2015).
More recently they have been used as antivirulence targets (Greene et al. 2014; Novotny et al.
2017). This work examines the effects of P. aeruginosa with deficient type IV pili. If a single
minor pilin protein is missing, the whole type IV pili is malformed and twitching and sensing are

200

no longer efficient (Giltner et al. 2010). It has also been reported that if one of the four

Figure 6.2 The role of the response regulator, AlgR, in colonizing and establishing an
infection in Pseudomonas aeruginosa. Phosphorylated AlgR is extremely important in
virulence factor production. By deleting the minor pilin protein, PilW, this process is
interrupted due to the lack of surface sensing capabilities in the type IV pili.
important minor pilins, PilVWXY1, are missing, then this complex cannot interact with AlgZ
(Marko et al. 2017). In a pilW mutant we showed increase AlgZ/R levels, and decreased
virulence factor production. More work is still required to show a direct interaction of AlgR with
the algZ promoter region and confirm the autoregulation effect. But there is major potential for a
pilicide compound to disrupt the of the type IV pili and send the AlgZ/R system into overdrive,
decrease virulence, and limit the ability for P. aeruginosa to establish an infection (Figure 6.2).
AlgR has been studied ad nauseam but there are still global experiments yet to be
performed. While CHIP-SEQ has been performed with AlgR to identify targets as well as
microarrays, no one has elucidated the difference between the AlgR regulon dependent and
independent of phosphorylation(Lizewski et al. 2004; Kong et al. 2015). Many researchers have
used phosphodeficient and phosphomimetic forms of AlgR, AlgRD54A or N and AlgRD54E,
however, we know these strains present phenotypically correct, but western blot analysis shows
lower levels of AlgR present (data not shown). Using iTRAQ with a pilW mutant strain, which
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we have shown has more AlgZ/R, would be a better strain to identify AlgR targets dependent of
phosphorylation. Understanding the phospho-dependent targets of AlgR could lead to more
virulence targets to combine with a minor pilin target and generate a multivalent vaccine.
Therefore never allowing the P. aeruginosa strain to initiate an infection in the human host.
Overall, this work was to investigate virulence regulation in P. aeruginosa by a variety of
factors. Genetic regulation is multifactorial in terms of sigma factors, response regulators, posttranscriptional regulation, and external sensing systems. By understanding regulation of
virulence factors in P. aeruginosa are regulated and visualizing these complex networks,
researchers can provide the individuals susceptible to this opportunistic pathogen a little more
hope with advanced treatments and preventative measures and less morbidity and mortality.
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